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Enhancement of posterior spinal fusion (PSF) has been an important research 
area for orthopaedics due to the limitation of autograft. With the advance in 
tissue-engineering techniques to enhance osteogenic potential of mesenchymal stem 
cells (MSCs) and the proven enhancing effect of low intensity pulsed ultrasound 
(LIPUS) on bone formation, the study hypothesized that the tissue-engineered MSCs 
plus LIPUS would enhance PSF. 
Firstly, the study was aimed to test the optimal condition for ostegenic 
differentiation of MSCs in vitro with LIPUS. With 10 minutes LIPUS daily treatment, 
the osteogenic potential of MSCs cultured in osteogenic medium was increased. 
Using the first part results, the second study investigated the effect of LIPUS and the 
differentiated MSCs in PSF using a standardized animal model. Four different groups 
were carried out: Group A (No MSCs and LIPUS); Group B (undifferentiated MSCs); 
Group C (Differentiated MSCs); Group D (Differentiated MSCs and LIPUS). The 
fusion masses were assessed by manual palpation, peripheral quantitative computer 
tomography (pQCT), high-resolution micro-radiography (uXray), and histology at 
week 7 post-operation. The fusion rate of Group D animals was 86% while others 
had only less than 20% fusion rate. The bone mineral content and bone volume (BV) 
of the fusion mass of Group D were better than those in Group A and C. 
Histologically, the gap distance between transverse process at the fusion site 
was smallest in Group D. The BV was consistent with the pQCT results that the 
Group D had largest BV. The degree of host-to-implanted integration was enhanced 
by 36% in Group D when compared with other groups. More cartilaginous tissue and 
more mineralized tissue inside the implanted material were observed in Group D. 
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The results showed the effect of LIPUS on enhancing bone formation in the PSF with 
differentiated MSCs. It is speculated that LIPUS enhanced the endochondral 
ossification and the osteogenic potential of MSCs and improved osteocoductivity of 
the implant for bone ingrowth. 
To further understand the growth of the fusion mass in PSF, A new in vivo 
monitoring method was developed to qualitatively and quantitatively observe the 
development of the fusion mass. With the advance in high-resolution peripheral 
quantitative computed tomography (HR-pQCT), a longitudinal study to follow the 
development of fusion mass of PSF was carried out to measure the bone formation 
and BMC at the fusion site. The study used HR-pQCT to monitor two groups of 
animals under PSF: 1) with differentiated MSCs and 2) with differentiated MSCs and 
LIPUS treatment. The aim was to develop a method to monitor the growth of fusion 
mass and to investigate the effect of LIPUS in PSF. It was shown that bone growth 
was not limited to the transverse processes at the fusion site but also around and 
within the implanted material. Through the quantitative analysis of bony tissue and 
bone mineral content of the fusion mass, it was shown that LIPUS can enhance the 
bone ingrowth into the implanted material and modify the bone volume changes 
during PSF. LIPUS treated animals had different pattern of the changes of bone 
mineral density and BV. It is suggested that the LIPUS may enhance the osteogenic 
potential of the implanted MSCs and the osteoconductivity of the fusion mass. 
In summary, with optimal in vitro LIPUS treatment for the MSCs and the 
combination of the tissue-engineered cell and biomaterial composite, LIPUS can 
enhance the osteogenic effect of the implanted composite in PSF. LIPUS could be a 
potentially useful non-invasive clinical application in enhancing bone formation and 
regeneration in PSF. 
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摘要 
由於缺乏自體骨’增強後路脊柱融合（posterior spinal fusion，PSF) —直是 
骨科重要的硏究領域。組織工程技術的進步可增強骨髓間質幹細胞(mesenhymal 







PSF的作用。將實驗動物分爲四組：A組（無MSCs和LIPUS ) ； B組（未成骨 
分化的MSCs ) ： C組（成骨分化的MSCs ) ； D組（成骨分化的MSCs和LIPUS ) � 
于術後1周對融合塊進行評價，參數包括手工檢測、外周定量電腦斷層掃描 
(peripheral quantitative computer tomography, pQCT )、高精度微 X ‘線。D ,組的融 
合率高達85%，而其他組的融合率均低於20%�pQCT顯示D組融合塊的骨礦 






















ALP Alkaline Phosphatase 
AN OVA Analysis of Variance 
BCIP 5-Bromo-4-chloro-3-indolyl phosphate 
bFGF Basic Fibroblast Growth Factor 
BM Basal Medium 
BMC Bone Mineral Content 
BMPs Bone Morphogenetic Proteins 
BV Bone Volume 
CPC Calcium Phosphate Ceramics 
DBM Demineralized Bone Matrix 
DMEM Dulbecco's Modified Eagle Medium 
FBS Fetal Bovine Serum 
HA Hydroxyapatite 
HR-pQCT High-resolution Peripheral Quantitative Computed Tomography 
LIPUS Low Intensity Pulsed Ultrasound 
MMA Methyl Methacrylate 
mRNA Messenger Ribonucleic Acid 
MSG Mesenchymal Stem Cell 
MTT 3-(4.5-Dimethvlthiazol-2-vn-2,5-diphenvltetrazolium bromide 
NaCl Sodium Chloride 
NBT Nitroblue tetrazolium 
OPLA Open-cell Polylactic Acid 
OS Osteogenic Medium 
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pQCT Peripheral Quantitative Computational Tomography 
PSF Posterior Spinal Fusion 
ROI Region of Interest 
SVG Van Gieson Stain 
TCP Beta-tricalcium Phosphate 
TV Tissue Volume 
viii 




Table of Contents ix 
List of Tables xv 
List of Tables xv 
List of Figures xvi 
Major Conference Presentations xix 
Publications in Preparation xxii 
Chapter 1 Study Background - 1 -
1. Introduction - 2 -
1.1. Spinal Deformities - 2 -
1.1.1.Treatment - 2 -
1.2. Spinal fusion - 4 -
1.2.1. Gold Standard of Spinal Fusion - 4 -
1.2.2. Decortication in Spinal Fusion - 4 -
1.2.3. Autograft in Spinal Fusion - 4 -
1.2.4. Local Factors Influencing Spinal Fusion - 5 -
1.2.5. Ultimate Goals of Spinal Fusion - 7 -
1.2.6. Limitations of Spinal fusion - 7 -
1.3. Alternatives of Different Components for Enhancing Spinal Fusion 
- 9 -
1.3.1. Bone Graft Substitute - 9 -
1.3.2. Bioactive Factors - 1 5 -
ix 
1.4. Limitations of the Alternative Methods in Spinal Fusion Enhancement.. - 19 -
1.4.1. BMPs - 19-
1.4.2. Gene Therapy -20 -
1.4.3. Biophysical Stimulation - 20 -
1.5. Recent Methods in Enhancing Spinal Fusion - 21 -
1.5.1. Low Intensity Pulsed Ultrasound -21 -
1.5.2. Mesenchymal Stem Cells in Spinal Fusion - 24 -
1.6. Conclusion - 26 -
Chapter 2 Hypothesis, Objectives and Plan of Study - 29 -
2. Hypothesis, Objectives and Plan of Study - 30 -
2.1 Study Hypothesis: -31 -
2.2 Study Objectives -31 -
2.3 Plan of Study - 3 2 -
2.3.1 For First Objective - 32 -
2.3.2 For Second Objective - 32 -
2.3.3 For Third Objective - 33 -
Chapter 3 In vitro Study of Effect of Low Intensity Pulsed Ultrasound on 
Mesenchymal Stem Cells - 34 -
3.1. Introduction - 35 -
3.2. Materials and Methods - 36 -
3.2.1. Experimental Animal - 36 -
一3.2.2. Materials and Reagents - 36 -
3.2.2.1. Dulbecco's Modified Eagle Medium (DMEM) - 36 -
3.2.2.2. Phosphate Buffered Saline (PBS) - 37 -
3.2.2.3. Osteogenic Medium (OS) - 37 -
XV 
3.2.2.4. Alkaline Phosphatase (ALP) Buffer - 37 -
3.2.2.5. ALP Substrate Buffer - 38 -
3.2.2.6. MTT Stock Solution - 38 -
3.2.2.7. MTT Working Solution - 38 -
3.2.2.8. Lysis buffer - 3 8 -
3.2.2.9. Alkaline Phosphatase (ALP) Working Reagents - 39 -
3.2.3. Isolation of Bone Marrow Derived Mesenchymal Stem Cells (BM 
derived MSCs) - 39 -
3.2.4. In vitro Low Intensity Pulsed Ultrasound Treatment - 40 -
3.2.4.1. In vitro LIPUS Devices - 40 -
3.2.4.2. Treatment Procedure and Experimantal Groupings - 40 -
3.2.5. Effect of LIPUS on Cell Viability and Osteogenesis in bone marrow 
derived-MSCs -41 -
3.2.5.1. Cell Viability Assay -41 -
3.2.5.2. Alkaline Phosphatase (ALP) Enzyme Activity - 42 -
3.2.5.3. Cell Morphology and Alkaline Phosphatase Cytochemistry - 42 -
3.2.6. Statistical Analysis - 43 -
3.3. Results - 4 3 -
3.3.1. Morphology -43 -
3.3.2. Total Number of Viable Cells - 44 -
3.3.3. ALP Activity Absorbance - 44 -
3.3.4. ALP staining -45 -
3.3.5. Qualitative Analysis - 45 -
3.3.6. Quantitative Analysis - 46 -
3.4. Discussion - 46 -
xi 
3.4.1. LIPUS have No Enhancing Effect on Proliferation ofMSCs in Basal 
Medium Nor Osteogenic Medium - 47 -
3.4.2. LIPUS Stimulate Proliferation ofMSCs in Early Period - 49 -
3.4.3. LIPUS Further Enhanced Osteogenesis ofMSCs in Osteogenic 
Medium - 49 -
3.4.4. 10 mins LIPUS treatment for 7 days can positively enhance osteogenic 
differentiation - 50 -
3.4.5. Optimum Conditions of LIPUS was Cell Type Dependent -51 -
3.4.6. LIPUS Promoted Osteogenesis in MSCs through Accelerated 
Mineralization - 52 -
Chapter 4 Enhancement of Posterior Spinal Fusion - The Effect of 
Tissue-Engineered MSG and Calcium Phosphate Ceramic composite treated with 
LIPUS in Vivo - 68 -
4.1. Introduction - 69 -
4.1.1. TCP Biomaterials - 7 0 -
4.2. Materials and Methods - 71 -
4.2.1. Materials and Reagents - 71 -
4.2.2. Preparation of MSG Derived Osteogenic Cells-tricalcium Phosphate 
Ceramics Composite - 73 -
4.2.3. Posterior Spinal Fusion Surgery - 74 -
4.2.4. In vivo LIPUS treatment - 75 -
4.2.5. Assessment of Fusion Mass - 76 -
4.2.6. Histology - 7 7 -
4.2.7. Statistical Analysis - 79 -
4.3. Results - 7 9 -
xii 
4.3.1. Fusion by Manual Palpation - 79 -
4.3.2. pQCT Analysis - 8 0 -
4.3.3. Histological Analysis - 81 -
4.4. Discussion - 85 -
4.4.1. Summary of the Findings from Different Assessment Methods - 85 -
4.4.2. Addition ofMSCs to TCP ceramic in Spinal Fusion - 87 -
4.4.3. The Needs of Differentiated MSG in Spinal Fusion - 89 -
4.4.4. bFGF Masked the Effect of OS in MSG - 91 -
4.4.5. LIPUS Enhanced Bone Formation - 95 -
4.4.6. LIPUS Enhanced Bone Formation through Mineralization - 96 -
4.4.7. LIPUS Enhanced Spinal Fusion through Bone Remodeling-induced 
Fusion Mass - 97 -
4.4.8. LIPUS Enhanced Bone Formation through Endochondral Ossification ..… 
- 9 9 -
Chapter 5 In Vivo Monitoring of Spinal Fusion in Animal Model with 
High-resolution Peripheral Quantitative Computed Tomography-A New Pilot Study -
122-
5.1. Introduction - 123 -
5.2. Materials and Methods - 124 -
5.2.1. Animal Groupings -124 -
5.2.2. Preparation of MSG Derived Osteogenic Cells-tricalcium Phosphate 
Ceramics Composite - 124 -
5.2.3. Posterior Spinal Fusion Operation Procedures - 125 -
5.2.4. LIPUS treatment - 125 -
5.2.5. High-resolution Peripheral Quantitative Computed Tomography..…-125 -
xiii 
5.2.6. Analysis with HR-pQCT - 126 -
5.3. Result - 128 -
5.3.1. Qualitative Observations from HR-pQCT Images - 128 -
5.3.2. Quantitative Analysis - 129 -
5.4. Discussion - 130 -
Chapter 6 Overall Summary, Discussion and Conclusion - 140 -
6.1. Overall Summary and Discussion - 141 -
6.2. Limitations and Further Studies - 145 -
6.3. Conclusions - 147 -
6.4. Summary Flowchart of the whole thesis - 148 -
References - 153 -
xiv 
List of Tables 
Page No. 
Table 1.1 The effects of low intensity pulsed ultrasound on in vitro 27 
cell model system 
Table 3.4.1 Summary of Optimum Conditions for Osteogenic 67 
Differentiation by LIPUS in Various Cell Types in Terms 
of ALP Activity. 
Table 4.2.1. Experimental treatment, group code and sample size. The 102 
fusion site of all the groups was decorticated. 
Table 4.3.1. Fusion rate by manual palpation. 106 
Table 4.3.2 Summary of all the results with different evaluations. 121 
XV 
List of Figures 
Page No 
Figure 3.3.1 Typical microphotograph of normal bone marrow derived 54 
mesenchymal stem cell in this study. 
Figure 3.3.2 Microphotograph of MSCs in passage 2 under different 55 
treatments at Day 1，4 and 7. 
Figure 3.3.3 Viable cell numbers of bone marrow derived 57 
mesenchymal stem cells cultured in basal medium with or 
without osteogenic supplements. 
Figure 3.3.4 Viable cell numbers of bone marrow derived 58 
mesenchymal stem cells with LIPUS cultured in basal 
medium. 
Figure 3.3.5 Viable cell numbers of bone marrow derived 59 
mesenchymal stem cells with LIPUS cultured in basal 
medium with osteogenic supplements. 
Figure 3.3.6 Alkaline phosphatase enzymic activity of bone marrow 60 
derived mesenchymal stem cells cultured in basal 
medium with or without osteogenic supplements. 
Figure 3.3.7 Alkaline phosphatase enzymic activity of bone marrow 61 
derived mesenchymal stem cells with 10 min LIPUS 
cultured in basal medium with or without osteogenic 
supplements. 
Figure 3.3.8 Alkaline phosphatase enzymic activity of bone marrow 62 
derived mesenchymal stem cells with 20 min LIPUS 
cultured in basal medium with or without osteogenic 
supplements. 
Figure 3.3.9 Effect of LIPUS on the alkaline phosphatase enzymic 63 
activity of bone marrow derived mesenchymal stem cells 
cultured in basal medium. 
Figure 3.3.10 Effect of long term LIPUS on the alkaline phosphatase 64 
enzymic activity of bone marrow derived mesenchymal 
stem cells cultured in osteogenic supplements. 
Figure 3.3.11 Effect of LIPUS (10 min daily for 7 days) on the alkaline 65 
phosphatase of bone marrow derived mesenchymal stem 
cells cultured under different treatments by NBT/BCIP 
staining. 
Figure 3.3.12 Effect of LIPUS (10 min daily for 7 days) on the labeled 66 
area of alkaline phosphatase of bone marrow derived 
mesenchymal stem cells cultured in osteogenic 
supplements by NBT/BCIP staining. 
Figure 4.2.1 BV and BMC of transverse processes measurement by 103 
pQCT. 
Figure 4.2.2 Gap distance between transverse processes measurement 103 
xvi 
Figure 4.2.3 Tissue volume (TV) (contour area) and bone volume 103 
(BV) (mineralized tissue) of transverse processes 
measurement. 
Figure 4.2.4 Length of transverse processes measurement 103 
Figure 4.2.5 Integrated length at interface between transverse 104 
processes and TCP block measurement 
Figure 4.2.6 Mineralized tissue in TCP measurement 104 
Figure 4.2.7 Mineralized tissue in TCP 104 
Figure 4.2.8 Cartilaginous tissue in intertransverse process region 105 
measurement 
Figure 4.2.9 Cartilaginous tissue in intertransverse process region 105 
Figure 4.3.1 Bone mineral content of transverse processes by pQCT. 107 
Figure 4.3.2 Bone volume of transverse processes by pQCT. 108 
Figure 4.3.3 General histomorphology of L5 and L6 transverse 109 
processes contacted with TCP ceramic stained with 
Stevenel's blue 
Figure 4.3.4 Gap distance between L5 and L6 transverse processes. 111 
Figure 4.3.5 Bone volume of L5 and L6 transverse processes. 112 
Figure 4.3.6 Tissue volume of L5 and L6 transverse processes. 113 
Figure 4.3.7 Bone volume/tissue volume of L5 and L6 transverse 114 
processes. 
Figure 4.3.8 Total length of L5 and L6 transverse processes. 115 
Figure 4.3.9 Integrated length/ total length of transverse processes. 116 
Figure 4.3.10 Mineralized tissue in TCP 117 
Figure 4.3.11 Cartilaginos tissue within the intertransverse process 118 
region. 
Figure 4.3.12 Sagittal undecalcified sections of transverse process with 119 
fluorescence labeling 
Figure 4.3.13 Fluorescent (calcein green) labeled area in transverse 120 
process. 
Figure 5.2.1 ROI of TCP implant valuation. 133 
xvii 
Figure 5.2.2 ROI of transverse processes evaluation 133 
Figure 5.3.1 HR-pQCT images observed in posterior view. 134 
Figure 5.3.2 HR-pQCT images observed in anterior view. 135 
Figure 5.3.3 HR-pQCT images observed in lateral side. 136 
Figure 5.3.4 Net bone mineral content (%) in proximal TCP implant 137 
Figure 5.3.5 Net bone mineral content (%) in distal TCP implant 138 
Figure 5.3.6 Bone volume in anteriorly and latertal to the implant. 139 
xviii 
Major Conference Presentations 
1. Hui CFF, Chan CW, Qin L, Li G，Lee KM, Hu YY，Leung KS, Cheng JCY. 
2008. Low intensity pulsed ultrasound enhances spinal fusion supplemented with 
tissue engineered biomaterial composite. The International Conference on 
Osteoporosis and Bone Research, October 23-25, Beijing, China. 
2. Hui CFF, Chan CW, Qin L，Li G，Lee KM, Hu YY, Leung KS, Cheng JCY. 
2008. Osteogenic enhancement of low intensity pulsed ultrasound on bone 
marrow mesenchymal stem cell. The International Conference on Osteoporosis 
and Bone Research, October 23-25, Beijing, China. 
3. Hui CFF, Chan CW, Qin L，Li G，Lee KM, Hu YY, Leung KS, Cheng JCY. 
2008 Low intensity pulsed ultrasound enhanced osteogenic differentiation on 
bone marrow mesenchymal stem cell. The Hong Kong Orthopaedic Association. 
The Hong Kong Orthopaedic Association, 29-30 November, Hong Kong. 
4. Chan CW, Hui CFF, Pan WM, Lee KM, Qin L，Hu YY, Leung KS, Cheng JCY. 
2008 Enhancement of Low Intensity Pulsed Ultrasound on Spinal Fusion 
augmented with Stem cell-Bioceramic Composite. Studies in health technology 
and informatics 140:361. 
5. Chan CW, Lee KM, Qin L, Yip RCL, Hui CFF, Hu YY, Cheng JCY. 2007. 
Tissue engineered composite of osteo-differentiated mesenchymal stem 
cell-bioceramics enhanced non-decorticated posterior spinal fusion. Hong Kong 
Journal of Orthopaedic Surgery. 11 :S75. 
6. Chan CW, Hui CFF, Qin L, Li G，Lee KM, Hu YY, Leung KS, Cheng JCY. 
2009. Low Intensity Pulsed Ultrasound Treatment on Spinal Fusion Augmented 
with Tissue Engineered Biomaterial Composite. The 55山 Annual meeting of 
xix 
Orthopaedic Research Society, 22 - 25 February, Las Vegas, Nevada, USA. 
7. Chan CW, Hui CFF, Pan WM, Lee KM, Qn L，Yip RCL, Hu YY, Leung KS, 
Cheng JCY. Low Intensity Pulsed Ultrasound Enhanced Spinal Fusion 
Implanted with Tissue Engineered Composite. The 8"' World Biontaterials 
Congress, 28 May-1 Jim, Amsterdam, The Netherlands. 
8. Chan CW, Lee KM, Qn L, Yip RCL, Hui CFF, Hu YY, Cheng JCY. Tissue 
engineered Composite of Stem cell-Bioceramics Enhances Non-decorticated 
Posterior Spinal Fusion. The S"' World Biontaterials Congress, 28 May-1 Jun, 
Amsterdam, The Netherlands 
9. Chan CW, Hui CFF, Lee KM, Qn L，Yip RCL, Hu YY, Cheng JCY. 
Effectiveness of Osteo-differentiated Stem Cell-Calcium Phosphate Ceramic 
Composite in Posterior Spinal Fusion. The 8^'' World Biontaterials Congress, 28 
May-1 Jun, Amsterdam, The Netherlands. 
10. Chan CW, Hui CFF, Pan WM, Lee KM, Qin L，Hu YY, Cheng JCY. 2008. 
Enhancement of low intensity pulsed ultrasound on spinal fusion augmented 
with stem cell-bioceramic composite. The 7th International Research Society 
of Spinal Deformities (IRSSD) meeting, Jul 9-12 Liverpool, United Kingdom. 
11. Chan CW, Hui CFF, Pan WM, Lee KM, Qin L，Hu YY, Cheng JCY. 2008. 
Tissue engineered stem cell-bioceramic composite enhance posterior spinal 
fusion without decortication. The 15th International Meeting on Advanced 
Spine Techniques, July 8-11, Hong Kong. 
12. Chan CW, Ng BKW, Hui CFF, Pan WM, Lee KM, Qin L，Hu YY, Cheng JCY. 
2008. Enhancement of tissue engineered stem cell-tricalcium phosphate 
composite on posterior spinal fusion with non-decortication approach. 
SICOT/SIROT 2008 XXIV Triennial World Congress, Aug 24-28, Hong Kong. 
XV 
13. Chan CW，Hui CFF, Pan WM, Lee KM, Qin L, Hu YY，Cheng JCY. 2008. 
Tissue engineered stem cell-bioceramic composite enhance posterior spinal 
fusion without decortication. The Scoliosis Research Society Annual 
Meeting, Sep 10-13, Salt Lake City, USA. (The John H Moe Award Nominee 
for Best Basic Science Presentation) 
14. Chan CW, Li G, Hui CFF, Lee KM, Qin L, Hu YY, Pan WM, Leung KS, 
Cheng JCY. 2008. The efficacy of low intensity pulsed ultrasound treatment on 
experimental spinal fusion implanted with tissue engineered composite. The 2nd 
International Symposium on Biotechnology in Musculoskeletal Repair. 
October 2-4，Lausanne, Switzerland 
15. Chan CW, Hui CFF, Qin L，Li G，Lee KM, Hu YY, Cheng JCY. 2008. 
Augmentation of undecorticated posterior spinal fusion with tissue engineered 
stem cell-tricalciiim phosphate composite. The International Conference on 
Osteoporosis and Bone Research, October 23-25, Beijing, China. 
16. Chan CW, Hui CFF, Li G, Qin L，Lee KM, Hu YY, Leung KS, Cheng JCY. 
2008. Efficacy of low intensity pulsed ultrasound treatment on spinal fusion 
augmented with tissue engineered biomaterial composite. The Hong Kong 
Orthopaedic Association, 29-30 November, Hong Kong. 
17. Chan CW, Qin L，Hu YY, Lee KM, Hui CFF, Yip RCL, Yeung HY, Cheng 
JCY. 2007. Enhanced spinal fusion by tissue engineered composite of 
mesenchymal stem cell-tricalcium phosphate bioceramics. The Second 
Congress of Chinese Orthopaedic Society-Chinese Orthopaedic Association. 
8-11 November. Zheng Zhou, Henan, China. Abstract book page 21. (The 
Excellent Oral Presentation Award paper). 
xxi 
Publications in Preparation 
1. Low intensity pulsed ultrasound enhances posterior spinal fusion implanted with 
mesenchymal stem cells-calcium phosphate composite without bone grafting 
Target Journal: Spine (Under review) 
2. The effect of low intensity pulsed ultrasound on the proliferation and 
differentiation of mesenchymal stem cells 
Target Journal: Ultrasound in Medincine and Biology (Manuscript In 
preparation) 
xxii 
Chapter 1 Study Background 
- 1 -
1. Introduction 
1.1. Spinal Deformities 
Spinal deformities are very common in all ages (Anderson, 1995) which include 
different types of scoliosis in children, adolescent idiopathic scoliosis as well as 
spinal degenerative disease in adults and geriatric population. Severe scoliosis 
without proper treatment may cause significant structural and functional disabilities 
and mortality due to cardiopulmonary failure (Lehmann and LaRocca, 1981). 
1.1.1. Treatment 
1.1.1.1. Observation 
Periodic clinical follow up observations is often prescribed for patients with 
mild spinal deformity. Serial clinical photographs and standard radiographs are taken 
at regular intervals to watch out for progression of the spinal deformties and 
associated clinical problems or complications. 
1.1.1.2. Bracing 
Children or adolescents with mild or moderate spinal deformity do not usually 
need extensive surgical correction may benefit from conservative treatment such as 
bracing. It is probably still the most widely accepted indication in treating skeletally 
immature patients with curves that measure between Cobb angle of 25 to 40 degrees. 
Radiological progression of the curve more than 5 degrees in patients in whom the 
previously recorded measurement was less than 25 degrees is another indication for 
bracing. 
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The primary goal of bracing for scoliosis is to prevent the progression of 
curvature during the rapid peri-pubertal growth phase. 
A number of studies have shown that bracing produces better results than 
observation alone. Lonstein and Winter reported that observation alone led to more 
failures than bracing, Nachemson and Peterson showed a success rate of 74% with 
bracing whereas the success rate with observation was only 34% (Nachemson and 
Peterson, 1995). In contrast, study also found bracing did not reduce the proportion 
of children with adolescent idiopathic scoliosis who require surgery for cosmetic 
improvement of their deformity (Goldberg et al.’ 2001). 
1.1.1.3. Surgical Treatment 
Spinal instrumentation and fusion plays a very important role in the treatment of 
many serious pathologic conditions, including spinal trauma, congenital abnomalies, 
degenerative diseases and tumors. It was first reported in 1911 in the United States 
for the treatment of severely affected spinal deformities by Hibbs and Albee (Albee, 
2007, Hibbs, 2007). The utilization of spinal fusion surgery in the treatment of 
degenerative disc disease also increased rapidly (Cowan et al, 2006). Moreover, 
spinal fusion became the most common surgery for autologous bone grafting since 
the 1990s (Sandhu et al., 1999). It is estimated that over 500,000 bone grafting per 
year are performed in the United States and half of these procedures related to spine 
fusion (Greenwald et al.’ 2001, Boden, 1998). 
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1.2. Spinal fusion 
1.2.1. Gold Standard of Spinal Fusion 
Harvesting and implantation of autologous iliac crest (IC) bone with 
decortications at the site of the spinal fusion are the "gold standard" to promote 
spinal fusion. 
1.2.2. Decortication in Spinal Fusion 
Decortication was first reported in 1924 by Hibbs. The cortical bone was poorly 
vascularized and thus had poor regeneration ability even after the periosteum was 
removed. So the cortex needed to be removed from the fusion site (Hibbs, 1988) 
Decortication is performed by meticulous subperiosteal dissection and removal of the 
cortex of posterior part of spinal vertebrae down to bleeding cancellous bone from 
the fusion site (Kaufman and Jones, 1989). Although decortication weakens the 
host bone biomechanics, it is believed that decortication provides important 
osteogenic component at the fusion site. The exposed bone marrow provides a rich 
source of progenitor cells for bone formation and mesenchymal stem cells which are 
capable to differentiate into bone forming cells. Previous studies have also shown 
that there is rich pool of growth factors favor to bone formation in bone marrow 
(Canalis et al., 1988). Taken together, it is generally accepted that decortication is the 
standard procedure for spinal fusion including posterior spinal fusion. 
1.2.3. Autograft in Spinal Fusion 
Autograft is a bone graft collected from one place in the body and transplanted 
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into another region in the same individual. Autograft is mainly collected from iliac 
crest and implanted to the fusion site. When implanted fresh, autografts contains 
many growth factors and osteoinductive agents such as bone morphogenetic proteins 
which are well-known in the enhancement of bone formation (Urist et al, 1982). 
An ideal autograft plays an important role in promoting bone formation at the 
fusion site. The functional roles of autograft are as follows: 
1) osteogenic effect: the present of osteoblasts and osteoprogenitor cells in fresh 
bone graft which are capable of forming new bone under favorable conditions 
(Burwell, 1964); 
2) osteoinductive effect: the present of many growth factors and osteoinductive 
agents e.g. bone morphogenetic proteins (Urist et al, 1982) which induce the 
differentiation of MSCs to osteoblasts and form new bone (Sampath et al., 1987); 
3) osteoconductive effect: the graft acts as a scaffold for infiltration of 
osteoprogenitor cells with blood vessels, and perivascular tissues from the host bed 
(Takaoka et al., 1988). 
1.2.4. Local Factors Influencing Spinal Fusion 
In addition to the aforementioned factors that affect the posterior spinal fusion, 
the components of the tissue bed that contribute most to the healing process in spinal 
fusion are its blood supply, cells associated with inflammatory response, and cells 
responsible for osteogenesis. 
The quality of the blood supply at the fusion site is an important factor of bone 
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healing as local blood supply contains many functions: 1) acts as a source of oxygen 
and nutrients to the healing tissue, as well as a control of local pH 2) acts as a vehicle 
for stimulating endocrine 3) acts as a conduction pathway for the inflammatory cells 
involved which then produce paracrine factors that may induce the earlier 
proliferation of osteoblastic progenitor cells as well as reduce the potential for 
infection 4) act as a source of endothelial cells, which produce paracrine factors that 
may enhance osteoblastic differentiation (Baran et al., 1978). 
The inflammatory response in the fusion site also represents a critical 
component in the healing process. After the surgical procedure, polymorphonuclear 
cells, lymphocytes, monocytes and macrophages migrate to the fusion site and 
perform their various functions. Among their functions, the most important one in 
affecting vascular endothelial cells and oseoblastic progenitors in the graft site is the 
local production of paracrine signals: cytokines, kinins and prostaglandins. These 
messages act as chemotactic signals and growth factors which will then affect the 
migration, differentiation and activity of a variety of cells including modulation of 
local blood flow and angiogenic response of local endothelial cells. 
Host bone itself is also known to have a profound effect on the healing process 
in spinal fusions and the role of autograft is described previously in Chapter 1.2.3.2. 
Osteogenic cells in the fusion site are another component affecting the outcome 
of bone fusion. Spinal fusion requires osteoprogenitor cells to enter the fusion area. 
Decortications allow blood cells and mesenchymal stem cells (MSCs) to migrate to 
the fusion site from bone marrow (Toribatake et al., 1998). MSCs then differentiate 
into osteoblasts which produce and deposit new bone matrix to the transplanted bone 
graft. Remodeling (Wolff's law) occurs in the fusion site and allows new bone 
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formation and mature fusion mass (Ludwig and Boden，1999). 
1.2.5. Ultimate Goals of Spinal Fusion 
The goals of spinal instrumentation and fusion in deformity treatment are to 
obtain a solid fusion with a balanced spine, to relieve pain, and to prevent further 
deformity. A secondary goal is to achieve curve correction and thus to improve the 
cosmetic appearance. 
1.2.6. Limitations of Spinal fusion 
From the literature, failure to achieve a solid fusion (non-union) occurs in 
5-35% (Steinmann and Herkowitz, 1992, DePalma and Rothman, 1968). Failure of 
spinal fusion could result in significant morbidity (Lehmann and LaRocca, 1981)). 
Delayed or non-union is often related biologically to a lack of osteogenic 
precursor cells and poor vascularization at the fusion site, especially in 
non-decorticated PSF in addition to abnormal mechanical stability or mobility 
(Stevenson et al, 1996). However, the pathology of non-union in PSF is still not well 
studied. In previous studies (Cheng et al, 2002，Guo et al, 2002，Boden et al, 1995b) 
of PSF in rabbit intertransverse fusion models, both membranous ossification and 
endochondral ossification were found and occurred in different regions of the fusion 
site. Membranous bone formation with active angiogenesis was found to occur early 
and near the peripheral sites of the fusion mass. A later repair response was observed 
between the adjacent transverse processes (central zone) where endochondral bone 
formation with fewer blood vessels occurred. The mechanical cartilage strength was 
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only 10% of that of trabecular bone by nanoindentation test (Guo et ai, 2001). It 
showed that the mixture of cartilage and trabecular bone was mechanically less 
homogeneous. This lag effect in the central zone helps explain why nonunion occur 
more often in the central zone of the fusion mass. 
In order to increase the fusion rate, it would be the best if enhancement of new 
bone in the central zone can be achieved by adding sufficient osteogenic cells at the 
fusion site. 
Although autograft is able to promote new bone formation (Buckwalter et ai, 
1996) significant problems and disadvantages are associated with bone grafting and 
decortication techniques itself. 
Besides the 5 to 35% non-union rate, harvesting of bone graft causes donor site 
morbidity as many as 30% of patients (Hacker, 2000, Ludwig et ai, 2000). The most 
common complications are significant blood loss, chronic donor site pain, infection, 
fracture, hematoma, increased operation time and costs (Schnee et ai, 1997， 
Arrington et ai, 1996，Banwart et ai, 1995, Fernyhough et al, 1992). More than 
35% of patients reported pain 6 months postoperatively and 19 to 31% of patients 
continued to report pain more than 2 years postoperatively (Sasso et al, 2005, Goulet 
et al.’ 1997). 
Although as of today, the concept of decorticated PSF remains as "gold 
standard" clinically for treating spinal deformities, motivation to search for better 
alternative to ensure the effectiveness，rate and quality of solid bone fusion is a 
common goal. 
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1.3. Alternatives of Different Components for Enhancing Spinal Fusion 
To enhance the bone formation in posterior spinal fusion, research has been 
carried to find alternatives to replace the key components for spinal fusion: 1) the 
scaffold; 2) biological factors 3) bone forming cells. The following section 
introduces the attempts reported in the literature. 
1.3.1. Bone Graft Substitute 
A bone graft substitute is unique because it can replace autogenous bone graft 
and reduce the morbidity associated with harvesting of autogenous bone graft . 
The substitute should support bone formation through direct interaction with 
target fusion bed and cells. It acts as an attached substrate to deliver the appropriate 
binding agent (growth factors/autogenous cells) to the local environment. 
A ideal scaffold should contain the following functions: 1) maximizes the 
effects of osteoinductive and ostegenic agents delivered to the fusion site; 2) acts as 
an osteoconductive scaffold with appropriate pore size for bone ingrowth, cellular 
and vascular passage; 3) limits local effects of space occupying delivery systems and 
not compete with or limit bone formation; 4) limited inflammatory response through 
its biocompatibility; 5) allows for timed removal of carrier structure by 
biodegradability and limiting deleterious effects of biomechanical nature of new 
bone formation. 
1.3.1.1. Allograft 
Allograft can function as an effective graft extender or carrier when autogenous 
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graft sources are limited. Allograft can act as osteoconductive scaffold for bone 
formation but has no osteoinductive or osteogenic potential. 
Controversial results reported from clinical and experimental studies using 
allograft bone in spinal fusion. Some investigators found allograft to be significantly 
inferior to using autogenous bone graft (Knapp and Jones, 1988) whereas other found 
little or even no difference between autograft and allograft (McCarthy et al., 1986, 
Malinin and Brown, 1981，Brown et al, 1976). The potential immunological reaction 
and infection transmission from the donor through allograft remains as one of the 
many concerns. 
1.3.1.2. Demineralized Bone Matrix (DBM) 
Urist first reported the osteoinductive capacity of DBM in 1956 (Urist, 2002) 
prepared form allograft bone by decalcification of cortical bone. This process leaves 
the extracellular matrix that contains type I collagen and the nonstructural proteins 
including small amounts of growth factors. Due to the collagen remained, DBM has 
variable osteoconductive potential (Ludwig and Boden, 1999). 
In animal spinal fusion models, DBM has been tested as bone graft substitute 
and as an autogenous bone graft extender. DBM consistently performs better than 
mineralized allograft bone but not as well as autogenous bone in small animal 
models (Morone and Boden, 1998，Cook et al, 1995). 
A rabbit bilateral posterolateral spine arthrodesis at L5-L6 model compared the 
efficacy in using autogenous iliac crest bone graft alone or in combination with 
demineralized bone matrix. Similar fusion rates (66-73%) have been reported based 
- 1 0 -
on manual palpation. Rabbits implanted with demineralized bone matrix had more 
mature fusion masses (Morone and Boden, 1998). 
Another report from Cook et al.’ compared the fusion rate of autograft, allograft, 
DBM and combination of allograft with DBM in posterior lumbar spinal fusion in 
adult mongrel dogs (Cook et al., 1995). Radiographic studies showed that autograft 
bone sites achieved stable fusion by 26 weeks after surgery but not in other groups. 
Some new bone formation at 6 and 12 weeks was observed in demineralized bone 
matrix alone and with allograft bone. Mechanically, the autograft fusion sites also 
demonstrated the highest torsional stability than that of all other fusion sites at all 
time periods. These indicate that DBM alone or with allograft bone is ineffective in 
achieving stable posterior spinal fusions. 
DBM has also been studied in human, Sassard et al., compared posterolateral 
fusion rate of patients implanted with local autogenous bone graft with DBM vs 
autograft alone. Low fusion rates were reported for both groups, 60% and 56% 
respectively without significant difference (Sassard et al, 2000). Canmmisa et al. 
reported similar findings of equivalent results when comparing DBM and autograft 
composite with autograft alone in posterolateral fusion (Cammisa et al., 2004). 
1.3.1.3. Collagens 
Due to its biocompatibility, ease of degradation and interaction with other 
bioactive molecules including proteins, collagen has a long history of use in surgical 
applications. The effectiveness of various types of collagen including sponges or 
together with other composites has been studied in spinal fusion. 
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Since the discovery of bone morphogenetic protein (BMP) by Urist in 1965， 
collagen has been widely studied as a carrier with BMPs. Absorbable collagen 
sponges (ACS) with rhBMP-2 has been used in intertransverse and interbody fusion 
models in animals (Martin et al., 1999，Suh et al, 2002，Hecht et al, 1999). Overall, 
addition of rhBMP-2/ACS led to higher fusion rates without significant adverse 
events or reactions to the BMP or carrier. rhBMP-2/ACS has also been studied in 
human. Burkus et al. showed that patients treated with rhBMP-2/ACS had superior 
outcomes including less length of surgery, operative blood loss, earlier return to work 
times, and greater fusion rates up to 24 months after surgery compared with autograft 
iliac crest bone (Burkus et al, 2003). 
Bovine bone-derived type I collagen also serves as a carrier for rhBMP-7 or 
OP-1 (Stryker Biotech, Hopkinton, MA) and has been reported in a rabbit 
single-level intertransverse process lumbar fusions model, 100% fusion rate was 
found in the OP-1 with collagen group at week 5 and more predominantly maturing 
bone was observed in this group (Grauer et al, 2001). 
In a prospective, randomized controlled clinical trial in posterior lumbar fusion, 
patients receiving iliac crest autograft and OP-1 implant (OP-1 in collagen carrier) 
between the decorticated transverse processes. This study did not demonstrate the 
superiority of OP-1 combined with autograft over an autograft alone, in which the 
fusion rate was approximately 45%. But the safety and the lack of adverse events 
related to the OP-1 putty implant support the safety of bone morphogenetic proteins 
and collagen in spinal surgery (Vaccaro et al, 2003). 
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1.3.1.4. Calcium Phosphate Biomaterials 
In recent years, natural and synthetic forms of calcium phosphate have been 
developed as materials for bone repair and augmentation. This group of materials 
closely resembles the mineral composition, properties, and microarchitecture of 
human cancellous bone and has a high affinity for binding proteins for tissue 
ingrowth, cell attachment, and diffusion of nutrients into the area. 
Calcium phosphate materials are classified by their chemical composition and 
whether it is of natural or synthetic (ceramic) origin. The most common calcium 
phosphate materials include hydroxyapatite (HA), p-tricalcium phosphate (p-TCP), 
biphasic calcium phosphate (combination of TCP and hydroxyapatite). Due to their 
chemical compositions, TCP is resorbed much faster than HA under normal 
physiological condition (Gatti et al, 1990). Therefore, TCP can be degraded faster 
and totally replaced by bone under optimal osteogenic condition. In addition to safe 
and non-allergenic good bone-bonding capacity, calcium phosphate ceramics were 
used as protein delivery system. 
Whereas p-TCP is purely osteoconductive, the addition of growth factors and 
bone marrow aspirate provides the potential for the addition of osteoinductive and 
osteogenic factors to the highly effective scaffold material. Ceramics combined with 
bone morphogenetic proteins and other growth factors has been studied widely 
(Boden et al, 1999，Cheng et al, 2002，Guo et al, 2002, Levine et al, 1997, Sandhu 
et al, 1997). Calcium phosphate ceramics also act as scaffold for cells attachment. 
Studies showed that bone marrow cells seeded on ceramics can form bone when 
implanted subcutaneously (Boo et ai, 2002, Hanada et al., 1997，Kadiyala et al.’ 
1997，Martin et al., 1997). 
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Boden et al have investigated several studies to examine the effect of biphasic 
calcium phosphate granules combined with rhBMP-2 in posterolateral spinal fusion 
models in human and non-human primate subjects (Boden et al., 1999，Boden et al., 
2002). Previous studies have found that although a composite of 60:40 HA:TCP 
acted as an effective carrier, the predominance of HA made its resorption slow and 
radiographic detection of bone formation more difficult (Boden et al, 1999). In a 
follow-up study, the HA:TCP ratio was changed to 15:85 which resulted in a 100% 
fusion rate. Additionally, the authors concluded that the new formulation of HAiTCP 
(15:85) was more compression-resistant and resulted in better radiographic 
visualization of new bone formation (Akamaru et al, 2003). In a pilot prospective 
randomized clinical trial, Boden et al. evaluated rhBMP-2 on a biphasic calcium 
phosphate carrier in single-level posterolateral lumbar fusion with or without 
instrumentation (Boden et al.’ 2002). Radiographic and clinical outcome data suggest 
that this BMP with HA/TCP composite delivery system is an effective in promoting 
solid fusion. 
1.3.1.5. Biodegradable Polymers 
Another type of carrier material is the biodegradable polymers including 
polylactic acid (PLA) and polyglycolic acid (PGA) which are organic compounds for 
delivery of osteoinductive agents. As these carriers are degraded, any containing 
factors may then be locally released, making these composites an ideal substrate for a 
growth factor/cell delivery system. 
Studies have been reported using various forms of biodegradable polymers to 
act as carriers of recombinant human BMP-2 in spinal fusion: poly [D，L 
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(lactide-coglycide)] (PLGA) (Muschler et al.’ 1994), open-cell polylactic acid 
polymer delivery vehicle (OPLA) (Sandhu et al, 1995)，collagen (Helistat) morsels 
/PLGA /OPLA (Fischgrund et al, 1997). And it has been described in the following 
Chapter 1.3.2.1. 
1.3.2. Bioactive Factors 
1.3.2.1. Bone Morphogenetic Proteins in Spinal Fusion 
Bone morphogenetic proteins (BMPs) are a series of soluble, 
low-molecular-weight glycoproteins which are well-known for inducing bone 
formation by Urist (Urist et al., 1982). The osteogenic effects ofBMP-2, BMP-4 and 
BMP-7 have been widely investigated in spinal fusion models. 
Recombinant human BMP-2 (Genetics Institute, Cambridge, MA) has been 
investigated in detail in different animal spinal fusion models combined with various 
carriers. In dogs: the protein rhBMP-2 was combined to the following carriers: type I 
collagen (David et al.’ 1999) sintered bovine bone, poly [D，L (lactide-coglycide)] 
(PLGA) (Muschler et al” 1994)，open-cell polylactic acid polymer delivery vehicle 
(OPLA) (Sandhu et al, 1995), collagen (Helistat) morsels /PLGA /OPLA 
(Fischgrund et al, 1997). In rabbits with following carriers: collagen (Minamide et 
al, 1999，Itoh et al, 1999) and autogenous bone graft (Holliger et al, 1996, 
Schimandle et al.’ 1995). In rhesus monkeys with collagen sponges (Martin et al, 
1999，Hecht et al, 1999)，hydroxyapatite-tricalcium phosphate (Boden et al, 1999). 
And in goat with a BAK device (Zdeblick et al., 1998). 
In Muschler et al. study, the score for union and mechanical testing showed no 
difference between autogenous cancellous bone and rhBMP2/PLGA. Union scores 
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for autogenous cancellous bone and rhBMP-2/PLGA sites were superior to those 
with PLGA alone. The use of such materials was considered to provide efficacy 
equivalent to autogenous cancellous bone (Muschler et al.’ 1994). In Sandhu et al. 
study, radiographically and mechanically solid fusion in rhBMP2 group carried by 
OPLA was superior to autogenous iliac bone in canines by three months (Sandhu et 
al., 1995). In rabbit spinal fusion model, Schimandle et al. also demonstrated that 
rhBMP-2 significantly increased the volume of the fusion mass when used with an 
autogenous iliac crest bone. All rabbits implanted with recombinant human bone 
morphogenetic protein-2 achieved solid spinal fusion by manual palpation and were 
fused radiographically, whereas only 42% of the autograft control fusions were solid 
(Holliger etal, 1996，Schimandle et al, 1995). 
Another bone-inducing growth factors is BMP-7 which is also known as 
osteogenic protein-1 (Stryker Biotech, Hopkinton, MA) was widely studied in spinal 
fusion model. Recombinant human BMP-7 has been used in spinal fusion preclinical 
experimental work using dogs (Paramore et al.’ 1999，Cook et al, 1994) and sheep 
(Cunningham et al., 1999) with collagen (Paramore et al, 1999, Cook et al, 1994) 
and "BAK" device (Cunningham et al.’ 1999) as carrier. Stable and rapid fusion was 
achieved with OP-1 than autologous grafting. Cook et al. reported that in OP-1 group, 
fusion were achieved completely by 12 weeks while autograft group was 26 weeks. 
Similar results were found in Paramore and Cunningham studies. 52% in OP-1 group 
fused while only 25% of control animals fused. Six in eight in OP-1 group fused 
while only two in six fused in autograft group . 
BMP-4 was also studied in rabbit spinal fusion model with 
hydroxyapatite-tricalcium phosphate (HA-TCP) ceramic blocks as the carrier (Cheng 
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et al., 2002, Guo et al., 2002). Even in undecortication approach, histology and 
high-resolution radiography showed 100% solid fusion in high dose BMP-4 group. 
Moreover, active multicentric endochondral bone formation, rapid membranous 
ossification accompanied with active angiogenesis were observed in the peripheral 
sites of the fusion mass. Cartilage was also found in the central zone of the 
intertransverse processes. 
With the addition of BMP-2, 4 and 7，the success spinal fusion rate was 
increased even up to 100% fusion (Guo et al., 2002, Cheng et al.’ 2002, Hecht et al., 
1999，Schimandle et al., 1995, Sandhu et al, 1995). It indicated that BMP-2, 4 and 7 
accelerated the bone formation (Zdeblick et al.，1998) and was able to attract and 
affect the differentiation of bone forming cells from tissues other than bone marrow 
(Holliger et ai, 1996). 
1.3.2.2. Gene Therapy 
Another stream of study uses genetically modified stem cells to increase the rate 
of fusion. Vectors used for gene therapy include naked DNA, liposomes and plasmid 
which contain the complementary DNA with the gene of interest, or viral vectors. 
The most commonly tested delivery vehicle for gene therapy in spinal fusion is 
adenovirus. 
Adenoviral vectors containing different genes related to osteogenesis are 
injected into the fusion site directly of the animals: BMP-9 (Helm et al., 2000)， 
BMP-2 (Zhu et ai, 2004, Alden et al.’ 1999)，Nell-l(Lu et al., 2007), BMP-7 (Zhu et 
al., 2004), BMP-6 (Laurent et al, 2004). 
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Moreover, bone marrow stem cells transfected with a specific gene 
BMP-7(Hidaka et al, 2003),BMP-9 (Dumont et al, 2002)，LMP-1 (Viggeswarapu et 
al, 2001) and Adv-BMP2 (Riew et al, 1998，Riew et al, 2003) by adenovirus was 
implanted to spinal fusion models. All the studies showed enhancement of solid 
fusion and bone formation at the fusion site. Active osteogenesis and large bone mass 
formation also found at the site of implantation. 
1.3.2.3. Biophysical treatment 
The third stream is to use biophysical treatment such as electrical stimulation 
(Kane, 1988，Hodges et al, 2003)，electromagnetic field (Linovitz et al.’ 2002) to 
improve spinal fusion. 
Through direct current electrical bone growth stimulation, fusion rate was 
increased, 81% patients with fusion whereas 54% in control group (Kane, 1988). A 
similar result from another study reported that fusion rates were significantly higher 
in stimulated patients (93% vs. 75%) (Meril, 1994). Most of the published work 
showed positive effect of direct current stimulation in spinal fusion (Hodges et al., 
2003). 
Statistically beneficial in spinal fusion in the overall patient population was also 
demonstrated with the adjunctive use of the combined magnetic field device 
(Linovitz et al., 2002). 
Recently, Low Intensity Pulsed Ultrasound (LIPUS) is reported to enhance 
autograft implanted spinal fusion and increase mechanical strength of the fusion 
mass (Glazer et al.，1998，Cook et al, 2001, Aynaci et al., 2002). 
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1.4. Limitations of the Alternative Methods in Spinal Fusion Enhancement 
1.4.1. BMPs 
Regarding the success of enhancing bone formation by BMPs, some limitations 
associated with the use of BMPs have been reported as followed. The optimal dosage 
is still unknown. Therefore, a single high dose of BMPs is currently used to produce 
and ensure significant osteoinduction as BMPs may not induce same and sufficient 
response in all patients (Peterson et al., 2005). However, it is difficult to deliver an 
adequate amount of protein in a single dose, and high and uncontrolled doses may be 
associated with increased adverse reactions (Bae et al., 2007). Adverse reactions 
include those related to inflammation and soft tissue edema which may occur in a 
dose-dependent manner (Bae et al., 2007). BMP-2 which is currently approved for 
human use has also been reported with local inflammatory reactions including 
postoperative radiculitis(Sanfilippo et al., 2007 ) and soft tissue edema in the lumbar 
spine and clinically significant postoperative neck swelling with its use for anterior 
cervical fusion (Buttermann, 2008, Perri et al, 2007, Vaidya et al., 2007，Shields et 
al, 2006, Smucker et al, 2006). Moreover, BMPs also restricted the spinal canal 
space contributing to symptomatic neurological findings due to ectopic bone 
formation (Wong et al, 2008，Mimatsu et al.’ 1997). Other reported complications 
associated with the applications of BMPs include vertebral osteolysis after posterior 
lumbar interbody fusion (Lewandrowski et al, 2007) and significant early graft 
subsidence resulting in a loss of graft structural support in interbody fusions (Vaidya 
et al” 2007). The cost of BMP is also a significant concern. 
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1.4.2. Gene Therapy 
Although studies indicated the feasibility of using viral transfected gene therapy 
in spinal fusion, the safety of the genetically modification of viral vector, host 
immune response, transfection rates with insufficient transgene expression, imprecise 
control of the timing of transgene expression, issues regarding toxicity, and 
cancer-inducing risk will need to be fully investigated. These make a great drawback 
of its clinical application. 
1.4.3. Biophysical Stimulation 
Controversial results in using electrical stimulation (Jenis et al., 2000) and also 
electromagnetic field (Kahanovitz et al., 1994) in spinal fusion have been reported. 
These indicate that they did not give consistent positive effect in treating spinal 
fusion. 
In a study using canine lumbar spinal fusions model, the effect of pulsed 
electromagnetic fields (PEMF) on the healing was evaluated. The results showed 
no statistical difference in the radiographic or histologic appearance of the fusion 
mass between the stimulated and control groups at either 6 or 12 weeks. The results 
of this study suggest that PEMF stimulation had no clear effect on the healing of the 
posterior spinal fusions (Kahanovitz et al, 1994). 
Similar results have been reported clinically. Radiographic fusion and fusion 
mass bone density were not significantly different among the direct current 
stimulated, electromagnetic field and control groups in patients with instrumented 
lumbar arthrodesis (Jenis et al.’ 2000). 
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1.5. Recent Methods in Enhancing Spinal Fusion 
1.5.1. Low Intensity Pulsed Ultrasound 
Low intensity pulsed ultrasound (LIPUS) is a kind of micromechanical 
stimulation provided by medical device incorporating ultrasound signal. It was 
approved for the acceleration of certain fresh fractures in 1994 and non-unions in 
2000 in the United States by the Food & Drug Administration (Pounder and Harrison, 
2008) based on earlier prospecitve, placebo-controlled, double-blind, randomized 
and multicenter-studies. 
Many in vitro studies (Gebauer et al, 2002, Azuma et al., 2001, Nolle et al, 
2001a, Wang et al, 1994) reported that LIPUS could stimulate a number of cellular 
processes (Table 1.1) associated with the repair processes through angiogenesis, 
chondrogenesis, endochondral ossification and osteogenesis. Several in vivo 
experimental studies demonstrated that LIPUS has beneficial effect on the healing 
process through enhancement of angiogenic, chondrogenic, and osteogenic activities. 
1.5.1.1. Clinical Studies 
LIPUS has been applied in the treatment and enhancement of fracture healing, 
(Leung et al., 2004b, Kristiansen et al, 1997, Heckman et al” 1994) delayed unions, 
and non-unions in the 1990s (Jingushi et al, 2007). 
LIPUS was found to induce significant acceleration of fracture healing by 25% 
faster than the untreated controls (Heckman et al.，1994). Two prospective 
double-blind, randomized, placebo-controlled clinical trials (Heckman et al, 1994, 
Kristiansen et al, 1997) provided the basis for the FDA approval for application of 
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LIPUS in fracture healing. Clinical and radiographic assessments revealed that 
LIPUS significantly were able to decrease the healing time by 38% (Heckman et al, 
1994) and 37% (Kristiansen et al., 1997) as compared to the placebo control group. 
Furthermore, the effects of LIPUS on complex tibial fractures showed 42% 
significant reduction in healing time of LIPUS treated group (Leung et al., 2004b). 
LIPUS is also effective in decreasing delayed union and nonunion rate 
clinically with a success rate of more than 80% (Jingushi et al, 2007, Frankel and 
Mizuho, 2002, Mayr et al” 2002, Nolte et al, 2001b). 
1.5.1.2. In Vitro Studies 
Studies have shown that LIPUS have important effect on proliferation and 
differentiation of the major cell types involved in new bone formation: stimulating 
chondrocyte differentiation (Parvizi et al” 2002, Parvizi et al., 1999，Zhang et al, 
2003); osteoblast differentiation (Takayama et al, 2007，Gleizal et al, 2006, Li et al, 
2006, Li et al., 2003, Yang et al” 2005，Sun et al, 2001, Warden et al., 2001, Naruse 
et al., 2000, Naruse et al, 2003，Doan et al., 1999，Kokubu et al, 1999); bone 
marrow mesenchymal stem cell (BMSC) (Schumann et al., 2006, Sena et al, 2005, 
Sant'Anna et al, 2005, Ebisawa et al., 2004); proliferation and differentiation of 
periosteal cells toward osteogenic lineage (Leung et al., 2004a); and preosteoblast 
differentiation (Bandow et al., 2007, Unsworth et al., 2007). 
1.5.1.3. In Vivo Studies 
Apart from the successful applications of LIPUS in fracture healing and 
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non-union, there is evidence of improved distraction osteogenesis, osteogenesis in 
bone-tendon junction repair as well as spinal fusion. 
LIPUS has been applied to distraction osteogenesis model in rabbits (Chan et al, 
2006b，Chan et al., 2006a, Shimazaki et al, 2000) and sheep (Mayr et al., 2001). The 
results showed that LIPUS was effective in increasing the bone mineral density, 
maturation of regenerate bone, bone formation and remodeling. LIPUS also reported 
to enhance osteogenesis in bone-tendon junction repair (Qin et al, 2006，Lu et al, 
2006) in a rabbit model. 
Studies reported LIPUS enhanced spinal fusion implanted with iliac crest 
autograft in animal models (Glazer et al, 1998，Cook et al.’ 2001，Aynaci et al., 
2002). Glazer et al. and Aynaci et al. compared spinal fusion rates in rabbits with 
autologous bone with or without the addition of LIPUS. In both studies, statistically 
significant increase in fusion rate 90% and 85% in US group as compared with 70% 
and 55% in control group. Superior fusion mass was also observed in treatment 
group by biomechanical testing. In a later study, Cook et al. using canine as spinal 
fusion model with the addition of LIPUS. 100% fusion rate in the LIPUS treatment 
group was reported as compared to 78% in control group. A statistically significant 
increase in mechanical stiffness was also found in the ultrasound treated fusion sites. 
In a more recent study, Chan et al. (Chan et al., 2007) reported the effect of LIPUS 
on bone formation in posterior spinal fusion with hydroxyapatite/tricalcium 
phosphate. Endochondral bone formation was found to be enhanced by LIPUS 
treatment. The inter-process distance decreased 29% significantly in the treatment 
group. Bone area ratio of fusion processes in LIPUS group was 50% greater than 
sham group significantly. Moreover, more cartilage was observed near the newly 
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formed bone area in LIPUS treatment group in contrast to the scarce cartilage tissue 
in the sham group. 
1.5.2. Mesenchymal Stem Cells in Spinal Fusion 
1.5.2.1. Origins and Characteristics of Mesencymal Stem Cells 
Stem cells are cells having the potential to clonally produce multiple lineages of 
cells and capacity for self-renewal. It is well known that bone marrow contains two 
populations of pluripotent progenitor cells: hematopoietic stem cells, which give rise 
to all circulating blood elements, and mesenchymal stem cells (MSCs) 
MSCs are present in many human tissues and serve as a readily available source 
of undifferentiated cells being capable to form specific tissues like bone, cartilage, fat， 
muscle, tendon and ligament (Caplan，1991, Caplan, 2005, Caplan，2007). MSCs are 
able to differentiate into osteogenic lineage to promote bone fusion (Gimble et al., 
1996，Halvorsen et al,’ 2000, Horwitz et al., 2002, Kimelman et ai, 2007, Shen et ai, 
2005). 
MSCs are originally isolated from bone marrow (Friedenstein et al., 1966). In 
addition to bone marrow, various tissues have been found to harbor MSG including 
adipose, muscle, tendon, dental pulp，periodontal ligament, umbilical cord blood, 
placenta, periosteum, liver, cartilage, synovium, synovial fluid, spleen, and thymus 
(Bi et ai, 2007, Gronthos et al.’ 2000, Nakahara et al., 1990，Pountos and 
Giannoudis, 2005, Romanov et al, 2003, Seo et al, 2004, Zannettino et al., 2008). 
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1.5.2.2. Osteogenic Differentiated MSCs for Spinal Fusion 
Recently, interest in using osteoprogenitor cells or osteogenic MSCs derived 
from bone marrow for spinal fusion has increased. Bone marrow aspiration allows 
the introduction of mesenchymal stem cells and ultimately osteoblasts to promote 
fusion. Studies reported that MSCs have potential benefits that may overcome some 
of the limitations described above in different alternative methods for spinal fusion. 
MSCs cultured with osteogenic differentiation medium are more effective in the 
formation of new bone in spinal fusion (Nakajima et al.’ 2007). Nakajima et al 
reported the fusion rate of differentiated MSCs group (80%) was the highest among 
the groups with autograft (67%) and undifferentiated MSCs (33%). New mature bone 
formation was also observed in the groups of autograft and differentiated MSCs 
histologically. This study demonstrated that osteogenic differentiated MSCs were 
more effective in enhancing fusion than undifferentiated MSCs. 
The number of differentiated MSG added to the fusion site can also affect the 
outcome of spinal fusion. Minamide et al.’ reported that implantation of 100 million 
bone marrow cells resulted in solid fusion (71%) and effect not observed in those 
with implantation of only 1 million cells. It illustrated that a critical number of 
osteoprogenitor cells must be present in order to obtain solid fusion (Minamide et al., 
2005，Risbud et al., 2006). 
Equivalent or better spinal fusion rates have been reported with bone graft 
substitutes combined with osteogenic MSCs derived from bone marrow which may 
serve as an alternative to autogenous bone grafting (Cinotti et al., 2004，Gupta et al., 
2007， Kai et al, 2003). Kai et al reported bone marrow derived osteoblasts 
combined with a porous calcium phosphate ceramic composite resulted in 100% 
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fusion as compared with 66% with autograft. Also, fusion mass in the group of bone 
marrow stroma derived osteoblasts was statistically significantly stiffer and stronger 
on biomechanical testing. This group also had a qualitative increase in bone 
formation on histological analysis. 
In larger animals, Gupta et al. (Gupta et al, 2007) also found equivalent fusion 
rates for osteoprogenitor-enriched tricalcium phosphate (33%) compared with 
autogenous bone graft (25%) in a sheep posterolateral lumbar spine model. Denser 
bone was also observed in the osteoprogenitor group. These studies suggested that 
the addition of osteogenic MSCs to various osteoconductive materials could enhance 
fusion rate similar or better than that of autograft. 
1.6. Conclusion 
Despite the advances in research related to bone fusion and particularly spinal 
fusion, the need to substitute for the "gold standard" of autograft to enhance bony 
fusion, further minimize the problems of non-union rate and associated 
complications of autograft harvesting in clinical practice remains an important area 
for multidisciplinary and cross-disciplinary research. The series of studies included 
in this thesis constituted part of our contribution to these collective efforts 
internationally while focusing on the optimizing the application of low intensity 
pulsed ultrasound on tissue engineer new bone substitute impregnated with bone 
marrow mesenchymal stem cells in a posterior spinal fusion model. 
- 2 6 -
Table 1.1 The effects of low intensity pulsed ultrasound on in vitro cell model system 
V e i l type Experimental Endings Study “ 
j^at Increased expression of alkaline 
• phosphatase, Runx2, Msx2, Dlx5, Takayama 
osteosarcoma ^ ^ . , . , ' . ‘ / 
eell line ROS Ostenx，bone sialoprotein, et al, 
o II mineralized nodule formation, and 2007 17/2.8 cells , . • i 、，. J， calcium content within nodules 
Mouse parietal Increased mRNA of Collagen I， Gleizal et 
bone Runx2 and ALP. al, 2006 
Rat calvarial , . . . ^ ,, , , . Li et al., ,, Increased in intracellular calcium ^“广 cells 2006 
Increased mineralized nodule 
Osteoblastic formation, collagen content, and ^^^ ^^ 
cell line- alkaline phosphatase activity, 置OQ3 
MC3T3-E1 increased the surface expression of •‘ 
alpha2, alphaS, and betal integrins 
ST2 cells o f ~ ~ Nsrusc et bone marrow Increased osteocalcin and IGF-1 , ‘ , al, 2003 stromal ‘ 
Rat calvarial , j T r r n i Li et al, 
cells Increased TGF-pl 
Osteoblast ^ 
Rat osteoblast Increased osteoblast proliferation, Sun et al, 
alkaline phosphatase, and TNF-alpha 2001 
Clonal rodent 
osteosarcoma Increased c-fos，COX-2, alkaline Warden et 
cells- phosphatase and osteocalcin ^qqi 
UMR-106 expression 
cells 
bone^marrow Increased cfos, IGF-1，osteocalcin， Naruse et 
stromal and bone sialoprotein expression al, 2000 
Human Increased collagen and 
. . . non-collagenous protein synthesis, Doan et 
gii^gi^l 1 beta, IL-8, bFGF and VEGF al.，1999 
osteoblasts, j ， ， production 
Osteoblastic increased integrins and cytoskeleton Lu et al., 
g^Qg"®" genes, TGF-P1 and TGF-P2, IGF-1 2009 
MC3T3-E1 Increased alkaline phosphatase Unsworth 
mouse significantly at day6. Increased et al., 
preosteoblast mineralization on day 10. 2007 
Preosteoblast MC3T3-E1 . , . X- AT R. 1 Bandow 
Increased mRNA of ALP, MCP-1， , 
mouse xyfTn 10 . r> AXTL^T et al” 
preosteoblast MIP-ip and RANKL 2007 
MC3T3-E1 I Increased PGE2 production and Kokubug/ 
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mouse regulation ofCOX-2 mRNA al., 1999~ 
preosteoblast 
„ Increased gene expression of „ 
Rat marrow . �广 r T v � ^ ^ n x i � ^ V K T Sena et 
stromal cell ？un’c-myc & COX-2, OPN & ON ^005 
at 3hr 
Mesenchymal 
stem cell Increased gene expression of SanfAnna 
Rat marrow Cbfa-1/Runx2, IGF-receptor, Alk-3， ^^  ^^ 
stromal cell alkaline phosphatase, osteopontin, 7nns， 
TGF-betal, BMP-7 at day3 
Increased cell proliferation, alkaline 
Periosteal Human phosphatase, osteocalcin, VEGF Leung et 
cells periosteal cell production and calcium nodules al, 2004 
formation 
Sternum of , � L � Zhang et 
chick embryos ^creased chondrocyte proliferation ，之‘ 
Chondrocytes ^ ^ , ^ Increased in intracellular calcium ^f'^^'^Lf^ ^ chondroncytes al, 2002 
Rat Increased aggrecan mRNA and Parvizi et 
chondroncytes proteoglycan synthesis al, 1999 
Human Doan et 
Fibroblast gingival Increased collagen synthesis ^^^^ 
Fibroblasts '， 
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Chapter 2 Hypothesis, Objectives and Plan of 
Study 
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2. Hypothesis, Objectives and Plan of Study 
Spinal deformities affect a large population with different ages. Adolescent 
idiopathic scoliosis is a common form of spinal deformity. For severe spinal 
deformities, posterior spinal fusion (PSF) coupling with instrumentation and 
correction of the deformity is one of the most common procedure performed. In PSF, 
decortication of the posterior elements of the spine followed with autograft 
implantation is the "gold standard". However, with 5-35% non-union rate, donor site 
complication, and limited autograft supply, there are continuous ongoing efforts to 
find effective bone substitutes to enhance bony fusion which are critically important 
for successful long term stabilization of the spinal deformity. 
The ideal graft material to promote spinal fusion should possess 
osteoconductive, osteoinductive and osteogenic properties. Although autogenous 
bone graft has all these three qualities and is the gold standard, research has focused 
on finding alternatives that have similar efficacy and to avoid the inadequate supply 
and morbidities associated with graft donor sites. Efforts have focused on introducing 
osteoinductive proteins, including bone morphogenetic proteins and gene therapy to 
spinal fusion. However, these alternative methods still have their limitations such as 
high cost and unnecessary viral factors exposure which prevent practical clinical 
application as mentioned previously in Chapter 1.4. 
Recently, success in using osteoprogenitor cells or osteoblasts derived from bone 
marrow MSCs with various osteoconductive scaffolds for spinal fusion has received 
increasing interest as described in Chapter 1.5.2. With the addition of the successful 
applications of LIPUS in various clinical, in vivo and in vitro orthropaedic reseach 
fields as mentioned in Chapter 1.5.1，this series of studies aim to apply LIPUS 
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induced micromechanical stimulation post-operatively on tissue engineered bone 
substitute in posterior spinal fusion. 
As the osteogenic effect of LIPUS on tissue engineered mesenchymal stem 
cells-bioceramics in spinal fusion is still not clear. This study could provide more 
understanding on the LIPUS treatment effect and the biological regulation occurring 
in posterior spinal fusion. 
2.1 Study Hypothesis: 
LIPUS may enhance bone regeneration and improve fusion in posterior spinal fusion 
implanted with tissue engineered stem cells-calcium phosphate ceramics. 
2.2 Study Objectives 
1. To study the optimum condition of LIPUS on osteogenic differentiation of 
MSCs; 
2. To determine the effect of LIPUS on bone formation in a standardized rabbit 
posterolateral spinal fusion model with calcium phosphate ceramic scaffold 
impregnated with mesenchymal stem cells; 
3. To develop a new method to monitor continuously the spinal fusion in vivo for 
better understanding the biology of spinal fusion using HR-pQCT. 
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2.3 Plan of Study 
2.3.1 For First Objective 
What is the effect of LIPUS on proliferation and osteogenic differentiation on 
MSCs? 
MSCs were isolated from bone marrow of rabbits and confirmed by morphology and 
presence of alkaline phosphatase. The effect of LIPUS on proliferation and 
osteogenic differentiation of MSCs were tested by MTT viability assay and alkaline 
phosphatase activity respectively. 
2.3.2 For Second Objective 
What is the effect of LIPUS on bone formation and fusion of decorticated PSF 
implanted with tissue engineered osteogenic cell-calcium phosphate ceramic 
composite? 
Rabbit bone marrow MSCs were isolated and proliferated in vitro. Cells were then 
loaded on TCP ceramic.TCP without cell (Group A), TCP with undifferentiated 
MSCs (Group B) and TCP with bFGF/OS treated MSCs (Group C) were implanted 
into L5 and L6 intertransverse processes of the same rabbit. In vivo LIPUS treatment 
in TCP with bFGF/OS treated MSCs (Group D) started on day3 after the PSF surgery. 
Samples were harvested after 7 weeks and underwent manual palpation, pQCT and 
histology analysis. 
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2.3.3 For Third Objective 
What addition information on spinal fusion can high-resolution peripheral 
quantitative computed tomography provide? 
Rabbits underwent decorticated PSF implanted with tissue engineered osteogenic 
cell-calcium phosphate ceramic composite with or without LIPUS treatment. Rabbits 
in both groups were scanned with high-resolution peripheral quantitative computed 
tomography (HR-pQCT) scanner in week 1, 4 and 10. Three-dimensional images 
were reconstructed and fusion mass was evaluated qualitatively and quantitatively. 
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Chapter 3 In vitro Study of Effect of Low Intensity 
Pulsed Ultrasound on Mesenchymal Stem Cells 
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3.1. Introduction 
Recently, interest in using osteogenic MSCs derived from bone marrow for spinal 
fusion has increased due to the self-renewal and osteogenic differentiation abilities of 
MSCs. A number of studies have shown LIPUS can influence proliferation and 
differentiation of the major cell types involved in new bone formation e.g. 
chondrocytes, osteoblasts and periosteal cells. 
Bone marrow aspirate combined with osteoinductive matrix has been applied to 
spinal fusion in human (Neen et al.’ 2006) and animal model (Kraiwattanapong et al, 
2005). However, these methods by itself were ineffective in increase the fusion rate. 
One of the reasons is that the number of osteogenic cells in the bone marrow aspirate 
is low and insufficient to promote adequate bone formation for solid fusion. Thus, 
new methods are being explored with the aim to increase both the number and 
maturation of osteoprogenitor cells from bone marrow aspirate to enhance spinal 
fusion (Gupta et al., 2007，Muschler et al, 2005, Helm and Gazit, 2005). 
Studies confirmed that in vitro expanded bone marrow derived osteoprogenitor 
cells were more effective than the freshly prepared bone marrow in the repair of 
segmental defects in cortical bone (Bruder et al.’ 1994, Bruder et al., 1998, Cinotti et 
al., 2004, Connolly, 1998， Gupta et al, 2007). For in vitro expansion of 
osteoprogenitor cells，it was found necessary to stimulate differentiation of the 
progenitor cells along the osteogenic lineage with the addition of osteogenic factors 
and supplements (Jaiswal et al, 1997, Kai et al, 2003, Minamide et al, 2005). In 
addition to biological means ，studies (Sena et al., 2005, Takayama et al, 2007, 
Leung et al, 2004a, Parvizi et al., 2002) have shown the effectiveness of 
low-intensity pulsed ultrasound (LIPUS) in stimulating proliferation and 
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differentiation of different cell types related to bone formation such as chondrocyte, 
preosteoblast, osteoblast, bone marrow derived mesenchymal stem cell (BMSC), and 
periosteal cells. However, up to now, there are no report on studies to optimize the 
osteogenic effects of LIPUS on bone marrow derived osteoblast. 
In this chapter, the study aims at optimization of the effect of LIPUS on 
osteogenic differentiation and proliferation of bone marrow derived MSCs in vitro. 
3.2. Materials and Methods 
3.2.1. Experimental Animal 
New Zealand White rabbits (13-15 weeks old) were used for the bone marrow 
extraction and mesenchymal stem cell isolation. The rabbits were obtained from the 
Univeristy Laboratory Animal Services Centre, All the procedures related to rabbits 
in this study have been approved by the animal ethical committee of the Chinese 
University of Hong Kong (Ref. no: 08/014/DRG) (Appendix I). 
3.2.2. Materials and Reagents 
3.2.2.1. Dulbecco's Modified Eagle Medium (DMEM) 
DMEM (Invitrogen，Carlsbad, USA) and 3.7g NaHCOS (Riedel-de Haen, 
Seelze, Germany) were dissolved in 800ml distilled water. After adjusting the pH to 
7.4，the final volume (1000ml) was made up with additional distilled water. The 
medium was then filtered with a bottle top filter (0.22-}xm membrane) under a 
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sterilized condition and stored at 4°C until use. 
3.2.2.2. Phosphate Buffered Saline (PBS) 
1.44 g Na2HP04 (Merck & Co.，Darmstadt, Germany), 0.24 g KH2PO4 (Merck 
& Co.，Darmstadt, Germany), 8.0 g NaCl (Merck & Co., Darmstadt, Germany) and 
0.2 g KCl (Merck & Co., Darmstadt, Germany) were mixed and dissolved in 900 ml 
distilled water. After adjusting the pH to 7.4, the final volume (1000 ml) was made 
up with additional distilled water. The solution was sterilized by autoclave and stored 
at 4 � C 
3.2.2.3. Osteogenic Medium (OS) 
89ml DMEM, 10 ml FBS (Gibco-Invitrogen, Carlsbad, USA) and 1.0 ml PNS 
antibiotic cocktail (Invitrogen, Carlsbad, USA) were mixed gently to prevent foam 
and bubbles. Then 1.0ml of 5mM ascorbic acid (Sigma, St. Louis, USA), 1.0ml of 
lOmM P-glycophosphate (Sigma, St. Louis, USA) and 0.1ml of 10'^  M 
dexamethasone (Sigma, St. Louis, USA) were added. The solution was mixed and 
stored at 4°C 
3.2.2.4. Alkaline Phosphatase (ALP) Buffer 
10.2g MgCl2.6H20 (Panreac，Barcelona, Spain), 12.1g Tris-HCl (Sigma, 
St丄ouis，USA), 5.8g NaCl (Amresco, Solon, USA) and 1.0ml 0.1% Tween-20 
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(Amresco, Solon, USA) were dissolved in 1000 ml distilled water and stored at room 
temperature 
3.2.2.5. ALP Substrate Buffer 
25 BCIP (Promega, Madison, USA) and 50 NBT (Promega，Madison, 
USA) were added into 4.9 ml ALP buffer. The solution was freshly prepared before 
staining and stored in the dark. 
3.2.2.6. MTT Stock Solution 
0.0 Ig MTT powder (Sigma, St丄ouis，USA) was dissolved in 10ml PBS. Stock 
solution was filtered through a 0.22-|xm membrane (Millipore, Bedford, USA) and 
stored in dark at -20°C. 
3.2.2.7. MTT Working Solution 
2.5 ml MTT stock solution was mixed in 7.5 ml plain DMEM (Invitrogen, 
Carlsbad, USA). The solution was freshly prepared and kept in dark. 
3.2.2.8. Lysis buffer 
0.985 g Tris-HCl (Sigma, St.Louis, USA) and 2.02 g 99%SDS (Amresco, Solon, 
USA) were mixed and dissolved in 100 ml MiliQ water and the pH was adjusted to 
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be 7.4. 
3.2.2.9. Alkaline Phosphatase (ALP) Working Reagents 
25 ml of 2-amino-2-methyl-l-propanol (Reagent A) was mixed gently with 50 
ml of 4-nitrophenylphosphate (Reagent B). The solution was stored at 4°C for a 
maximum storage period of 2 months. The solution was pre-warmed to 37°C before 
usage. 
3.2.3. Isolation of Bone Marrow Derived Mesenchymal Stem Cells (BM derived 
MSCs) 
Bone marrow (15-20 mL) was aspirated from proximal femur, distal tibia, 
trochanter and iliac crest of male New Zealand White rabbits (13-15 weeks) and 
collected in heparin tubes. After mixed with equal portion of DMEM, the bone 
marrow was centrifuged (1500 rpm, 10 min) to descending the mononuclear cells 
(MNCs). After centriguation，the plasma and fat were discard. MNCs were seeded 
into 75cm^ plastic tissue culture flasks (Corning, Corning, USA) with DMEM, 10% 
fetal bovine serum (Invitrogen，Carlsbad, USA), and 1% penici 11 in-streptomycin-
nemomycin (PSN) solution (Invitrogen, Carlsbad, USA). Cells were then incubated 
at 37°C in a humidified atmosphere of 5% CO2. . Half and total volume of medium 
added for the initial incubation was changed after Day 4 and 7 culture, respectively, 
to remove red blood cells and the suspending cells (Minamide et al., 2007). The 
medium was changed twice a week. At 80 - 90% confluence, the primary MSCs 
(Passage 0) were subcultured with 0.25 % Trypsin-EDTA solution (Gibco, 
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Invitrogen, Canada) and passaged into 150cm flasks (Corning, Corning, USA) 
(1x106 cell number) for further proliferation. 2 ng/rtiL basic fibroblast growth factor 
(bFGF) (Sigma St.Louis, USA) was added to the culture in passage 1 for 7 days to 
stimulate the proliferation ofMSCs (Minamide et al., 2007). 
3.2.4. In vitro Low Intensity Pulsed Ultrasound Treatment 
3.2.4.1. In vitro LIPUS Devices 
A low-intensity pulsed ultrasound (LIPUS) (the Sonic Accelerated Fracture 
Healing system 2A, Exogen®, Smith & Nephew, Inc, West Calwell, NJ) was used to 
transmit the therapeutic ultrasound at 1.5 MHz with 200|LIS pulsed frequency and 1.0 
kHz repetition rate. The power of the LIPUS devices is 30 士 5.0 mW/cm^ spatial 
average and temporal average (SATA) incident intensity. The calibration of the 
LIPUS parameters had been done by the manufacturer and set at the standard level 
for all tests in the current series of studies. The device was designed to fit the 6-well 
plate (Appendix II). 
3.2.4.2. Treatment Procedure and Experimental Groupings 
MSCs at passages 2 or 3 were used for LIPUS treatment. Cells were seeded on 
the 6-well plates at a density of 3x10"^  cell per well either with basal medium (BM) or 
osteogenic medium (OS) for 24 hours. Then the cultured plates were placed on the 
LIPUS machine with a thin layer of standard ultrasound coupling gel 
(Pharminnovations, NJ, USA). Cells were treated daily with LIPUS (0，10 and 20 
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minutes) for 7 days. The effect of LIPUS on cell variability and osteogenic potential 
of MSCs were assessed by the following biochemical assays 24 hours after Day 1， 
Day 4 and Day 7 of LIPUS treatment. 
Therefore, there are 4 main groups: 1) BM; 2) OS; 3)BM+LIPUS; 4) 
OS+LIPUS. The 2 groups with LIPUS treatment (BM+LIPUS and OS+LIPUS) was 
further subgrouped into 10 minutes LIPUS and 20 minutes LIPUS treatment. 
3.2.5. Effect of LIPUS on Cell Viability and Osteogenesis in bone marrow 
derived-MSCs 
3.2.5.1. Cell Viability Assay 
The effect of LIPUS on cell viability of the bone marrow derived MSCs was 
assessed by MTT assay to determine the total number of viable cells at Day 1，Day 4 
and Day 7 after LIPUS treatment. The assay measures the reduction of MTT by 
mitochondrial dehydrogenase present in viable cells to form a purple formazan 
product representing the number of cells. Briefly, the medium in each well was 
removed and washed twice with sterile PBS. The MTT solution was added (1 ml/well) 
and incubated for 4 hour at 37�C in darkness. Then, 50)0.1 hydrochloric acid (IN) 
(Merck & Co.，Darmstadt, Germany) was added to stop the reaction. The additional 
of 1.5ml Isopropanol (Merck & Co.，Darmstadt, Germany) was mixed in each well 
gently until all the purple precipitates were dissolved. The absorbance was measured 
at wavelength of 570nm using a microplate reader (Gemini, Osaka, Japan). All 
measurements were performed in triplicate and 4 samples were tested in each group 
(n=4). 
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3.2.5.2. Alkaline Phosphatase (ALP) Enzyme Activity 
Alkaline phosphatase (ALP) enzyme activity was used to determine the ALP 
activity which converts p-nitrophenylphosphate substrate to p-nitrophenol. The ALP 
activity of cells at Day 1, 4 and 7 after treatment were measured. In brief，the 
medium was removed and the well was rinsed with sterile PBS twice. The cells were 
then lysed with 500|il lysis buffer in each well at room temperature. 50|LI1 lysed cells 
were transferred to the well of 96-well plate. 150|j,l pre-warmed PNPP substrate from 
a commercial kit (Biosystems, Barcelona, Spain) was added. The absorbance was 
measured the production of p-nitrophenol at wavelength 405 nm for 2 min at 37°C 
with a microplate reader (Victor3™ Multilabel Counter, PerkinElmer, Finland). The 
ALP activity (U/L) per minute was normalized by the total number of viable cells at 
the adjacent welll which undergoing the same treatement at the same experiment 
period. All measurements were performed in triplicate. 
3.2.5.3. Cell Morphology and Alkaline Phosphatase Cytochemistry 
The cell morphology of different groups was characterized by light microscopy. 
The osteogenic potential of the cultured cells was assessed by alkaline 
phosphatase cytochemistry at Day 1，4 and 7 after LIPUS treatment. Purple 
precipitate was evaluated under microscope and images were acquired for the 
quantification of the stained area in the whole well with Metamorph Image Analysis 
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System (Universal Imaging Corporation ，Downingtown, PA, USA). 
3.2.6. Statistical Analysis 
The results were expressed in mean 士 1 standard deviation. Differences in the 
cell variability, ALP activity, ALP stained area were evaluated by one-way analysis 
of variance (ANOVA) among different time points and followed by Bonferroni post 
hoc comparisons. When two groups of samples were compared, Student's's t-test was 
used. Statistical significance was set at alpha = 0.05. All these statistical analysis was 
done with SPSS 13.0 for Windows (SPSS, Chicago, IL, USA). 
3.3. Results 
3.3.1. Morphology 
Mesenchymal stem cells were isolated from rabbit bone marrow and cultured in 
basal medium (Figure 3.3.lA). The cells showed spindle shape in passage 0-1 
(Figure 3.3.1A-B). MSCs in passage 2 were then cultured with different mediums 
(BM and OS) and treated with LIPUS. At Day 1 (Figure 3.3.2 A-Dl), cells expressed 
similar confluency (30-40%), size, and spindle shaped among four groups. At Day 4， 
cells in BM (Figure 3.3.2 A2) were spindle shape and had higher confluency 
(50-60%) and smaller cell size than OS group (Figure 3.3.2 C2) which was 40% 
confluency with larger size and polygonal shape cells. Cells in BM and BM + LIPUS 
were spindle shaped (Figure 3.3.2 A-B2) and showed similar confluency (50 -60%), 
cell size. Cells in OS with or without LIPUS also expressed similar confluency 
(40%), size and polygonal shape at Day 4 (Figure 3.3.2 C-D2). At Day 7，cells in BM 
(Figure 3.3.2 A3) remained spindle in shape, smaller in size with higher confluency 
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(90-100%) than cells with OS (Figure 3.3.2 C3) which showed polygonal shape, 
larger in size and with lower confluency (40%-50%). Cells in BM with or without 
LIPUS at Day 7 (Figure 3.3.2 A-B3) showed similar confluency (90-100%), spindle 
shape and small size. In OS groups (Figure 3.3.2 C-D3) with or without LIPUS, 
similar confluency (40-50%)，large polygonal shape cells were observed at Day 7. 
3.3.2. Total Number of Viable Cells 
Both BM and OS groups showed similar cell number at Day 1 and Day 4 
(Figure 3.3.3). At Day 7，cells cultured in BM had 20% higher variable cell number 
than that in OS though not significant. 
Cells cultured within BM (Figure 3.3.4) or OS (Figure 3.3.5) with or without 
LIPUS showed increase of cell number from Day 1 to 7 in all groups. Within each 
medium, all groups showed similar cell number at Day 1, Day 4 and Day 7, 
regardless the LIPUS treatment duration (0 min.，10 min.，20 min.). 
3.3.3. ALP Activity Absorbance 
Cells cultured in BM and OS showed low and similar ALP activity at Day 1 to 4 
(Figure 3.3.6-3.3.8) either with or without LIPUS. At Day 7，cells in BM groups (0， 
10 and 20 min LIPUS) remained low ALP expression whereas a dramatically 
significant increase in ALP activity was found in OS 0, 10 and 20 min LIPUS groups 
at Day 7 with 382% (p<0.001 by Student's t-test)，530% (p<0.00l by Student's t-test) 
and 526% (p=0.003 by Student's t-test)as compared to BM 0, 10 and 20 min LIPUS. 
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Cultured BM medium (Figure 3.3.9), cells in 0, 10 and 20 min LIPUS groups 
showed similar ALP activity at Day I, 4 and 7. An overall slightly decline in ALP 
was observed in all groups at Day 4 followed by a slightly increase at Day 7. 
With the cells culture in OS medium (Figure 3.3.10)，ALP activity increased 
33% and 19% at 10 min LIPUS and 20 min LIPUS, respectively when compared 
with the group without LIPUS. The ALP activity was found to be significantly higher 
at lOmin LIPUS group at Day 7 (p=0.035 By Post Hoc Tests, Bonferroni) when 
compared with no LIPUS group. However, there is no difference in ALP activity 
between 10 min LIPUS treatment and 20 min LIPUS treatment. 
3.3.4. ALP staining 
ALP activity was highest at 10 min. LIPUS treatment at Day 7. The highest 
enzyme activity may not signify the expression level of ALP at individual cells. It is 
desirable to see whether the cells were also express high level of the ALP. Therefore, 
a cytochemical assay on the ALP was preformed. 
3.3.5. Qualitative Analysis 
Figure 3.3.11 showed the alkaline phosphatase cytochemical staining. By gross 
examination, all the wells had purple staining indicating the presence of ALP in the 
cells. It was observed that there were slightly increased purple stained area in cell 
cultured with basal medium plus LIPUS when compared with those in basal medium 
alone. For the cells cultured in OS, the purple stained area was larger and the color is 
darker in wells treated with LIPUS. When the stained area was compared between 
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different culture medium with LIPUS, the OS treated cell with LIPUS had larger 
stained area. 
It is of interest that when the cells treated with LIPUS in either BM or OS 
medium, the stained areas were more focused at the center of the culture wells. 
3.3.6. Quantitative Analysis 
The stained area was further quantified in each group with the image analysis 
system. The stained area in cells with BM plus LIPUS is slightly higher than that of 
cells with BM alone. However, the difference was not statistically significant (Figure 
3.3.12). When the cells cultured in OS medium, the stained area increased 76% when 
compared with that cultured in BM. When the cells cultured in OS treated with 
LIPUS, the stained area was further increase by one fold when compared with cells 
in OS alone. When the comparison was between OS+LIPUS group and BM group, 
the difference in stained area reached to nearly 3 folds. 
3.4. Discussion 
Although there are several studies demonstrated the up-regulation of early 
response and osteogenesis-related genes in bone marrow derived stem cells after 
LIPUS stimulation (Naruse et al, 2000, Naruse et al, 2003，Sena et al., 2005, 
Sant'Anna et al., 2005), there is limited information on LIPUS effect on MSCs at the 
cellular level. Therefore, in this study, the effect of LIPUS on proliferation and 
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osteogenic differentiation were investigated. In addition, the optimum condition for 
the effect of LIPUS on the osteogenic differentiation of MSCs was explored. 
3.4.1. LIPUS have No Enhancing Effect on Proliferation of MSCs in Basal 
Medium Nor Osteogenic Medium 
From the results (Figure 3.3.4)，MSCs cultured in basal medium with 0，10 and 
20 min LIPUS had similar cell numbers at Dayl, 4 and 7. These imply that LIPUS 
had no effect in enhancing proliferation of the bone marrow derived stem cells in 
basal medium. The result was consistent to several similar studies with various cell 
types cultured with basal medium.Takayama et al (Takayama et al, 2007) studied 
the proliferation of the ROS cells, a rat osteoblastic cell line, in basal medium with 
and without transient LIPUS stimulation for up to 14 days (20 mins /day) of culture. 
LIPUS stimulation did not affect the rate of cell proliferation throughout this 14 days 
treatment. Hiyama et al (Hiyama et al.’ 2007) examined the proliferation effect of 
LIPUS (20 mins/ day, 2 days treatment) on nucleus pulposus cells in basal medium 
isolated from mature beagles. No significant difference was found between groups 
with or without LIPUS. Parvizi et al. (Parvizi et al, 1999) did not find any 
significant difference in the effect of LIPUS (10 mins/ day, 5 days) on proliferation 
of rat primary chondrocyte cultured in basal medium Vs controls at different time 
points. Another authors used LIPUS (20 mins/day, 7 days) in chondrocytes from 
chick embryo cultured in basal medium again showed no differences on cell 
proliferation (Zhang et al” 2003). In contrast, significant stimulating effect of LIPUS 
on cell proliferation were reported in some other cell types. Leung et al. (Leung et al, 
2004a) demonstrated the LIPUS could enhance cell proliferation in human periosteal 
cells after 2 days of treatment. Significant enhancement of cell proliferation in Day 3 
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and 4 in primary culture from parietal bone from mice in basal medium (5 mins/ day, 
4 days) was also observed (Gleizal et al, 2006). The rat alveolar mononuclear 
cell-calvaria osteoblast co-culture system was also studied (Sun et al, 2001). After 
low-intensity pulse ultrasound stimulation (20mins/day, 7days), the osteoblast cell 
counts were significantly increased. Based on the reported studies and the results in 
the present study, it is possible that the differentiation stage and the cell types that 
under investigation would affect the outcome of the proliferation results. It is 
speculated that those cells responding to the LIPUS in term of proliferation were 
osteogenic differentiated cells. These cells have the ability to sense the mechanical 
force and turn it to biological events. However, in the present study, the MSCs started 
with an undifferentiated stage while still cultured in BM which tend to keep the 
MSCs in undifferentiated stage under a short term culture. The cells may not develop 
the mechanical force sensing mechanism. Thus, it seems reasonable that our result of 
the LIPUS effect on MSCs proliferation cultured in BM is negative. 
The second major finding in this study showed that LIPUS stimulation have no 
effect on proliferation of the bone marrow derived stem cells in an osteogenic 
medium. From the results (Figure 3.3.5)，MSCs with LIPUS 0，10 and 20 min 
stimulation had similar cell numbers in osteogenic medium at Dayl, 4 and 7 
consistent with Ebisawa et al. (Ebisawa et al., 2004) findings. In human 
mesenchymal stem cells (hMSCs), no significant differences in cell proliferation was 
reported after hMSCs was stimulated with LIPUS (20 mins/day, 10 days) in 
osteogenic medium when compared to the control group. 
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3.4.2. LIPUS Stimulate Proliferation of MSCs in Early Period 
Cell proliferation was determined in Dayl, 4 and 7 in this study. LIPUS showed 
similar cell numbers in Dayl and 4. But there is no information between Dayl to 4. 
Leung et al. demonstrated the LIPUS proliferation effect on human periosteal cells 
(Leung et al., 2004a) after 2 days treatment. However, the stimulatory effect start 
fading off after 4 days. It may also imply that there is a critical period for ultrasound 
to stimulate cell proliferation, in this case was in the early period (within Day 1 to 3) 
when cell proliferation is most active. After this critical period, the LIPUS effect on 
cell proliferation may be fading out as the effect may be shift to cellular 
differentiation. 
3.4.3. LIPUS Further Enhanced Osteogenesis of MSCs in Osteogenic Medium 
In the present study, a rapid increase of ALP activity was found in MSCs 
cultured in ostegenic medium at Day 7 (Figure 3.3.10). ALP is a marker of 
osteoblastic differentiation. The results indicated that LIPUS enhanced the 
osteogenic differentiation of bone marrow derived MSCs cultured with OS but not in 
BM groups at Day 7. The finding is different from some of the reported series which 
have shown that that LIPUS elevated the ALP activity in various cell types cultured 
with basal medium only. Takayama et al. (Takayama et al.’ 2007) studied the 
osteogenic differentiation of the ROS cells, a rat osteoblastic cell line, in basal 
medium only with and without L IPUS stimulation for up to 14 days (20 mins /day) 
of culture. ALP activity was most significant at Day 7 with LIPUS stimulation 
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Unsworth et al. (Unsworth et al.’ 2007) also demonstrated that the activity of ALP of 
LIPUS treated MC3T3-E1, mouse preosteoblast cells, in basal medium only which 
was significantly increased at days 6，8 and 10 as compared to control group. 
Another author demonstrated the LIPUS osteogenic effect on human periosteal cells 
(Leung et al., 2004a). Cells cultured in basal medium only with LIPUS treatment had 
a significant increase in ALP activity at Day 4. In contrast, in the findings of Sun et 
al., rat alveolar mononuclear cell-calvaria osteoblast coculture system in OS was 
studied with LIPUS stimulation (20 mins/ Day 7days). A significant increased in 
ALP activity was found at 7 days after LIPUS treatment (Sun et al., 2001) which is 
consistent with findings in the current study. By comparing the results of ALP 
activity between BM and OS groups in this study, it implied that LIPUS alone cannot 
convert bone marrow derived MSCs into osteogenic lineage without the presence of 
OS. This is important because this underlies the importance of LIPUS used as a 
non-contact, non-invasive means for MSCs differentiation. Once the MSCs is pushed 
to osteogenic differentiation, they start to develop sensing tools for responding to the 
LIPUS. The present study would indicate that it might not be necessary to use 
various recombinant growth factors, which content potential hazard of contamination 
during protein production, to induce the MSG differentiation in vitro. This would 
help to generate a safer osteogenic cells for implantation. 
3.4.4. 10 mins LIPUS treatment for 7 days can positively enhance osteogenic 
differentiation 
The current study showed the ALP activity of MSCs cultured in OS was low on 
Day 1 and 4 after LIPUS treatment. However, the ALP activity rapidly increased on 
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Day 7 after LIPUS treatment. In addition, similar ALP activities were determined in 
both 10 min and 20 min. LIPUS treatment for 7 days in MSCs cultured with OS 
medium though 10 min group had the highest ALP activity. This result is supported 
by other studies. Significant increased in ALP activity was found in human periosteal 
cells after 2 and 4 days (10 min/ day) LIPUS stimulation (Leung et al., 2004a). Ten 
minutes LIPUS stimulation was applied daily to osteoblasts (MC3T3-E1). Elevated 
ALP activity was demonstrated in mouse osteoblast after the exposure to 10 min 
LIPUS for 11 days (Yang et al., 2005). In chondrocytes, Parvizi et al. lOmin LIPUS 
daily for 5 days enhanced endochondral ossification through stimulating aggrecan 
mRNA expression and proteoglycan synthesis (Parvizi et al.’ 1999). 
3.4.5. Optimum Conditions of LIPUS was Cell T^pe Dependent 
From the current findings, optimum osteogenic condition of MSG was at Day 7 
after daily 10 min LIPUS in OS. In osteoblasts, the optimum condition of LIPUS was 
at Day 7 with 20 min daily LIPUS stimulation in basal medium (Takayama et al., 
2007) as well as in osteogenic medium (Sun et ai, 2001). The optimum conditions of 
preosteoblast cells and human periosteal cells were 6 days and 4 days LIPUS 
stimulation in basal medium, respectively (Unsworth et ai, 2007, Leung et al., 
2004a). These suggested that long-term LIPUS stimulation at proper medium, daily 
LIPUS treatment and duration period could enhance the differentiation and 
maturation of cells. It also indicated that different cell types have different optimum 
conditions of LIPUS for osteogenic differentiation (Figure 3.4.1) 
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3.4.6. LIPUS Promoted Osteogenesis in MSCs through Accelerated 
Mineralization 
Elevation of mRNA expression of ALP further confirmed LIPUS as a potential 
osteogenic stimulus. ALP mRNA increased at 24 hours (Warden et al., 2001), 3 days 
(Gleizal et al., 2006, SanfAnna et al, 2005), 10 days (Unsworth et al, 2007) and 1 
week (Bandow et al., 2007) significantly after LIPUS exposure. Although the 
increases of mRNA and the enzymatic activity for ALP ultrasound-treated cultures do 
not exactly mirror each other, both the elevated expression of mRNA and functional 
protein of ALP confirm LIPUS can act as a potential osteogenic stimulus. 
Although the exact mechanism stimulating osteogeniesis through LIPUS 
remains a question, there is an interesting correlation between LIPUS stimulus and 
cellular response. From the results, ALP significantly increased after 7 days LIPUS . 
It implied that mineralization would be enhanced subsequently by LIPUS as LIPUS 
effectively accelerated the mineralization phase of fracture healing process in clinical 
trials (Leung et al.’ 2004b, Kristiansen et al., 1997, Heckman et al., 1994) as well as 
delayed unions and non-unions (Jingushi et al., 2007). 
High ALP activity was found to correlate with matrix formation in osteoblasts 
facilitates the initiation of mineralization (Gerstenfeld et al., 1987). ALP breaks 
down inhibitors of mineralization such as pyrophosphate and increases the local 
concentration of inorganic phosphate (Anderson et al, 1997). With the accumulation 
of calcium ion and inorganic phosphate in the extracellular matrix vesicles, 
hydroxyapatite is produced and forms crystalline needle-like structures. Further 
nucleation of hydroxyapatite then initiates tissue calcification and thus leads to 
mineralization (Balcerzak et al., 2003). Studies demonstrated that LIPUS accelerated 
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mineralization. There is evidence to suggest ultrasound stimulates osteogenesis 
through calcium signaling and calcification of cartilage. LIPUS has been shown to 
exhibit a significantly four-fold increase the levels of calcium nodules in human 
periosteal cells after LIPUS treatment (Leung et al., 2004a). Similar observation was 
shown in preosteoblastic cell line. MC3T3 cultures stimulated with LIPUS for up to 
25 days showed a significant increase in the degree of mineralization as determined 
by alizarin red staining (Unsworth et al.，2007). In addition, LIPUS increased the 
intracellular calcium concentration in chondrocytes and the percentage of calcified 
cartilage in the physis in fetal mice. This result suggested a stimulatory effect of 
LIPUS on endochondral ossification is due to stimulation of bone cell differentiation 
and calcified matrix production (Korstjens et al, 2004, Parvizi et al., 2002). 
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Figure 3.3.1 Typical microphotograph of normal bone marrow derived mesenchymal 
stem cell in this study. (A) Mesenchymal stem cells were isolated from bone marrow 
and cultured in basal medium in passage 0 (ay 14). (B) Mesenchymal stem cells in 
passage 1 (day 21). The morphology of MSCs were mainly spindle in shape during 
passage 0-1 (16X). 
- 5 4 -
BM H ^ ^ ^ B H H I B ^ W ^ h I H mjmss^^^jMl 
BM+us m ^ Q ^ H J B H j l ^ ^ ^ ^ l ^ f f i ^ H ^ ^ M 
OS ^ n u Q i ^ ^ i i ^ m m m 
os+us m i ^ ^ ^ H H ^ B H B ^ ^ ^ H 
Figure 3.3.2 Microphotograph of MSCs in passage 2 under different treatments at 
Day 1，4 and 7. (Al-3) Cells cultured in basal medium (BM); (Bl-3) Cells cultured 
in BM with LIPUS treatment; (CI-3) Cells cultured in basal medium with osteogenic 
supplements (OS) and (Dl-3) Cells cultured in OS with LIPUS treatment. (16X). 
At Day 1 (A-Dl), cells expressed similar confluency (30-40%), size and spindle 
shape among four groups. At Day 4, cells in BM (A2) expressed spindle shape, 
higher confluency (50-60%) and smaller cell size than OS group (C2) which was 
40% confluency with larger size and polygonal shape cells. Cells in BM and BM + 
LIPUS (A-B2) showed similar confluency (50 -60%), size and spindle shape. Cells 
in OS with or without LIPUS (C-D2) also expressed similar confluency (40%), size 
and polygonal shape at Day 4. At Day 7，cells in BM (A3) remained spindle in shape, 
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smaller in size with higher confluency (90-100%) than cells with OS (C3) which 
showed polygonal in shape, larger in size and with lower confluency (40%-50%). 
Cells in BM with or without LIPUS at Day 7 (A-B3) showed similar confluency 
(90-100%), spindle shape and small size. In OS groups (C-D3) with or without 
LIPUS，similar confluency (40-50%), large polygonal shape cells were observed at 
Day 7. 
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Figure 3.3.3 Viable cell numbers of bone marrow derived mesenchymal stem cells 
cultured in basal medium with or without osteogenic supplements. The cell viability 
was determined after 1，4，7 days by MTT assay. A general increase of cell number 
from Day 1 to 7 in both groups was observed. Both groups showed similar cell 
number at Day I and Day 4. At Day 7，cells cultured in BM had 20% higher variable 
cell number than that in OS though not significant. 
There were no significant differences between BM and OS groups within all 
time points by Student's t-test. 
(The error bar represents 1 standard deviation of means.) 
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Figure 3.3.4 Viable cell numbers of bone marrow derived mesenchymal stem cells 
with LIPUS cultured in basal medium. The cell viability was determined after 1, 4，7 
days by MTT assay. A general increase of cell number from Day 1 to 7 in all groups 
was observed. All groups showed similar cell number at Day 1，Day 4 and Day 7. 
There were no significant differences among groups at all time point one-way 
ANOVA. 
(The error bar represents 1 standard deviation of means.) 
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Figure 3.3.5 Viable cell numbers of bone marrow derived mesenchymal stem cells 
with LIPUS cultured in basal medium with osteogenic supplements. The cell 
viability was determined after I, 4, 7 days by MTT assay. A general increase of cell 
number from Day I to 7 in all groups was observed. All groups showed similar cell 
number at Day 1，Day 4 and Day 7. 
There were no significant differences among different groups at all time point 
one-way ANOVA. 
(The error bar represents I standard deviation of means.) 
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Figure 3.3.6. Alkaline phosphatase enzymic activity of bone marrow derived 
mesenchymal stem cells cultured in basal medium with or without osteogenic 
supplements. The ALP activity was determined after 1，4 and 7 days by ALP assay. 
At Day I to 4，cells cultured in BM and OS showed low and similar ALP activity. At 
Day 7，cells in BM group remained low ALP expression whereas a dramatically 
increase (382% as compared to BM) in ALP activity was found in OS group. 
#Student，s t-test; p<0.001 when BM compared with OS at Day7. 
(The error bar represents 1 standard deviation of means.) 
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Figure 3.3.7 Alkaline phosphatase enzymic activity of bone marrow derived 
mesenchymal stem cells with 10 min LIPUS cultured in basal medium with or 
without osteogenic supplements. The ALP activity was determined after 1，4 and 7 
days by ALP assay. At Day 1 to 4，cells cultured in BM and OS showed low and 
similar ALP activity. At Day 7，cells in BM group remained low ALP expression 
whereas a dramatically increase (530% as compared to BM) in ALP activity was 
found in OS group. 
#Student，s t-test; p<0.00l when BM compared with OS at Day7. 
(The error bar represents 1 standard deviation of means.) 
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Figure 3.3.8 Alkaline phosphatase enzymic activity of bone marrow derived 
mesenchymal stem cells with 20 min LIPUS cultured in basal medium with or 
without osteogenic supplements. The ALP activity was determined after 1, 4 and 7 
days by ALP assay. At Day 1 to 4，cells cultured in BM and OS showed low and 
similar ALP activity. At Day 7，cells in BM group remained low ALP expression 
whereas a dramatically increase (526% as compared to BM) in ALP activity was 
found in OS group at Day 7. 
#Student，s t-test; /7=0.003 when BM compared with OS at Day7. 
(The error bar represents 1 standard deviation of means.) 
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Figure 3.3.9 Effect of LIPUS on the alkaline phosphatase enzymic activity of bone 
marrow derived mesenchymal stem cells cultured in basal medium. All groups had 
similar ALP activity at Dayl, 4 and 7. An overall slightly decline in ALP was 
observed in all groups at Day 4 followed by a slightly increase at Day7. 
There were no significant differences among all the groups by one-way ANOVA 
at any time point. 
(The error bar represents 1 standard deviation of means.) 
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Figure 3.3.10 Effect of long term LIPUS on the alkaline phosphatase enzymic 
activity of bone marrow derived mesenchymal stem cells cultured in osteogenic 
supplements. From Dayl to Day4, all groups had low and similar ALP activity. At 
Day 7, all groups had a dramatically increase in ALP. At Day7, ALP activity 
increased 33% and 19% at 10 min LIPUS and 20 min LIPUS respectively when 
compared with no US group. And the ALP activity was peaked at 10 min LIPUS 
group at Day? which was statistically significant when compared with no LIPUS 
group. 
* Post Hoc Tests, Bonferroni ； /7=0.035 when OS group compared with others at 
Day7. 
(The error bar represents 1 standard deviation of means) 
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Figure 3.3.11 Effect of LIPUS (10 min daily for 7 days) on the alkaline phosphatase 
of bone marrow derived mesenchymal stem cells cultured under different treatments 
by NBT/BCIP staining. Cells that were stained purple indicate a positive pool, as 
denoted above. (A) Cells cultured in basal medium (BM). (B) Cells cultured in BM 
with LIPUS treatment. (C) Cells cultured in basal medium with osteogenic 
supplements (OS). (D) Cells cultured in OS with LIPUS treatment. (A-D2) Close up 
of the ALP stained cells from A-D respectively. Generally, all the groups expressed 
ALP as stained positively in purple color. Staining in OS groups (C-D2) expressed 
darker purple ALP than BM groups (A-B2). In the LIPUS groups (B, D), cells were 
more concentrated in the middle of the well plate than no LIPUS groups (A, C). 
Overall, OS+US group had the largest and darkest ALP positive staining (D). 
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Figure 3.3.12 Effect of LIPUS (10 min daily for 7 days) on the labeled area of 
alkaline phosphatase of bone marrow derived mesenchymal stem cells cultured in 
osteogenic supplements by NBT/BCIP staining. The labeled area of ALP staining in 
BM+LIPUS and OS were 15% and 76% higher than BM respectively although there 
was no significant difference. Whereas an 85% increase in ALP staining when OS 
was compared with OS+LIPUS significantly. 
# Student's t-test; p<0.001 when OS compared with OS+ LIPUS group. 
(The error bar represents 1 standard deviation of means.) 
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Table 3.4.1 Summary of Optimum Conditions for Osteogenic Differentiation by 
LIPUS in Various Cell Types in Terms of ALP Activity. 
Optimum Conditkm or LIPUS 
CcDiypc Ct»n Studied literature 
IVcatmeBt 
Medium Daity Dnratkm Period 
Jenny 
Preosteoblast Basal medium 20min day 6 Unsworth, preosteoblast cdls q^q? 
一 b l a s t .on^ daylO ^ ^ 
IWtcdceU Humau^rteai easalmedium 20mm day4 巧 JST* 
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Chapter 4 Enhancement of Posterior Spinal Fusion 
-The Effect of Tissue-Engineered MSG 
and Calcium Phosphate Ceramic 
composite treated with LIPUS in Vivo 
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4.1 Introduction 
In Chapter 3, it is observed that LIPUS can enhance the osteoblastic activity of 
the MSC-derived differentiated osteoblastic cells in vitro. This provides a possible 
method for enhancement of osteogenic activities for tissue engineering of bone 
substitute material. In bone tissue engineering for spinal fusion, the aim is to look for 
an alternative to replace conventional autograft or allograft to reduce the associated 
morbidity and availability. To substitute for the autograft that is the 'gold standard' in 
clinical practice, the alternative solution needs to possess the following: 1) 
osteoconductive scaffold; 2) osteogenic cell population; 3) osteoinductive growth 
factors. 
Bone related scaffold has been studied extensively in the past and one of which 
has been used widely in orthopaedic applications is calcium phosphate ceramics 
(CPC). CPC is an osteoconductive material with high degree of biocompatibility and 
appropriate structural pores allowing inward migration of mesenchymal stem cell, 
adhesion, proliferation, and differentiation into osteoblasts at the fusion site (Spivak 
and Hasharoni, 2001). Most of the CPC are composed of either hydroxyapatite (HA) 
or beta-tricalcium phosphate (TCP). Due to its chemical composition, hydroxyapatite 
(HA) is resorbed very slowly under normal physiological condition in contrast to 
TCP which is resorbed completely and much faster. (Gatti et al, 1990) Studies have 
shown that bone marrow cells seeded on CPC can form bone when implanted 
subcutaneously (Boo et al., 2002, Kadiyala et al, 1997, Hanada et al., 1997，Martin 
et al., 1997, Yaylaoglu et al” 1999). Thus, TCP would be a good candidate as 
scaffold for the present application on the posterior spinal fusion model. In the 
present study，pure beta-tricalcium phosphate ceramic (Chronos), is used as the 
- 6 9 -
scaffold carrier with standardized pores of 100 to 500 \im enabling rapid 
vascularization and ingrowth. It is also structured with many micropores (50 |im) 
which could further accelerate resorption. 
As discussed in chapter 3, LIPUS has been shown to enhance spinal fusion with 
autologous bone graft (Aynaci et al., 2002, Cook et al., 2001, Glazer et al, 1998). 
Although the details molecular mechanism is unknown, the LIPUS effect was 
reported to enhance bone formation through the enhancement of endochondral 
ossification. Therefore, LIPUS is chosen in this spinal fusion study to provide 
continuous biophysical stimulation for bone formation. 
In the present chapter, it is hypothesized that the combination of the MSCs and 
TCP together with the stimulation by LIPUS would enhance the bone formation in 
posterior spinal fusion. 
4.1.1. TCP Biomaterials 
TCP is a reliable osteoconductive agent that has been used extensively in various 
clinical settings over the past 20 years. In the present study, pure beta-tricalcium 
phosphate ceramic (Chronos)，is used as the scaffold carrier with functional pores of 
200 to 400 \im in diameter (Yeung et al, 2004) enabling rapid vascularization and 
ingrowth. It is also structured with many micropores (50 |im) which could further 
accelerate resorption. 
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4.2. Materials and Methods 
4.2.1. Materials and Reagents 
4.2.1.1.Tricalcium phosphate ceramic (TCP) 
Standardized custom made blocks of TCP 6 x 8 x 30 mm^ (ChronOS®，Synthes， 
Inc., West Chester, USA) was sterilized by autoclave before usage. 
4.2.1.2.Calcein 
0.5 g calcein (Sigma, St.Louis, USA) was dissolved in 80 ml distilled water. 
After adjusting the pH to 7.4, final volume of 100 ml was made up with additional 
distilled water. The solution was stored at room temperature and kept in darkness. 
4.2.1.3.4% Buffered Formalin 
10 g NaH2P04 (Merck & Co.，Darmstadt, Germany), 16.25 g Na2HP04 
(Merck & Co.，Darmstadt, Germany) and 250 ml formaldehyde (Scharlau, Sentmenat, 
Spain) were mixed and dissolved in 2.5 L distilled water. 
4.2.1.4.Washing solution 
500 g NaCl (Amresco, Solon, USA) and 125 g NaOH (Merck & Co.，Darmstadt, 
Germany) were dissolved into 2.5 L distilled water. 
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4.2.1.5.Water-free Methyl Methacrylate (MMA) 
A pear-shaped separating funnel was pre-washed with small amount of Methyl 
Methacrylate (MMA) (Merck & Co.，Darmstadt, Germany) first. 550 rtiL MMA was 
poured into the funnel. 300 mL washing solution (1st time) was added and the 
solution was then shaken vigorously. The aqueous waste layer of the solution was 
discarded. Another 300mL washing solution (2nd time) was poured into the funnel 
for washing the solution. These procedures were repeated 3 times. To remove 
washing solution left in the MMA solution, the MMA solution was then further 
shaken with distilled water (3 times) instead of washing solution. The remaining 
MMA in the separating funnel was drained into a dehydrating bottle with 60 g CaC12 
pellet (Fluke, China) for 15 min to achieve complete dehydration. Dehydrated MMA 
was filtered and stored at 4°C. 
4.2.L6.MMA solution I 
280 ml butylmethacrylate (Merck & Co” Darmstadt, Germany), 50 ml 
methylbenzoate (Merck & Co., Darmstadt, Germany) and 9.6 ml Polyethylene glycol 
400 (Fluka, Belgium) were added and dissolved in 480 ml water-free MMA. The 
solution was stored at 4°C. 
4.2.1.7.MMA solution II 
0.4 g dry benzoyl peroxide (Uni-Chem) was added and dissolved in 100 mL 
MMA solution I and stored at 4°C. 
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4.2.1.8.MMA solution III 
0.8 g dry benzoyl peroxide (Uni-Chem) was added and dissolved in 100 rtiL 
MMA solution I and stored at 4°C. 
4.2.1.9.PMMA solution 
400 |j,l N,N-dimethyl-p-toluidine (Merck & Co.，Hohenbrunn, Germany) was 
added to 100 ml MMA solution III. The solution was freshly prepared before usage. 
4.2.1.10. Stevenel's Blue 
1.0 g methylene blue (Sigma-Aldrich, St Louis, USA) and 1.5 g potassium 
permanganate (Sigma-Aldrich, St Louis, USA) were mixed in 75 ml distilled water. 
The solution was boiled in boiling water bath until all the precipitates were 
redissolved. It was then filtered after standing cool. 
4.2.1.11. Van Gieson Stain (Picro-Fushin) 
5.0ml 1% Acid Fuchsin aqueous solution (Gurr, BDH Chemical Ltd., Poole, 
England) was added into 100 ml saturated aqueous picric acid (Sigma, St.Louis, 
USA). The solution was stored at room temperature. 
4.2.2. Preparation of MSC Derived Osteogenic Cells-tricalcium Phosphate 
Ceramics Composite 
MSCs were aspirated, isolated and cultured from bone marrow of rabbits as 
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described previously (Chapter 3.2.3.)- 5M MSCs were trysinised and centrifuged at 
1500 rpm for 5 min to collect the cells. Cells were then loaded evenly on the TCP 
ceramics in 35 mm culture dish. Plain DMEM was added to the TCP carefully to just 
cover the TCP blocks with the seeded cell surface for cell attachment for one day 
before surgery. TCP ceramics without cell acted as control group. 
4.2.3. Posterior Spinal Fusion Surgery 
4.2.3.1.Groupings 
16-20 weeks old New Zealand White male rabbits were used in this study. They 
were randomly divided into four groups with different treatments (Table 4.1). Group 
A: TCP alone; Group B: TCP + MSG cultured in basal medium only; Group C: TCP 
+ MSG cultured in basal medium with bFGF and osteogenic supplement for one 
week; Group D: TCP + MSG cultured in basal medium with bFGF and osteogenic 
supplement for one week and in vivo LIPUS. Each rabbit underwent a standard 
posterior spinal fusion procedure with decortications with different treatments of 
tissue engineered cell-ceramics and assessed at internvals for 7 weeks. 
4.2.3.2.0peration Procedures and Sampling 
A standardized posterolateral spinal fusion (Cheng et al., 2002，Boden et al.’ 
1995a) with decorticaton of the posterior structure over the transverse processes was 
used in the present study. In brief, rabbit was put under general intravenous 
anesthesia by low dose of sodium pentobarbital (50 mg/kg per ml; Alfasan 
Woerden-holland, Holland). Transverse processes of the rabbit at L5 and L6 lumbar 
vertebra were exposed after removal of periosteum. For decortications, the dorsal 
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cortical layer of the transverse processes was removed by an air-driven blur until 
bleeding occurs and the bone marrow was exposed (2.5mm in diameter) (Synthes, 
Mathys AG, Bettlach, Switzerland). The TCP composite implants for different groups 
were put on the transverse processes of L5 and L6 of the same rabbit. The muscles 
and skin were then closed by layers. 
All the rabbits were injected with fluorochrome (calcein) at post-operational 
week 6 for histomorphometry study. 
The animals were sacrificed 7 weeks after surgery by overdosed pentobarbital. 
The L5 and L6 transverse processes with the implant was harvested en block. The 
specimens were fixed overnight in 4% formaldehyde and then with 70% ethanol for 
further analysis. 
4.2.4. In vivo LIPUS treatment 
4.2.4. IJrt vivo LIPUS devices 
A low intensity pulsed ultrasound (LIPUS) machine (Exogen 2000+®，Smith & 
Nephew, Inc，Memphis, TN, USA) was used to generate the ultrasound impulse 
at 1.5 MHz pulsed frequency, 200 |is pulse duration and 1.0 kHz repetition rate. The 
power of the LIPUS devices is 30 士 5.0 mW/cm^ spatial average and temporal 
average (SATA) incident intensity. The standardized power tuning and intensity of 
the LIPUS devices were calibrated by the manufacturer. 
42A2.In vivo LIPUS Treatment Procedures 
The LIPUS treatment of rabbits in Group D required theraputic ultrasound 
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treatment started on Day 3 post-operation. Rabbits were under general anesthesia 
with low dose of 10% ketamine (Alfasan, Woerden, Holland)/2% xylazine (Alfasan, 
Woerden, Holland) (0.6 ml: 0.6 ml, v:v) during LIPUS treatment. The LIPUS probe 
with coupling gel was carefully placed on the back of the shaved skin of fusion site 
of the rabbit on where the implant can be palpated. LIPUS was applied 20 min. per 
day, 5 days per week, up to postoperative week 7(Appendix III). 
4.2.5. Assessment of Fusion Mass 
To assess the fusion mass at week 7 post-operation, a fluroscent labeling with 
calcein green was given to the all animals by injection at week 6 post-operation. 
Then the animals were euthanized at Week 7 post-operation by overdosed 
pentobarbital. The fusion mass at L5 and L6 transverse processes was harvested en 
block. The specimens were fixed overnight in 4% formaldehyde and then with 
graded alcohols for further tissue processing. 
4.2.5.1.Manual palpation 
After harvesting the samples at Week 7，the fusion mass of transverse processes 
with implant was assessed with manual palpation by 2 assessors in a blinded fashion. 
The stiffness between L5 and L6 transverse processes was assessed as complete 
fusion and no fusion. (Boden et al, 1995a) 
4.2.5.2.Peripheral Quantitative Computational Tomography (pQCT) 
The mineralized tissue at the fusion site was evaluated with a multi-layer pQCT 
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(Densiscan 2000，Scanco Medical AG, Bassersdorf, Switzerland) (Cheng et al., 2000). 
Eight sections (8 mm) in each sample were scanned sagittally parallel to the 
longitudinal axis of TCP implant. The scanning resolution is 0.3 mm with 1 mm 
thickness per scanned section. The middle six CT sections were used for bone 
volume (BV) and bone mineral content (BMC) analysis as the complete TCP 
ceramics and the transverse processes were clearly identifiable (Figure 4.2.1). 
4.2.6. Histology 
4.2.6. l.MMA Embedding 
After pQCT measurement, the specimens were embedded with methyl 
methacrylate (MMA) according to well established protocol (Cheng et al., 2002, Guo 
et al.’ 2002) for undecalcified histology. In brief, samples were dehydrated with 70%, 
95% and 100% ethanol (3 times each, changed for 3 consecutive days). Samples 
were then embedded with xylene (3 times, changed for 3 consecutive days). 
Dehydrated samples were then further embedded with MMAI, MMAII and MMAIII 
(3 times each, changed for 3 consecutive days) and stored in 4°C. Samples were 
transferred to a vacuum desiccator in fume hood for 1 hour each day during the 
whole embedding procedures. Finally, PMMA was used to solidify the samples and 
nitrogen gas was sprayed to surface of PMMA solution to expel oxygen for more 
than 2 min. Samples stored at -20°C until totally harden. 
Due to the failure in MMA embedding, some samples were damaged. The 
sample size for further histoloical analysis in Group A, B, C and D was 5 , 5 , 6 and 6， 
respectively. 
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4.2.6.2.Sectioning, Polishing of MMA Embedding Samples 
MMA embedded samples were sectioned into 500 |xm sagittally and parallel to 
the longitudinal axis of TCP implant by saw microtome (SP1600，Leica 
Microsystems GmbH, Wetzlar, Germany). Two adjacent slices in the middle region 
of the fusion mass were selected for histomorphometry study. The slices were 
grounded and polished to approximately 100 |xm (Phoenix 4000，Wirtz Buehler, 
Germany). One of the polished slices was assessed under fluorescence microscopy. 
Another one was for Stevenel's Blue Counter Stained with Van Gieson Stain (SVG). 
4.2.6.3.Labeled Fluorochrome Evaluation 
Labeled calcein green in the new bone region of the polished slice were 
observed through L5 filter under a fluorescence microscopic system (Leica Q500MC, 
Leica Cambridge Ltd., Cambridge, UK). Images were captured and fluorescent area 
at the fusion mass was analyzed by using the Metamorph Image Analysis System 
(Universal Imaging Corporation, Downingtown, PA, USA) to determine the newly 
mineralized tissue in week 6. 
4.2.6.4.Stevenel，s Blue Counter Stained with Van Gieson Stain (SVG) 
The Stevenel's Blue stain was prewarmed to 60 °C first. The polished slide was 
stained with Stevenel's Blue stain for 5 min in 60 °C oven and then rinsed with 
distilled water. Van Gieson Picro-Fucsin was stained for another 5 min at room 
temperature. Excess dye was washed out with 100 % ethanol for 1 min. Images were 
captured under light microscopy (Leica Q500MC, Leica Cambridge Ltd., Cambridge, 
UK). The SVG stain combination stains mineralized bone as red to orange, 
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non-mineralized osteoid, muscle, tendon as pale blue to green and cartilaginous 
tissue as purple. The gap distance (Figure 4.2.2), tissue volume (TV) (Figure 4.2.3), 
bone volume (BV) (Figure 4.2.3)，tissue volume/ bone volume (TV/BV)，length of 
transverse processes (Figure 4.2.4) and osteointegration at interface between 
transverse processes and TCP block (Figure 4.2.5), mineralized tissue in TCP (Figure 
4.2.6) and cartilaginous tissue in intertransverse process region (Figure 4.2.7) were 
analyzed by using the Metamorph Image Analysis System (Universal Imaging 
Corporation, Downingtown, PA, USA). 
4.2.7. Statistical Analysis 
The results were expressed in mean 士 one standard deviation. Differences in the 
various variables assessed by manual palpation, pQCT and histology were compared 
by the one-way analysis of variance (ANOVA) among different groups and followed 
by a post hoc multiple comparisons. Student's t-test was also used to compare 
between groups. Statistical significance was set at p < 0.05. All these statistical 
analyses were done with SPSS 13.0 (SPSS, Chicago, IL, USA) for Windows 
software. 
4.3. Results 
Fixed comparisons in each evaluation were made 1) Group A vs. B or C or D; 2) 
Group B vs. C and 3) Group C vs. D 
4.3.1. Fusion by Manual Palpation 
By manual palpation，Group B, Group C, and Group D showed 17%, 14% and 
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86% solid fusion at week 7 post-operation(Table 4.3.1) and 0% in Group A. Group D 
showed the highest solid fusion rate which was significantly higher than Group A 
(p=0.005) and Group C (^=0.029). Similar fusion rate was found in Group B and C. 
4.3.2. pQCT Analysis 
4.3.2.1.Bone Mineral Content of Transverse Processes 
By pQCT analysis, Group B, Group C, and Group D showed 14%, 31% and 
28% increase in BMC of the transverse processes at the fusion site underneath the 
implanted TCP, respectively when compared to Group A (Figure 4.3.1). Group C had 
15% increased in BMC when compared with Group B though it had not reached 
statistical significance. Moreover, Group C and D showed similar BMC value. 
4.3.2.2.Bone Volume of Transverse Processes 
Comparing with Group A, Group C had 7.7 % lower BV of the transverse 
processes (Figure 4.3.2) contrasting with Group D which showed significantly higher 
BV value by 22% of Group A (p=0.023 by Post-hoc test, Bonferroni). Similar BV 
was observed between Group A and B. Group C had an 11% decrease in BV when 
compared with Group B though it was not significant. Moreover, Group D had 
significantly increase in BV value (32%) (p=0.002) as compared with that of Group 
C. 
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4.3.3. Histological Analysis 
4.3.3.1.Qualitative Histological Analysis 
Histology of the transverse processes at Lumbar vertebra L5 and L6 contact 
interphase with TCP ceramic with Stevenel's staining (Figure 4.3.3). TCP implants in 
all groups showed crack fracture at the middle part after 7 weeks implantation. New 
bone was found in the TCP implant in all groups. 
Large gap distance between L5 and L6 transverse process were still observed in 
Group A, B and C implying incomplete fusion. The lengths of transverse processes in 
Group A, B, C were shorter than that of Group D. Gap distance between 
intertransverse processes in Group D was significantly shorter. Moreover, long 
transverse processes length, large cartilaginous tissue, less trabecular bone and long 
integrated length in the interface of implant and L5 and L6 were also found in this 
group (Figure 4.3.3 D). 
4.3.3.2.Gap Distance between Transverse Processes 
Group B and C showed 12% and 69% increased in gap distance, respectively 
when compared to Group A (Figure 4.3.4). Whereas Group D showed smallest 
inter-transverse processes gap distance which was 67% decreased as compared with 
Group A. There were no significant differences when Group A compared with other 
groups. Group C had a 51% increase in distance when compared with Group B 
though it was not statistical significant. Moreover, Group D showed 81% decrease in 
gap distance significantly as compared with Group C (p二0.004). 
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4.3.3.3.Bone Volume of Transverse Processes 
Both Group A and B had similar BV values (Figure 4.3.5). Whereas Group C 
and D showed 80% and 26% increased in BV of transverse processes respectively 
when compared to Group A. While Group C showed high BV of the transverse 
processes which was significantly different from Group A (p=0.042) When 
compared with Group B, the BV of Group C increased significantly by 84% (p二 
0.007). Group C also had 30% increased BV as compared to Group D though not 
significant. 
4.3.3.4.Tissue Volume (TV) of Transverse Processes 
Group A and C had similar TV of transverse porcesses (Figure 4.3.6). The TV of 
Group D was 6% higher than that of Group A. While Group B had a lower TV than 
that of Group A by 14%. There were no significant differences when Group A 
compared with others. 15% increase in TV was found in Group C compared with 
Group B. And 7% increase was also found in Group D as compared to Group C 
though not statistically significant. 
4.3.3.5. Bone Volume/ Tissue Volume of Transverse Processes 
Group A had low BV/ TV value (Figure 4.3.7). Group B and D showed 16% and 
18% increased in BV/TV of transverse processes respectively when compared to 
Group A. While Group C showed high BV/TV of the transverse processes which was 
94% increased as compared to Group A though not significant. There were no 
significant differences when Group A compared with other groups by one-way 
ANOVA. By comparing BV/TV to Group B and D, Group C had 67% and 39% 
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increased respectively though not significant. 
4.3.3.6.Total Length of Transverse Processes 
Group D showed long total length of the transverse processes (Figure 4.3.8) 
which was 18% increased as compared to Group A significantly by Post-hoc test, 
Bonferroni; /7=0.017. Group A, B and C had similar transverse process length. Group 
D also had 24% increase in Group C which was statistically significantly by 
Student's t-test; p= 0.003. 
4.3.3.7.Integrated/ Total Length between Transverse Processes and TCP 
Group A and B had similar integrated/total length of transverse processes 
(Figure 4.3.9). Group C showed low relative integration which was 8% lower than 
Group A. Whereas Group D showed high value which was 36% increased as 
compared to Group A. There were no significant differences when Group A 
compared with other groups by one-way ANOVA. Group B and D had 5% 
(non-significant) and 48% (significant, Student's t-test; p=0.003) increased in 
relative integrated length as compared to Group C respectively. 
4.3.3.8.Mineralized Tissue in TCP Implant 
Group A and C had similar mineralized tissue in TCP (Figure 4.3.10). Group B 
and D showed 44% and 225% increased respectively when compared to Group A. 
Group D had high mineralized tissue in TCP which was significant by Post-hoc test, 
Bonferroni; /7=0.019 as compared to Group A. Group B and D had 29% and 216% 
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(significantly, Student's t-test; /7=0.005) respectively higher mineralized tissue in 
TCP than Group C. 
4.3.3.9.Cartilaginous tissue within the Intertransverse Processes 
Group B，C and D showed 135%, 248% and 1024% (significant, Post-hoc test, 
Bonferroni; p=0.003) increased cartilaginous tissue region respectively when 
compared to Group A (Figure 4.3.11). Group C had 48% higher cartilaginous tissue 
than Group B. And Group D had 223% (significant, Student's t-test; p=0.026) higher 
cartilaginous tissue than Group C. 
4.3.3.10. Qualitative Analysis of Fluorescence Labeled Area in New Bone Region of 
Transverse Process 
Group A and B (Figure 4.3.12A-B) had low labeled area. 
Stronger and larger trabecular bone area in transverse processes was found in 
Group C (Figure 4.3.12C) than Group B (Figure 4.3.12B). 
Larger labeled area in TCP implant was observed in Group D (Figure 4.3.12D) 
than Group C (Figure 4.3.12C). Moreover, longer transverse processes length and 
integrated length at interface between TCP implant and transverse processes was 
observed in Group D. 
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4.3.3,11. Quantitative Analysis of Fluorescence Labeled Area in New Bone Region 
of Transverse Process 
Group A and B had similar low CG labeled area (Figure 4.3.13). Group C and D 
showed higher labeled area which were 41% and 26% increase in CG labeled area 
respectively when compared to Group A though not significant. Group C had 52% 
and 10% larger labeled area than Group B significantly (Student's t-test; /7=0.001) 
and Group D respectively. 
4.4. Discussion 
4.4.1. Summary of the Findings from Different Assessment Methods 
In this chapter, various parameters were assessed through manual palpation, 
histology and pQCT. These evaluations could be summarized into assessment of 
bone formation, size of fusion mass, osteointegration, osteoconductivity, and 
endochondral ossification. 
Bone formation in fusion mass could be partially determined by manual 
palpation. High fusion rate (86%) was found in group D whereas low fusion rate in 
group B (17%) and C (14%) as well as group A (0%). Indicating Group D had high 
bone formation which could be reflected from the stiffness of the transverse 
processes. By pQCT, BMC and BV of the transverse processes were assessed. Group 
C and D had high BMC (31% and 28% increased respectively as compared to Group 
A). This indicated that these 2 groups had more bone formed at the transverse 
processes in terms of amount of mineralized tissue. BV by pQCT also demonstrated 
high bone volumn of transverse processes in Group D (22% increased as compared 
to Group A). 
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For the comparison of the size of the fusion mass in different groups，through 
histology, the gap distance between L5 and L6 transverse processes was one of the 
indications. Shorter gap distance (67% shorter than Group A) and larger TV of 
transverse processes (6% larger than Group A) in Group D were observed. These 
results indicate a larger fusion mass in Group D. Moreover, longer transverse 
processes length was found in Group D (18% longer than Group A) which was 
correlated with its short gap distance. The transverse processes length in Group D 
(30.9士2.87mm) was longer than the TCP implant length (30mm) and the gap 
distance was not zero (0.97士0.13). It indicated the multiple growth directions of 
transverse processes. Shorter gap distance reflected the transverse processes grew 
toward each other. But they might also grow along and surround the edges of TCP as 
shown in the qualitative observations in Figure 4 . 3 . 3 . . 
Apart from bone formation and size of fusion mass, the ratio of integrated 
length over total length of transverse process in the interface between the host bone 
and TCP implant could reflect the osteointegration potential in each group. Higher 
integrated length was observed in Group D (36% higher than Group A) while lowest 
integrated length was found in Group C (8% lower than Group A). This observation 
was also correlated with the qualitative observations (Figure 4.3.3). This indicated 
that Group D had the best osteoinegration potential among the four tested groups. 
Mineralized tissue in TCP could be interpreted as the osteoconductivity of the 
implant. Large mineralized tissue was found in TCP in Group D (216% larger than 
Group C) which implied LIPUS may enhance the osteoconductivity of TCP implant. 
However, in the present study, it is not known the exact mechanism. 
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Cartilaginous tissue in the intertransverse processes reflected the ability of 
endochondral ossification. Large cartilaginous tissue in Group D (223% higher than 
Group C) indicated LIPUS was effective in enhancing the endochondral ossification 
though the underlying mechanism of this enhancement remains unknown. 
4.4.2. Addition of MSCs to TCP ceramic in Spinal Fusion 
Recently, reports in literature have identified new graft materials as alternatives 
to the standard autograft so as to avoid the donor site morbidity which is reported in 
as much as 30% of patients mentioned previously (Chapter 1.2.5). Although newer 
graft materials avoid the complications of IC donor site morbidity, they must 
demonstrate equivalent or better rates fusion to ultimately replace this standard. 
Varied osteoconductive scaffolds have been studied, including collagen, 
demineralized bone matrix, hydroxyapatite, and calcium phosphate ceramic materials 
(Chapter 1.3.1). In the present study, tricalcium phosphate (TCP) was used as a 
carrier. From the findings, it was obvious that TCP alone could not enhance bone 
formation and osteoconductivity as Group A expressed lowest bone formation in 
terms of BMC, BV/TV and mineralized tissue in TCP. Moreover, no fusion and large 
gap distance in Group A imply the low efficacy of TCP alone in enhancing posterior 
spinal fusion. 
As the efficacy of the osteoconductive material or osteoinductive stimulus 
depends entirely on the presence of a sufficient number of osteoprogenitors at the 
fusion site. Bone marrow is one of the sources containing mesenchymal stem cells 
(MSCs), which can proliferate and differentiate into osteogenic specific phenotypes 
such as osteoblasts and osteocytes (Caplan, 1991, Caplan, 2005, Caplan, 2007). As 
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MSCs represent a very small (0.001-0.01%) population of the total nucleated cells in 
marrow (Bruder et al,, 1998). In vitro expansion was used to increase the cell number 
of undifferentiated MSCs. Combination of MSCs with TCP was used in the study to 
provide a stable and fixed environment for the cells to stay at the fusion site. Gan et 
al (Gan et al., 2008) reported that some MSCs entered into the scaffolds through 
inter-pore connection and adhered to the wall of TCP pores within 2 hours of 
incubation. After culturing for 2 weeks, it was found that the TCP was covered by 
proliferating spindle cells on the surface, as well as the inside of the scaffolds 
through a confocal microscope. Cells migrated into and colonized the inside of 
porous scaffold which caused effective cell proliferation. This demonstrated that TCP 
is an effective scaffold for MSCs migration and attachment. Moreover, the 
biodegradable porous TCP ceramic provided calcium ions to the local environment 
for the mineralization of extracellular matrix when the ceramic degraded in situ. 
Studies showed that bone marrow stem cells seeded on ceramics can form bone when 
implanted siibcutaneously (Boo et al, 2002, Hanada et al., 1997，Kadiyala et ai, 
1997，Martin et ai, 1997). 
With the implant of undifferentiated MSG and TCP (Group B), bone formation, 
osteoconductivity and endochondral ossification were enhanced as compared to TCP 
alone (Group A). Bone mineral content, bone volume over tissue volume showed 
14% and 16% respectively higher than TCP alone. 44% increased in mineralized 
tissue in TCP also implied that implant with MSCs and TCP promoted bone 
formation in TCP implant thus indicated the promoted osteoconductivity of TCP 
implant. Endochondral ossification was accelerated as demonstrated in 135% 
increased in cartilaginous tissue in Group B as compared to Group A. Moreover, 17% 
fusion rate in Group B which further confirmed the stimulating effect of MSC in 
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spinal fusion. 
Although the results of implant with undifferentiated MSG and TCP were better 
than TCP alone, the bone formation and fusion rate were still infavorable when 
compared with autograft assuming that autograft had a fusion rate of more than 65%. 
Similar findings observed in Minamide et al study. The fusion rate was 0% in the 
undifferentiated MSG group in rabbits with single level bilateral posterolateral 
intertransverse process fusion. Less mature bone formation was present in the grafted 
fragment and the new bone was not connected mutually through histology 
observation (Minamide et al.’ 2007). In another study by Riew et al, no new-bone 
formation in any of the thoracic disc spaces after undifferentiated MSCs were 
injected in each of three pigs after six weeks (Riew et al.’ 2003). Therefore, it is 
necessary to guide the differentiation of MSG along the osteogenic lineage. 
4.4.3. The Needs of Differentiated MSG in Spinal Fusion 
Apart from increasing the number of MSCs, it is also necessary to induce and 
differentiate the MSCs into osteoblasts with the addition of osteogenic factors e.g. 
osteogenic supplements before loading to carriers and implantation to the fusion site 
(Jaiswal et al.’ 1997，Kai et al., 2003, Malaval et al., 1994, Minamide et al, 2005, 
Ohgushi et al., 1996). The implantation of the cultured bone marrow cells with 
dexamethasone in porous HA particles resulted in good bone formation in vivo 
(Ohgushi et al, 1996，Okumura et al., 1997，Yoshikawa et al, 1996). These 
investigators showed that porous HA particles and dexamethasone enhanced the 
differentiation of the MSG into osteogenic cells. 
Undifferentiated MSG might take longer time to differentiate into osteogenic 
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cell after implantation. In contrast, during in vitro expansion, MSCs were led to 
differentiate into various stages of osteoblastic lineage by osteogenic supplements 
(e.g. dexamethasone). The osteogenic cells were able to synthesize bone matrix 
protein (Cao et al, 2005) such as osteocalcin and alkaline phosphatase to assist 
osteogenesis (Martin et al, 1997) and bone promoting growth factors such as BMP-2 
(Bi et al., 1999) and BMP-4 (Ogura et al., 2004) which enhanced spinal fusion.. 
Moreover, MSCs derived osteogenic donor cells themselves might also contribute to 
the formation of bone. The MSC-TCP composite might act as cell delivery system. 
Fresh bone marrow released to fusion bed after decortications interplayed with the 
differentiating MSCs to promote bone regeneration and bone integration into 
ceramics and enhance spinal fusion finally. 
In the current study, with the further addition of osteogenic supplements into 
MSC (Group C), bone formation and endochondral ossification were elevated as 
compared to undifferentiated MSC group (Group B). Bone volume, tissue volume 
and bone volume over tissue volume in Group C were increased 84% significantly, 
15% and 67% respectively through histology when compared to Group B. Similar 
findings were observed in our previous study, the volume (BV) of fusion transverse 
processes in differentiated MSC group was increased by 54.3% (p<0.05) compared 
to cell free TCP group in undecorticated approach of spinal fusion(Cheng et al, 
2007). The tissue volume of the newly formed bone was also significantly higher in 
the differentiated MSC group (2.3 fold at L5 and 3.6 fold at L6). Moreover, the 
volume of fusion of the transverse process in differentiated MSC group was 16.1% 
greater than autograft group significantly. Another study by Yeung et al., the fusion 
mass volume was increased by 40% when compared to cell-free ceramic in 
non-decorticated spinal fusion (Yeung et al., 2005). The highest BMC value was 
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found in the differentiated MSG group among all the groups which was 15% higher 
than undifferentiated MSG group. Besides, the CG labeled area also increased 70% 
in this group as compared to the undifferentiated one. Under fluorescent microscopy, 
more active bone formation and remodeling was observed in the differentiated MSG 
group in undecortication spinal fusion (Cheng et al, 2007). These indicated that 
osteogenic differentiation of MSG with the addition of OS could enhance bone 
formation in spinal fusion. 
On the other hand, endochondral ossification was also accelerated as 
demonstrated in 48% increased in cartilaginous area with Group C as compared to 
Group B. The accelerating ossification effect by differentiated MSG was similar to 
the observation of using BMP4 in our previous study. The intertransverse interval 
was filled with cartilage and active ongoing endochondral bone formation was found 
in HA/TCP with BMP4 group. Multiple endochondral ossification centers were also 
observed in the intertransverse gap through histological observation (Cheng et al, 
2002). 
Although the bony fusion rates in these two groups were similar, Group B (17%) 
and Group C (14%), osteogenic differentiated MSG promoted the bone and cartilage 
formation. These results implied that osteogenic MSCs performed better bony quality 
of the fusion site than undifferentiated MSG group. 
4.4.4. bFGF Masked the Effect of OS in MSG 
Low solid fusion rate (14%) was still found in Group C which was unexpected. 
Several papers reported that the addition of osteogenic MSCs to various 
osteoconductive materials results in a fusion rate similar or better than that of 
autograft. Nakajima et al. reported the fusion rate of differentiated MSCs group (80%) 
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was the highest among the groups with autograft (67%) and undifferentiated MSCs 
(33%). New mature bone formation was also observed in the groups of autograft and 
differentiated MSCs histologically. This study demonstrated that osteogenic 
differentiated MSCs were more effective in enhancing fusion than undifferentiated 
MSCs (Nakajima et al., 2007). Kai et al. reported bone marrow derived osteoblasts 
combined with a porous calcium phosphate ceramic composite resulted in 100% 
fusion as compared with autograft 66%. Also, fusion mass in the group of bone 
marrow stroma derived osteoblasts was statistically significantly stiffer and stronger 
on biomechanical testing. This group also had a qualitative increase in bone 
formation in histological analysis. In larger animals, Gupta et al. also found 
equivalent fusion rates for osteoprogenitor-enriched tricalcium phosphate (33%) 
compared with autogenous bone graft (25%) in a sheep posterolateral lumbar spine 
model. Denser bone was observed in the osteoprogenitor group. 
This low bony fusion rate in Group C might due to the addition of bFGF in the 
osteogenic medium during in vitro expansion. bFGF might mask the effect of 
osteogenic supplements and thus leading to low fusion rate, lower integrated length 
(26%), lower mineralized tissue in TCP (29%) and larger gap distance (51%) than 
Group B. 
Controversial findings were shown in the ability of bFGF to promote 
osteogensis. bFGF is a strong mitogen for bone derived cells and induces bone 
formation by stimulating proliferation and differentiation of mesenchymal 
osteoprogenitor cells when administrated systemically or locally to fracture site 
(Kawaguchi et al, 1994). Pitaru et al. reported that bFGF stimulates osteogenic 
differentiation of dexamethasone-treated bone marrow mesenchymal stem cells as 
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evidenced by enhanced alkaline phosphatase activity, osteocalcin production, and 
bone nodule formation (Pitaru et al, 1993). Hanada et al reported that rat bone 
marrow-derived mesenchymal stem cells combined treatment with bFGF and BMP-2 
stimulated osteogenesis more than those exposed to each factor alone (Hanada et al, 
1997). In contrast, in the findings of Minamide et al, bFGF showed weak osteogenic 
promoting effect. In Minamide et al. study, bFGF was also added to the MSCs 
culture and implanted to the fusion site (Minamide et al, 2007). 3/7 complete fusion 
rate was observed in bFGF treated MSG group in manual palpation and radiographs. 
By histological observation, less mature bone formation was present in the grafted 
fragments, and the new bone was not connected mutually in mesenchymal stem cell 
cultured with bFGF group. 
Results from in vitro study also showed the bFGF treated MSCs maintained in 
undifferentiated stage of osteogenic lineage with higher proliferation potential. 
Martin et al investigated the effects of different growth factors on the proliferation 
and osteogenic potential of primary cultures of human bone marrow stromal cell. 
bFGF was the most effective mitogens in promoting growth of these cells in vitro. 
The size of colonies formed in clonal conditions was approximately 2.5 times larger 
in presence of bFGF. Also the morphology of BMSC was affected: cells cultured in 
10% FCS alone became flattened, whereas bFGF expanded cells maintained a 
fibroblast-like elongated phenotype. Levels of alkaline phosphatase activity in 
BMSC expanded with bFGF were significantly lower (56%) than control (Martin et 
al, 1997). Another paper (Lee et al, 2009) also demonstrated enhanced growth 
(81-103% as compared to control) of human ATSCs by bFGF and DEX. And more 
than 97% of ATSCs that were expanded in the presence of bFGF and DEX 
maintained the expression of MSG cell surface markers, which was similar to 
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untreated ATSCs. Thus, cells were still in the undifferentiated stage. Therefore, in the 
current study, bFGF/OS treated cells might remain at the undifferentiated stage. It 
might take time to differentiate into mature osteogenic cells after implantation and 
resulted in later bone formation. From the current study, high fluorescent labeled area 
(injected in week 6) (Figure 4.3.13) in transverse processes was found in 
differentiated MSC (bFGF/OS treated MSC) group. This implied that the bFGF with 
osteogenic supplements treated MSCs enhanced bone regeneration mainly in the 
later stage, from week 6-7. 
Besides, the proliferative nature of bFGF/OS treated MSCs in Group C may 
also differentiate into other cell types and tissue such as fibrous tissue (Amizuka et 
al.’ 1998)，cartilaginous tissue (Chuma et al, 2004) and even adipose tissue rather 
than bone (Tsutsumi et al.’ 2001). It depended on the micro-environment in vivo. In 
Lee et al. study, expanded cells after bFGF treatment were then collected, reseeded, 
and cultured for an additional 14 days in osteogenic medium or adipogenic medium 
without bFGF. And these bFGF treated cells had higher tendency to differentiate into 
osteocytes or adipocytes under the influence of osteogenic and adipogenic medium 
respectively. However, in this study, bFGF and OS were added to the MSCs at the 
same time. Therefore, the proliferation of the MSCs was enhanced instead of 
osteogenic differentiator!. Cells treated with bFGF/OS were remained in the 
proliferative stage of MSCs and implanted to fusion site. MSCs in this stage might 
differentiate into chondrocytes, adipocytes rather than osteocytes or osteoblasts in the 
fusion site in Group C which leading to low fusion rate. 
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4.4.5. LIPUS Enhanced Bone Formation 
Several studies demonstrated LIPUS promoted bone formation in spinal fusion 
implanted with autograft or HA/TCP. Glazer et al and Aynaci et al. investigated the 
effects of LIPUS on posterolateral intertransverse process fusion by using bone graft 
in rabbit model whereas Cook et al. performed in dog model. Chan et al. 
demonstrated LIPUS effect in rabbit model implanted with HA/TCP. From histologic 
observation, new bone formation within the fusion mass, cartilage, intramembranous 
woven bone, and new osteoid was present with LIPUS (Glazer et al, 1998)，higher 
cellularity and higher new formed bone area in whole fusion bed in LIPUS treatment 
group (Chan et al, 2007). The LIPUS group had significant osteoblast activity, 
significant bone formation and mature fusions, and diminished fibrosis, as compared 
with the control group (Aynaci et al., 2002). The degree of graft incorporation and 
amount of new bone formation and remodeling was advanced in ultrasound-treated 
sites compared with control sites through radiography (Cook et al., 2001) 
By manual palpation, Group D (LIPUS group) showed a significant increase in 
fusion rate (86%) which was better than that of the autograft (70%). This finding was 
consistent with others. Aynaci et al. showed 85% fusion after 6 weeks LIPUS 
stimulation and 55% in autograft group in both histologic and mechanical fusion. In 
dog model, Cook et al. reported 100% histologic fusion rate was observed in all 
ultrasound-stimulated sites at 12 weeks after surgery and an 86% was observed upon 
manual palpation, suggesting an acceleration of fusion. In mechanical fusion, seven 
ultrasound treated sites (86%) were solidly fused compared with three of nine control 
sites (33%). Overall, the mechanical stiffness at 6 and 12 weeks after surgery of 
fusion sites treated with ultrasound was greater when compared with the control sites. 
The 12-week ultrasound-treated sites had the greatest mean torsional stiffness, which 
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was approximately one third greater than the mean stiffness of the 12-week control 
sites. 
Short gap distance was also found in LIPUS group among groups which further 
confirmed the enhanced osteogenesis by LIPUS in spinal fusion. Chan et al. (Chan et 
al” 2007)determined the effect of LIPUS on posterior spinal fusion implanted with 
cell-free HA/TCP. LIPUS treatment group was observed to have smaller fusion gap 
and more fusion mass in micro-radiograph. It was further verified by significant 
decrease of inter-process distance in LIPUS treatment group (29%,/7=0.006). 
The manual palpation, pQCT and histologic results of this study suggested that 
the use of a low intensity pulsed ultrasound in rabbit model may have an accelerative 
effect on spinal fusion through enhancing bone mineralization, bone remodeling and 
endochondral ossification. 
4.4.6. LIPUS Enhanced Bone Formation through Mineralization 
By pQCT, high BMC in the LIPUS group was observed which was 28% higher 
than Group A. And LIPUS group also had high bone volume which was 22% and 
32% greater than TCP and differentiated MSG group significantly. From 
histomorphological analysis, high tissue volume of LIPUS group was also observed 
though not significant to others. All these findings implied that LIPUS may promote 
the solid fusion rate through enhancing mineralization. Similar findings were 
observed in several reports. Bone area ratio of fusion processes in LIPUS group 
implanted with HA/TCP in rabbit spinal fusion was also found to be 50% greater 
than sham group significantly (Chan et al, 2007). Active LIPUS-treated fractures 
had 14.3% and 16.9% significantly greater fracture site BMC on DXA and pQCT 
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respectively than inactive LIPUS-treated fractures after 40 days LIPUS stimulation 
in bilateral midshaft femur fractures in adult rats (Warden et al., 2006). Moreover, 
LIPUS induced changes in mineralization at tissue level after distraction 
osteogenesis (Chan et al.’ 2006a, Eberson et al, 2003). LIPUS on bone 
mineralization was demonstrated by increased BMC and volume of the mineralized 
tissue in distraction callus in rabbits by three-dimensional pQCT measurement. The 
BMC was greater than the control group by 68.2% significantly. The volume of the 
mineralized tissue in LIPUS group was also greater than that of the control group 
significantly(Chan et al., 2006a). Eberson et al. found that LIPUS was able to 
stimulate osteogenesis as reflected by the increase in the newly formed bone volume 
and the acceleration of bone mineralization in terms of BMC and BMD of the newly 
formed bone at the healing interface in unilateral femoral lengthenings performed on 
SD rats. In another study, in vivo experiments using rabbits showed that LIPUS 
application for 3 weeks significantly increased mineralized tissue volume and 
mineral content by microCT in the porous HA ceramic impanted in the femoral 
condyle in comparison with similarly implanted HA ceramic that was not exposed to 
LIPUS (Iwai etal., 2007). 
4.4.7. LIPUS Enhanced Spinal Fusion through Bone Remodeling-induced 
Fusion Mass 
"Remodeling serves the needs of replacement, maintenance, and homeostaiss，. 
"Existing bone that becomes damaged is replaced with a like amount of bone without 
alteration in size and shape" (Geddes 1996). Two major cell types responsible for 
bone remodeling: osteoclasts which resorb bone and osteoblasts which form new 
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bone. Osteoclastic resorption of bone pockets that are then filled by osteoblast 
activity. In some places, either as bone-lining cells on a trabeculum or as infilling 
after an osteoclastic cutting cone in cortical bone, osteoblasts lay down new bone; in 
others osteoclasts resorb the mineralized matrix. This cyclic ssequence is also called 
the activation-resorption-reversal-formation (ARRF) sequence. Remodeling is not 
only required to replace dead or damaged tissue, it also gives bone the capacity to 
adapt to changes in loading and to respond to nutritional and/or metabolic changes 
(Bain and Rubin, 1990，Qin et al, 1998). 
LIPUS stimulated the bone formation through increasing bone remodeling. 
Group D had high integrated length in the interface of TCP and transverse processes 
which was significantly to Group C by 48%. Group D also expressed high 
mineralized tissure in TCP among all groups and which was 216% higher than Group 
C significantly. These promoted bone formation may be due to the increased 
osteoblast and decreased osteoclast activity and number after LIPUS stimulation. 
Similar findings were observed in various LIPUS studies. LIPUS accelerated 
bone ingrowth into the pores of HA ceramic (Iwai et al.’ 2007). In vivo experiments 
using rabbits showed that LIPUS stimulation for 2 weeks significantly increased 
osteoblast number and bone area in the central part of the porous HA ceramic 
implanted in the femoral condyle as compared to implanted HA ceramic alone. The 
effect of LIPUS stimulation (10 min) on the differentiation of osteoblasts and 
osteoclastogenesis was studied in osteoblastic cell line MC3T3-E1 and primary 
osteoblasts. Flow cytometry showed that LIPUS stimulation for 10 min transiently 
increased the surface expression of alpha2, alpha5, and betal integrins. Effect of 
long-term LIPUS stimulation on the osteoclastogenesis was also examined using rat 
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bone marrow stromal cells. LIPUS stimulation also markedly inhibited RANKL plus 
M-CSF-induced osteoclastic differentiation. These findings suggested that LIPUS 
has a regulatory effect on the integrin expression and the differentiation of 
osteoblasts and osteoclastogenesis, which may contribute to the beneficial effects of 
LIPUS on the fracture repair (Yang et al., 2005). Osteoclastogenesis needs the fusion 
of monocytes to form multinuclear cells. The fusion process may involve the 
alteration of interaction between cell integrin and extracellular matrix. Therefore, the 
actin cytoskeleton and the alteration of integrin expression may also play important 
roles for the transduction of LIPUS stimuli to osteoclasts. Others in vitro study 
showed that the osteoclast cell counts were significantly decreased while osteoblast 
cell number increased under LIPUS treatment.(Sun et al.’ 1999) Moreover, following 
LIPUS, synthesis of IL-6 and TNFalpha were decreased from osteoblast (Li et al., 
2003) which in turn declined osteoclast activity (Kudo et al., 2003, Lee et al., 2001). 
These enhanced incorporation and remodeling of the fusion mass with the host 
bone bed in the LIPUS group is an important finding as it implied in increasing the 
rigidity of the fused construct using the posterior noninstriimented surgical model of 
spine fusion. 
4.4.8. LIPUS Enhanced Bone Formation through Endochondral Ossification 
Bone formation can be obtained through 2 mechanisms. One involves MSG 
differentiating directly into osteoblasts, which then proceed to form bone. Another 
involves MSG proceeds via chondrocytes, which then form cartilaginous templates 
of the future bone, this process is called endochondral ossification. This cartilaginous 
template then gradually replace by invading osteoblasts which then replace the 
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hypertrophic cartilage and allow ossification to occur. 
The newly formed bone in transverse processes might have involved the 
biological processes of endochondral ossification. Cartilaginous tissue was 
dramatically increased in Group D. And it showed high cartilaginous tissue which 
was 1024% and 223% significant increased when compared to Group A and C 
respectively. 
LIPUS stimulated endochondral ossification in many in vivo and in vitro studies. 
In a standard rat femur fracture model, aggrecan, a common gene associated with 
cartilage formation, was significantly higher on day 7 after fracture treated with 
ultrasound. This study showed LIPUS may alter chondrocyte maturation and 
endochondral bone formation (Yang et al, 1996). Proteoglycan rich cartilage stained 
by safranin O was observed near the newly formed bone area in LIPUS treatment 
group while very less or even no cartilage tissue in samples of the sham group in 
spinal fusion implanted with HA/TCP (Chan et al, 2007). Endochondral ossification 
was elevated in another study in distraction osteogenesis in rabbit model. An 
upregulation of proteoglycan in safranin O-stained histology was observed in the 
whole distraction callus following LIPUS treatment. Cartilaginous area fraction of 40 
min LIPUS was significantly greater than the control group in the intercortical region 
(Chan et al, 2006a). 
Apart from in vivo studies, a number of in vitro studies have reported the effect 
of LIPUS on stimulating chondrogenesis, endochondral ossification in various cell 
types. In chondrocytes, chondrogenesis has been demonstrated by increased 
proteoglycan synthesis through upregulation of aggrecan gene expression after 
LIPUS stimulation (Parvizi et al., 1999). Besides chondrocytes, mesencyhmal stem 
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cells were studied with LIPUS. Accelerated differentiations of MSCs into 
chondrocytes have been reported. Ebisawa et al. determined the effects of LIPUS on 
the differentiation of human MSCs toward chondrocytes and cartilage matrix 
formation. Chondrogenesis was enhanced after LIPUS stimulation in 
TGF-beta-treated cell pellets. Aggrecan deposition was increased by 2.9 and 8.7-fold 
by treatment with TGF-beta alone and with both TGF-beta and LIPUS respectively. 
It indicated that LIPUS enhanced TGF-beta-mediated chondrocyte differentiation of 
MSCs in pellet culture and that application of LIPUS may facilitate formation of 
chondrocytes and maturation of cartilage tissue (Ebisawa et al, 2004). The LIPUS 
effect on chondrogenic differentiation of human bone marrow-derived mesenchymal 
stem cells cultured in aggregate or scaffold with chondrogenic medium was 
examined (Schumann et al, 2006). Ultrasound application for 40 minutes daily 
resulted in a statistically significant increase of the proteoglycan and collagen content 
after 21 days in culture. Ultrasound treated cell-scaffold constructs showed a 
significant increase of chondrogenic marker gene expression and extracellular matrix 
deposition. This study indicated that LIPUS enhanced the chondrogenesis of 
mesenchymal stem cells in cell aggregates and cell-scaffold constructs. Therefore, it 
may conclude that LIPUS stimulated bone formation in spinal fusion via 
endochondral ossification. 
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Table 4.2.1 Experimental treatment, group code and sample size. The fusion site of 
all the groups was decorticated. 
Group code Treatment Sample size 
A T ^ 7 
B TCP and MSC 6 
“ TCP, bFGF/OS treated “ 
MSC 
“ TCP, bFGF/OS treated ~ 
MSC and in vivo LIPUS 
- 1 0 2 -
Figure 4.2,1 BV and BMC of transverse processes measurement by pQCT. 
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Figure 4.2.2 Gap distance between transverse processes measurement 
Figure 4.2.3 Tissue volume (TV) (contour area) and bone volume (BV) (mineralized 
tissue) of transverse processes measurement. 
Figure 4.2.4 Length of transverse processes measurement 
- 1 0 3 -
^ H g H H H H H M H P 
I ...…,w ^ " ^ ^ ^ ^ R b i h b p ^ ^ ^ ——： 
Figure 4.2.5 Integrated length at interface between transverse processes and TCP 
block measurement 
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Figure 4.2.6 Mineralized tissue in TCP measurement 
Figure 4.2.7 Mineralized tissue in TCP (lOOX). 
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Figure 4.2.8 Cartilaginous tissue in intertransverse process region measurement 
• 
Figure 4.2.9 Cartilaginous tissue in intertransverse process region (lOOX). 
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Table 4.3.1 Fusion rate by manual palpation. 
Group % of Fusion p-value 
A — 0% (0/7) * 
B 17% (1/6) / 
C 14% (1/7) # 
D 86% (6/7) * /7=0.005;#P=0.029 
Group D showed the highest solid fusion rate (86%) whereas the lowest one was 
Group A which had no fusion (0%). Similar fusion rate was found in Group B and C. 
*#Fisher exact test when compared with Group D. 
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Figure 4.3.1 Bone mineral content of transverse processes by pQCT. 
Group B, C and D showed 14%, 31% and 28% increased in BMC respectively when 
compared to Group A. However, there were no significant differences among all the 
groups by one-way ANOVA. Group C had 15% increased in BMC when compared 
with Group B though it was not significant by Student's t-test. Moreover, Group C 
and D showed similar BMC value. 
(The error bar represents 1 standard deviation of means.) 
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Figure 4.3.2 Bone volume of transverse processes by pQCT. 
Group C showed low BV of the transverse processes which was 7.7% decreased as 
compared to Group A. Whereas Group D had high BV value which was 22% 
increased as compared to Group A significantly. Similar BV was observed between 
Group A and B. Group C had an 11% decrease in BV when compared with Group B 
though it was not significant by Student's t-test. Moreover, Group D showed 32% 
increase in BV value significantly as compared with Group C. 
* Post-hoc test, Bonferroni; p=0.023 when Group A compared with other groups. 
^Student's t-test; p= 0.002 when Group C compared with Group D. 
(The error bar represents 1 standard deviation of means.) 
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Figure 4.3.3 General histomorphology of L5 and L6 transverse processes contacted 
with TCP ceramic stained with Stevenel's blue (16X). A) Group A; B) Group B; C) 
Group C and D) Group D. TCP implants in all groups were fractured into 2 parts 
after 7 weeks implantation. New bone was formed in TCP implant in all groups. 
Large distance between L5 and L6 transverse processes still observed in Group A, B 
and C which implied non-solid fusion (A-C). And lengths of transverse processes in 
these three groups were shorter than that of Group D. Distance between 
intertransverse processes in Group D (D) was obviously the shorter. Moreover, long 
transverse processes length, large cartilaginous tissue, less trabecular bone and long 
integrated length in the interface of implant and L5 and L6 were also found in this 
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group. (TCP- tricalcium phosphate implant; TP- transverse process; 
ITP-intertransverse process; C-cartilaginous tissue) 
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Figure 4.3.4 Gap distance between L5 and L6 transverse processes. 
Group B and C showed 12% and 69% increased in gap distance respectively when 
compared to Group A. Whereas Group D showed small inter-transverse processes 
gap distance which was 67% decreased as compared with Group A. There were no 
significant differences when Group A compared with other groups by one-way 
ANOVA. Group C had a 51% increase in distance when compared with Group B 
though it was not significant by Student's t-test. Moreover, Group D showed 81% 
decrease in gap distance significantly as compared with Group C. 
# Student's t-test; /?=0.004 when Group C compared with Group D. 
(The error bar represents 1 standard deviation of means.) 
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Figure 4.3.5 Bone volume of L5 and L6 transverse processes. 
Group A and B had similar BV values. Group C and D showed 80% and 26% 
increased in BV of transverse processes respectively when compared to Group A. 
While Group B showed high BV of the transverse processes which was significant to 
Group A. 84% statistically significant increased in BV was found in Group C as 
compared to Group B. Group B also had 30% increased BV as compared to Group D 
though not significant. 
* Post-hoc test, Bonferroni; p=0.042 when Group A compared with other groups. 
#Student，s t-test; p= 0.007 when Group C compared with Group B 
(The error bar represents 1 standard deviation of means.) 
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Figure 4.3.6 Tissue volume of L5 and L6 transverse processes. 
Group A and C had similar TV values. Group D had high TV which was 6 % increase 
in TV as compared to Group A. While Group B showed low TV of the transverse 
processes which was 14% lower than Group A. There were no significant differences 
when Group A compared with others by one-way ANOVA. 15% increase in TV was 
found in Group C compared with Group B. And 7% increase was also found in 
Group D as compared to Group C though not significant. 
(The error bar represents 1 standard deviation of means.) 
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Figure 4.3.7 Bone volume/tissue volume of L5 and L6 transverse processes. 
Group A had low BV/ TV value. Group B and D showed 16% and 18% increased in 
BV/TV of transverse processes respectively when compared to Group A. While 
Group C showed high BV/TV of the transverse processes which was 94% increased 
as compared to Group A though not significant. There were no significant differences 
when Group A compared with other groups by one-way ANOVA. By comparing 
BV/TV to Group B and D, Group C had 67% and 39% increased respectively though 
not significant. 
(The error bar represents I standard deviation of means.) 
- 1 1 4 -
* 
i ’ I I # li 
y 沾 
l i — — 
— 
I .. - ..— 
考 ^ 1 r ^ ^ ^ ^ ^ --
H 
n=5 n=5 n=6 n=6 
Group 
Figure 4.3.8 Total length of L5 and L6 transverse processes. 
Group D showed long total length of the transverse processes which was 18% 
increased as compared to Group A significantly. Group A, B and C group had similar 
transverse process length. Group D also had 24% increase in Group C which was 
statistically significantly. 
* Post-hoc test, Bonferroni; p=0.017 when Group A compared with other groups. 
#Student，s t-test; p= 0.003 when Group C compared with Group D 
(The error bar represents 1 standard deviation of means.) 
- 1 1 5 -
ft 
1 0 0 ] j \ 
I I t ' 
80 m n 
0 H 1 ^ 1 — , 
n=5 n=5 n=6 n=6 
Group 
Figure 4.3.9 Integrated length/ total length of transverse processes. 
Group A and B had similar integrated/total length of transverse processes. Group C 
showed low relative integration which was 8% lower than Group A. Whereas Group 
D showed high value which was 36% increased as compared to Group A. There were 
no significant differences when Group A compared with other groups by one-way 
ANOVA. Group B and D had 5% (non-significant) and 48% (significant) increased 
in relative integrated length as compared to Group C respectively. 
#Student’s t-test; /7=0.003 when Group C compared with Group D. 
(The error bar represents 1 standard deviation of means.) 
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Figure 4.3.10 Mineralized tissue in TCP. 
Group A and C had similar mineralized tissue in TCP implant. Group B and D 
showed 44% and 225% increased respectively when compared to Group A. Group D 
had high mineralized tissue in TCP which was significant as compared to Group A. 
Group B and D had 29% and 216% (significant) respectively higher mineralized 
tissue in TCP than Group C. 
• Post-hoc test, Bonferroni; /7=0.019 when Group A compared with other groups. 
#Student，s t-test; /7=0.005 when Group C compared with Group D. 
(The error bar represents 1 standard deviation of means.) 
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Figure 4.3.11 Cartilaginous tissue within transverse processes. 
Group B, C and D showed 135%, 248% and 1024% (significant) increased 
cartilaginous tissue respectively when compared to Group A. Group C had 48% 
higher cartilaginous tissue than Group B. And Group D had 223% (significant) 
higher cartilaginous tissue than Group C. 
#Post-hoc test, Bonferroni; p=0.003 when Group A compared with Group D. 
* Student's t-test; p=0.026 when Group C compared with Group D 
(The error bar represents 1 standard deviation of means.) 
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Figure 4.3.12 Sagittal undecalcified sections of transverse process with fluorescence 
labeling (calcein green CG injected in week 6). (A) Group A; (B) Group B; (C) 
Group C and (D) Group D. (16X). 
Group A and B (A-B) had low labeled area. Stronger and larger labeled trabecular 
bone area in transverse processes was found in Group C (C) than Group B (B). 
Larger labeled area in TCP implant was observed in Group D (D) than Group C (C). 
Moreover, longer transverse processes length and integrated length at interface 
between TCP implant and transverse processes was observed in Group D. 
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Figure 4.3.13 Fluorescent (calcein green) labeled area in transverse process. 
Group A and B had similar low CG labeled area. Group C and D showed higher 
labeled area which were 41% and 26% increase in CG labeled area respectively 
when compared to Group A though not significant. Group C had 52% and 10% larger 
labeled area than Group B group significantly and Group D respectively. 
There were no significant differences when Group A compared with other groups by 
one-way ANOVA. 
#Student，s t-test;/7=0.00l when Group C compared with Group D. 
(The error bar represents 1 standard deviation of means.) 
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Table 4.3.2 Summary of all the results with different evaluations, (mean 士SD) 
Group Group A Group B Group C Group D 
Fusion 0/7d 1/6 1/7 ‘ d ^ 二0.005) 
>=0 .029) 
0.202士0.046 0.231士0.057 0.266±0.062 0.259±0.064 (g) 
582士 36.3 
, 3 � 476±15.9' 492士63.1 440士 65.lb >=0 .023) 
( _ ) V - 0 . 0 0 2 ) 
2.97±0.37 3.30土0.95 4 9 = : o.97±0.13^ (mm) (p 二0.004) 
2 . 6 1 士 0 . 6 8 
BV OTtransverse ^ 4 4 ^ 0 . 7 1 . 4 2 ± 0 . 3 8 � >=0 .042) 1.82士0.68 
processes (mm ) �(严0.007) 
TV of transverse 5 o8±0.62 5.23士0.85 6.02±1.39 6.42±1.33 
processes (mm ) 
BV/TV of 
transverse 0.235土0.105 0.273士0.068 0.456±0.186 0.278士 0.062 
processes 
Total length of 30.9±2.87 
transverse 26.3±2.52' 26.0±1.13 25.0±1.65'' >=0 .017) 
processes V 二0.003) 
(mm) ^ 
Integrated length/ 
total length of 7Q 1 8 
transverse 58.7士4.29 57.2士 16.7 54.1±9.20卜 b qq® 
processes ‘ 
(mm) 
Mineralized 0.038士 0.014 
tissue in TCP 0.0l2±0.0ll ' 0.017±0.015 0.012±0.01lb >=0 .019) 
(mm2) b(p=ooo5) 
• 1.728±0.916 
Cartilapnous o.l54±0.211' 0.361±0.356 0.535±0.645'' >=0 .003) 
t 隱 e (mm ) V 0 . 0 2 6 ) 
二 二 ng 4.92.0.528 4 . 5 湖 5 � 二 ； 6 . 1 9 . 1 . o 7 ~ 
a Post-hoc test, Bonferroni when Group A compared to other groups 
e Student's t-test when Group B compared to Group C 
''Student's t-test when Group C compared to Group D. 
In fusion rate, 
dpisher exact test between Group A and D 
^Fisher exact test between Group C and D. 
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Chapter 5 In Vivo Monitoring of Spinal Fusion in 
Animal Model with High-resolution 
Peripheral Quantitative Computed 
Tomography—A New Pilot Study 
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5.1. Introduction 
Apart from plain radiographic image, the common methods for assessing the 
fusion mass and bone formation in animal study were mainly through histology or 
clinical CT scan (1mm slice thickness) (Minamide et al., 2007, Minamide et al, 
2005, Suh et al, 2002). Histology is an invasive and destructive method and provides 
a 2 dimensional picture of the fusion mass. To have a comprehensive histological 
view of the fusion mass, selected serial sectioning with demanding technical skill is 
necessary. The other alternative is using clinical computed tomography to depict the 
fusion mass. However, the resolution of clinical CT is very limited within millimeter 
at best. When applying to small animals such as rabbit, the image would not be clear 
enough to allow reasonable quantitative analysis. They can only provide a gross 
evaluation (Suh et al, 2002). Ideally, it would be good to have the technology and 
technique to allow objective three-dimensional histomorphometric analysis 
qualitatively and quantitatively to monitor the change following the spinal fusion 
procedure in small animals. This will provide better understand of the biology of 
bone regeneration longitudinally in vivo. 
High-resolution Peripheral Quantitative Computed Tomography Scan 
(HR-pQCT) has potential to measure important components of bone quality 
including bone mineral density, micro-architectural morphology and bone mechanics 
longitudinally with reasonably accurate results which are high correlated with 
micro-computed tomography and dual energy X-ray absorptiometry (DXA) 
(MacNeil and Boyd, 2007) with the gold standard measurements. 
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In this pilot study, we examined the feasibility of HR-pQCT to assess the 
longitudinal pilot study on morphology changes of transverse processes and bone 
mineral content of TCP implant at fusion site in vivo. 
5.2. Materials and Methods 
5.2.1. Animal Groupings 
New Zealand White male rabbits (16-20 weeks old) were used for three 
dimensional longitudinal monitoring. They were randomly divided into two groups 1) 
Control group without LIPUS treatment; 2) LIPUS group with daily LIPUS 
treatment. Similar to the previous study, the animals underwent the standardized 
posterolateral spinal fusion with decortication of the transverse process of the lumbar 
vertebrae L5 and L6. The TCP and tissue-engineered MSCs composite implant was 
then placed in direct contact on the transverse processes without any additional 
fixation. 
5.2.2. Preparation of MSC Derived Osteogenic Cells-tricalcium Phosphate 
Ceramics Composite 
The composite was produced from a combination of the osteogenic cells derived 
from bone marrow MSCs and tricalcium phosphate ceramic (TCP). The TCP was 
commercially available (ChronOS®，Synthes，Inc., West Chester, USA). The 
procedures of isolation of MSCs from bone marrow and the culturing condition to 
induce the cells to osteogenic linkage have been described in the previous chapter 
(Chapter 4). 
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5.2.3. Posterior Spinal Fusion Operation Procedures 
All the procedures were the same as described in the previous Chapter 4 
5.2.4. LIPUS treatment 
The in vivo LIPUS treatment in LIPUS group started on day 3 after the PSF 
surgery. LIPUS was applied 20 min per day, 5 days per week, up to postoperative 
weeks 10. The treatment procedures were the same as described previously (Chapter 
4.2.3). 
5.2.5. High-resolution Peripheral Quantitative Computed Tomography 
High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) 
was used (XtremeCT, Scanco Medical AG, Switzerland) to scan the fusion site in 
vivo at week 1，4，and 10 post-operation. 
Low dose of 10% ketamine was used for anesthesia (Alfasan, Woerden, Holland) 
/ 2% xylazine (Alfasan, Woerden, Holland) (0.6 ml: 0.6 ml, volume:volume). The 
rabbit was placed dorsally in a 12 cm diameter tube. A scout view was preformed to 
obtain an anterior-posterior radiography of the fusion site to define the region of 
interest (ROI) for the final scan. The definition of ROI was to cover the whole block 
of TCP with 2 to 3 mm margin proximal and distal to the TCP block. The voxel size 
of the scan is 41|im and isotropic. There is no gap between individual slices of the 
scan. The total number of slices of each scan was at least 880 slices. 
For the quantification of the bone mineral density, phantom scan was preformed 
daily to calibrate the bone mineral density measurement to mg of HA/cm3. The 
range of the calibration is from 0 - 800 mg HA/cm^. 
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5.2.6. Analysis with HR-pQCT 
5.2.6.1.Image Processing and Qualitative Evaluation 
After the primary scan, the system workstation automatically reconstructed the 
scan to form a two-dimensional image for further image processing. Due to the 
irregular shape of the spinal column and minor difference in the location of the 
implanted TCP block, and to minimize the error of the user-dependent ROI of the 
new formed bone of the fusion mass the reference axis and plane for all analysis was 
done with reference to the TCP block. . To set the reference plane and axis, the 
images of the scan of individual fusion mass were re-aligned with refernce to the 
longitudinal axis and posterior surface plane of the TCP block. The whole fusion 
mass was reconstructed into three dimensional (3D) image using the built-in image 
processing program (Image Processing Language, IBT/ETH/Scanco Medical AG, 
Zurich). With the inscribed 3D coordinate, the long axis and the xz-plane of the new 
reference plane were defined. Using the "align_z" command with the coordinates, 
the fusion mass would be translated to newly defined reference plane. Afterward, the 
3D image was resampled losslessly to form a new stack of 2D image for analysis. 
After the re-alignment and resampling, becoming orthogonal, the TCP block was 
segmented with an approximately 8x6mm rectangular ROI (199 x 150 pixels) which 
is the physical size of the TCP implant at axial view. Then, the whole TCP block 
could be isolated. Meanwhile, the rectangular ROI was acted a reference to define 
the ROI for the evaluation of the new bone formation at the inter-transverse 
processes region (Figure 5.3.1 & 5.3.2) and at the lateral side of the implanted TCP 
block (Figure 5.3.3). Study of the extend of new bone formation at the 
inter-transverse process region would provide information on the efficacy of the 
newly engineered composition to enhance bone formation at the fusion site. To 
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segment the bony tissue from the fusion mass, standardized parameters were used in 
the individual fusion mass (Threshold: 135; Sigma: 1.5; Support: 2) to minimize the 
inter-observer variation. 
5.2.6.2.Descriptive analysis of the fusion mass 
Three-dimensional reconstruction of the fusion mass was preformed with the 
standard reference plane relative to the TCP block. The fusion mass was examined 
under the 3D view program in the workstation provided by the HR-pQCT 
manufacturer. The observation on the spatial distribution of the new bone formation 
was made at the posterior, anterior, oblique, and axial view of the fusion mass. Since 
the TCP block could be segmented from the fusion mass virtually, the observation at 
different views was also performed with the removal of TCP block. Fusion was 
assessed with the segmented images of individual fusion mass. 
5.2.6.3.Quantitative analysis of the fusion mass 
Using the build in 3D histomorphometric analysis program, different parts of 
the fusion mass were analysed at the defined ROI at different time points. In the 
present study the analysis was focused on the bone volume and bone mineral content 
(BMC) of the fusion mass. Firstly, the BMC of the TCP block was measured to 
depict the amount of new bone ingrowth. Secondly, it is important to evaluate the 
new formed osseous tissue at the fusion mass. Thus, the bony tissue at the anterior 
side and the lateral side of the TCP block were analyzed to represent the fusion mass 
volume. The medial side of the TCP was not analyzed because from the gross 
observation it was found that the TCP block was very close to the vertebral body that 
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vary between different samples. The bony volumes of the two sides were combined 
together to represent the newly formed bone volume (BV). The proximal and distal 
part of the TCP were closer to the decortication site and the host bony tissue while 
the middle portion was more in contact with surrounding muscle and connective 
tissue at the fusion bed. Thus with such intrinsic micro-environment difference, the 
analyses of the fusion mass was also divided into 3 parts: i) proximal; ii) middle; iii) 
distal. Figure 5.2.1 and 5.2.2 explains how to define the ROI around the TCP for 
quantitative analysis. Briefly, the analysis aimed to define the amount of bony tissue 
formed within the ROI 2 mm from the anterior side and 4 mm from the lateral side of 
the TCP. Based on the pilot observation of the bone formation at the fusion site, this 
coverage would be able to represent the newly formed bone around the TCP without 
having to include the bony tissue of the vertebral body into the calculation. 
5.2.6.4.Statistical analysis 
The results were expressed in mean 士 1 standard deviation. The comparison of 
different parameters among two groups was done by Student's's t-test. Statistical 
significance was set at alpha = 0.05. All these statistical analysis was done with 
SPSS 13.0 for Windows (SPSS, Chicago, IL, USA). 
5.3. Result 
5.3.1. Qualitative Observations from HR-pQCT Images 
In week 1，the sites of decortication in L5 and L6 transverse processes could be 
distinguished clearly in both groups (Figure 5.3.1 A & B). At week 4, the 
decortications sites become indistinguishable and many small mineralized tissue 
were found on the posterior surface of the transverse processes in week 4 (Figure 
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5.3.1 C & D) and 10 (Figure 5.3.1 E & F). 
Gap distance between L5 and L6 transverse processes declined gradually from 
week 1 (Figure 5.3.2 A & B) to week 4 (Figure 5.3.2 C & D) and week 10 (Figure 
5.3.2 E & F) in both groups. Newly mineralized tissue mainly concentrated within 
the intertransverse processes region in anterior view (Figure 5.3.2 C-F). Mineralized 
bone was also found on the TCP in week 4 (Figure 5.3.3C & D) and week 10 
(Figures.3.3E & F) in both groups. But larger amount of bone formation on TCP was 
found in control group (Figure 5.3.3C & E) than in LIPUS group in week 10 (Figure 
5.3.3D&F). 
TCP implants in control group and LIPUS group were spontaneously cracked 
into 2 parts in week 4 (Figure 5.3.IC) and 10 (Figure 5.3.IF), respectively causing 
slightly movement of TCP implants as compared to week 1 (Figure 5.3.1 A-B). 
Moreover, the roughness of TCP increased from week 1 to 10 in both groups which 
is more apparent in the control group (Figure 5.3.IE). 
5.3.2. Quantitative Analysis 
5.3.2.1.Bone Mineral Content in TCP 
At the proximal part of TCP (Figure 5.3.4)，BMC increased gradually by 10% 
and 12% in week 4 and 10 respectively comparing to week 1 in LIPUS group. In the 
control group, 5% net BMC increased was observed at week 4 followed by a drop of 
2% at week 10. LIPUS group had 5% and 15% (significantly by Student's t-test; 
/7=0.01) higher BMC than control group at week 4 and week 10 respectively. 
In the distal part of TCP (Figure 5.3.5)，BMC increased gradually by 13% and 
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16% in week 4 and 10 respectively as compared to week 1 in LIPUS group. In the 
control group, 1% net BMC increased was observed in week 4 followed by a drop in 
of 3% at week 10. LIPUS group had 12% and 20% (significantly by Student's t-test; 
p=O.Oll) higher BMC than control group in week 4 and week 10，respectively. 
5.3.2.2.Bone Volume Anterior and Lateral to the Implant 
All samples in control group expressed similar BV pattern from week 1 to 10 
(Figure 5.3.6). BV increased from week 1 to 4 then declined in week 10. In LIPUS 
group (LIPUS-2 &3)，similar low BV remained throughout the process. But LIPUS-1 
showed a different pattern. Its BV increased rapidly from week 1 to 4 and decreased 
gradually after week 4. 
5.4. Discussion 
In the present pilot study with the advanced HR-pQCT, it was shown possible to 
study the fusion mass longitudinally with qualitative and quantitative analysis. The 
changes occurring at the TCP implant surface and the underlying transverse process 
can be monitored (Figure 5.3.1 and Figure 5.3.3). This information cannot be 
appreciated easily with conventional histology or plain radiography. The bone 
formation around the TCP can be observed in detail with HR-pQCT with 
three-dimensional reconstruction. At the beginning (Week 1)，the transverse process 
surface was relatively smooth in both control and LIPUS group. Along the course of 
the spinal fusion at week 4 and week 10, it was observed that the surface of the 
enlarging transverse processes became porous and had early mineralized tissue. It is 
similar to the process happened to the cortical bone during fracture healing where 
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resorption of the original cortical bone occurs before it is integrated with the newly 
formed bone at the fracture site. Analogous to the complex cellular events in fracture 
healing, it is likely that the porous surface of the transverse process underwent a 
remodeling phase whereby the original cortical bone of the transverse process was 
resorbed through activation of osteoclasts. This is reflected in the decrease of the 
BMC locally. Therefore, when the bone is scanned with HR-pQCT and reconstructed 
with a defined segmentation parameter, the lower mineralized tissue below the 
detection threshold will not show up in the images. It was observed that the 
roughness of the surface of the transverse processes of control group was more 
obvious in Week 4 than that of the LIPUS group. It may indicate that the remodeling 
phase of the control group at the transverse processes during the first 4 weeks of 
spinal fusion was more active than the LIPUS group. 
With longitudinal follow up, the TCP implant was found to crack around the 
midpoint at different time point between the two groups. It is likely that during the 
first 4 weeks, the fusion mass of the control group is more active as shown by the 
more prominent porosity of the surface of the transverse process when compared 
with that in the LIPUS group, the surface of the transverse process was relatively 
smooth (Figure 5.3.1C&D) This would imply that LIPUS could have effect on TCP 
implant though the exactly mechanism and reasons are still not clear. This might 
account for the more frequent observed breakage of the TCP in control group. 
During the first week post-operatively, the fusion site did not have obvious 
changes and the decortication site was clearly visible and well defined. Therefore, the 
image at week 1 post-operation was conveniently used as the reference for the 
subsequent analysis at different follow-up time points. 
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Significant net increased in BMC in proximal (15%) (Figure 5.3.4) and distal 
(20%) (Figure 5.3.5) parts of TCP of LIPUS group were observed in week 10 as 
compared to control group. This indicated that LIPUS could either enhance the bone 
formation or slow down degradation of TCP or both. Once the ceramic material is 
embedded in implant site, its long term behavior will depend on the transformation 
process of bone. Recruited osteoclast would cut grooves in the endosteal 
surface,which will be filled in turn by osteoblasts later. As soon as the osteoclasts are 
in contact with the TCP surface, resorption will be initiated like that of endogenous 
bone. LIPUS stimulation may influence the promoted BMC in TCP resulting in 
increase in osteoblast and decrease osteoclast activity and number as discuss in 
Chapter 4 (Iwai et al, 2007, Yang et al, 2005，Sun et al, 1999, Li et al., 2003，Kudo 
et al, 2003). 
In summary, HR-pQCT is a feasible, safe and non-invasive method allowing the 
uncoverage of important, new information of bone microstructure in spinal fusion 
sequentially. And it enables better understanding of the biology mechanism and 
sequence of bony fusion in vivo. 
However, there are limitations of the current model of HR-pQCT. HR-pQCT 
can only detect mineralized tissue. Therefore, the changes of vascularization and 
endochondral ossification enhanced by LIPUS remain unclear at this stage. 
Histological studies is still necessary for part of the study. In addition, the high cost 
of scanning and non-widely available of HR-pQCT worldwide also create some of 
the limitations in application of this new technology. 
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Figure 5.2.1 ROI of TCP implant evaluation. 
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Figure 5.2.2 ROI of transverse processes evaluation 
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Figure 5.3.1 HR-pQCT images observed in posterior view. 
(A, C& E) Control group in week 1，4 and 10 respectively; (B，D& F) 
Combined group in week 1，4 and 10 respectively. Sites of decortication in L5 and 
L6 transverse processes could be distinguished clearly in week 1 (A & B). But the 
decortications sites become blur and many tiny mineralized bones were found in 
posterior surface of transverse processes in week 4 (C & D) and 10 (E & F). TCP 
implants in control group and LIPUS group were fractured into 2 parts in week 4 (C) 
and 10 (F) respectively causing slightly movement of TCP implants as compared to 
week 1. Moreover, the roughness of TCP increased from week 1 to 10 in both groups 
which was more obvious in control group (E). 
(TCP-TCP implant; V-Vertebra; L5-Transverse process in fifth lumbar vertebrae 
& L6-Transverse process in sixth lumbar vertebrae; D-site of decortication) 
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Figure 5.3.2 HR-pQCT images observed in anterior view. 
(A, C& E)Control group in week I, 4 and 10 respectively; (B，D& F) Combined 
group in week 1，4 and 10 respectively. Distance of intertransverse process declined 
gradually from week 1 (A & B) to week 4 (C & D) to week 10 (E & F) in both 
groups. And tiny mineralized bones were mainly concentrated within the 
intertransverse processes region. 
(TCP-TCP implant; V-Vertebra; L5-Transverse process in fifth lumbar vertebrae 
& L6-Transverse process in sixth lumbar vertebrae; ITP- intertransverse process) 
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Figure 5.3.3 HR-pQCT images observed in lateral side. 
(A, C& E) Control group in week 1, 4 and 10 respectively; (B, D& F) 
Combined group in week 1，4 and 10 respectively. Tiny mineralized bone was 
formed on the TCP in week 4 (C & D) and week 10 (E & F) in both groups. But 
larger bone formation on TCP was found in control group (C & E) then in LIPUS 
group (D & F). 
(TCP-TCP implant; V-Vertebra; L5-Transverse process in fifth lumbar vertebrae 
& L6-Transverse process in sixth lumbar vertebrae) 
- 1 3 6 -
• control HUPUS 
13096 f ‘ .,_.__.. 1 • ' ' " " " " • ' “‘ “'•'* • — — • “ ― “ — 一 
ft 
PM 120X 一 — — — 
^ I I I 
1 B U i r — — 
100* … … m ^ m i ^ ^ ^ ^ . . . . . . . — - - -
90% ^ .....—— 
...... -
她 — • L — • — • 一 
1 4 10 
WMk 
Figure 5.3.4 Net bone mineral content (%) in proximal TCP implant 
In LIPUS group, BMC increased gradually by 10% and 12% in week 4 and 10 
respectively as compared to week 1. In control group, 5% net BMC increased was 
observed in week 4 and followed by a drop in BMC (2%) in week 10 in control 
group as compared to week 1. LIPUS group had 5% and 15% (significantly) BMC 
higher than control group in week 4 and week 10 respectively. 
#Student，s t-test; /7=0.01 when control group compared with LIPUS group at 
week 10. 
(n=4 in control group and n=3 in LIPUS group. The error bar represents 1 
standard deviation of means.) 
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Figure 5.3.5 Net BMC in distal TCP implant 
In LIPUS group, BMC in distal part of TCP increased gradually by 13% and 
16% in week 4 and 10 respectively as compared to week 1. In control group, 1% net 
BMC increased was observed in week 4 and followed by a drop in BMC (3%) in 
week 10 in control group as compared to week 1. LIPUS group had 12% and 20% 
(significantly) BMC higher than control group in week 4 and week 10 respectively. 
#Student，s t-test; /7=0.011 when control group compared with LIPUS group at 
week 10. 
(n=4 in control group and n=3 in LIPUS group. The error bar represents 1 
standard deviation of means.) 
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Figure 5.3.6 Bone volume anterior and lateral to the TCP implant. 
In control group, BV increased from week 1 to 4 then declined in week 10. In 
LIPUS group (LIPUS-2 &3)，similar low BV remained throughout the process. But 
LIPUS-1 showed a different pattern. Its BV increased rapidly from week 1 to 4 and 
decreased gradually after week 4. 
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Chapter 6 Overall Summary, Discussion and 
Conclusion 
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6.1. Overall Summary and Discussion 
Low intensity pulsed ultrasound was approved for its effectiveness in 
accelerating fracture healing and non-unions clinically (Pounder and Harrison, 2008). 
Many in vitro (Table 1.1) and in vivo experimental studies (Gebauer et al, 2002， 
Azuma et al, 2001, Nolte et al, 2001a, Wang et al., 1994) also demonstrated that 
LIPUS has beneficial effect on bone healing and can stimulate a number of cellular 
activities associated with the repair processes through angiogenesis, chondrogenesis, 
endochondral ossification and osteogenesis. However, there is still limited 
information on use of LIPUS in enhancing spinal fusion. Therefore, in the present 
series of studies, it was hypothesis that LIPUS could enhance bone regeneration and 
improve fusion in an animal spinal fusion model. The first objective of the study was 
to determine the potential and optimized condition of LIPUS on directing the 
proliferation and osteogenic differentiation of MSCs derived from bone marrow. An 
in vitro study of bone marrow derived MSCs was described in Chapter 3. MSCs 
cultured in BM or OS showed similar cell numbers from Day 1 to 7 under LIPUS 
treatment. For osteogenic differentiation, MSCs in OS exhibited lower ALPase 
activity from Day 1 to 4 with a delayed surge at Day 7. ALPase activity was 
significantly increased by 33% at Day 7 in the group with OS and daily LIPUS (10 
minutes) treatment. LIPUS was found to have the optimum osteogenic effect on 
MSC when delivered for lOmin daily at standard setting of 1.5 MHz pulsed 
frequency, 200 \is pulse duration and 1.0 kHz repetition rate for 7 days in osteogenic 
medium . 
The second study was conducted in vivo to study the effect of LIPUS on bone 
formation in a standardized rabbit posterolateral spinal fusion model with calcium 
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phosphate ceramic scaffold impregnated with mesenchymal stem cells (MSG). It was 
found that higher fusion rate (86%) was found in differentiated MSG with LIPUS 
treatment group in contrast to the low fusion rate (0-17%) in other groups by manual 
palpation. Using pQCT, fusion mass of the animals treated with osteogenic 
differentiated MSCs and LIPUS had significantly higher BMC and BV by 28% and 
22% (significantly) respectively than that of control group. Histological analysis also 
showed a 67% decrease in gap distance, 6% increase in tissue volume, significant 
18% increase in length of L5 and L6 transverse processes, 225% significant increase 
in bone in growth into the TCP, 36% increase in osteointegrated length at the 
interface and 10-fold significant increase in cartilaginous tissue in intertransverse 
process were observed in differentiated MSCs with LIPUS group than control. 
Conventional histology and histomorphometry have its limitation in that they 
are a cross sectional destructive procedure and cannot allow in vivo continuous 
monitoring of the fusion biology during the course of spinal fusion. To minimize the 
number to animal used for analysis, the new high resolution peripheral Quantitiative 
CT (HR-pQCT) is capable of non-destructive in vivo 3-dimensional measurement of 
the fusion mass both qualitatively and quantitatively. Thus, the third objective was to 
develop a new method to monitor continuously the spinal fusion in vivo for better 
understanding the biology of spinal fusion using HR-pQCT. Our pilot study revealed 
that bone morphological changes of fusion mass and TCP implant in week 1, 4 and 
10 could be clearly observed from the three-dimensional images in multi-view by 
HR-pQCT. In the LIPUS treated group, an increase of mineralized tissue was 
observed at the fusion site from week 1 to 10 and BMC in proximal and distal TCP 
were 15% and 20% significantly higher than control group in week 10. 
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From the observation of the in vivo study, it was evident that LIPUS enhanced 
bone formation, size of fusion mass, osteointegration, osteoconductivity of implant 
and endochondral ossification. This is in agreement with the observation in in vitro 
study which showed that LIPUS promoted ostegenic effect of MSCs. All these 
observations support the study hypothesis. 
LIPUS was determined to be effective in enhancing bone formation in both in 
vivo and in vitro phases. Another positive result observed in this study was the higher 
percentage of the animals that attained a solid fusion with LIPUS treatment. 
Through histology and HR-pQCT analysis, LIPUS was also found to enhance 
osteoconductivity of TCP ceramic with differentiated MSCs. LIPUS treatment group 
had 216% significantly higher mineralized tissue in TCP than no LIPUS group 
through histomorphological analysis. Significant elevation of bone mineral content in 
proximal (15%) and distal (20%) parts of TCP ceramic in LIPUS group as compared 
to non treatment group in week 10 further confirmed the LIPUS treatment enhanced 
the osteoconductivity of TCP in spinal fusion. 
ALP which is a common bone marker for osteogenic differentiation was 
promoted in MSCs treated with LIPUS in OS medium. In the animal study, bone 
volume of L5 and L6 transverse processes measured by pQCT in LIPUS group was 
32% higher than non-treated group significantly. Through histomorphological 
analysis, length of transverse processes in LIPUS group was found to be 24% larger 
than non-treatment group significantly. And gap distance of LIPUS group was 81% 
shorter than the non-treatment group significantly. Significant increase in fusion rate 
in LIPUS group (86%) as compared to no treatment group (14%) further confirmed 
the effect on LIPUS on promoting the osteogenesis in the fusion site. 
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Differentiated MSG with LIPUS had 48% (significant) increased in relative 
integrated length as compared to differentiated MSG alone. And this observation was 
confirmed from the 3D images of HR-pQCT. Early mineralized tissues were 
observed at the interface between the TCP and transverse processes. These implied 
that LIPUS enhanced the osteointegration between the TCP and fusion mass. 
LIPUS was confirmed in this series of studies to be effective in promoting bone 
formation and fusion rate in spinal fusion through enhancing osteoconduction and 
osteointegration in the fusion site. One of the possible mechanisms is mechanical 
signal transduction in the fusion site by LIPUS. 
Mechanical stimulation by LIPUS acts as the normal functional loading that 
would occur under physiological conditions and represents one potential mechanism 
by which ultrasound may exert its effect on fracture healing (Hadjiargyrou et al, 
1998). Cells in bone are equipped with mechanisms to sense diverse physical forces 
to transducer signals for adjustment of their microenvironment and modalities such 
as ultrasound produce these mechanical stimuli (Naruse et al, 2003). As ultrasound 
waves transmit through tissues, absorption of the waves is proportionate to the 
density of the tissue. This may explain how ultrasound therapy can be targeted to the 
fracture gap, since the density of bone is higher than the surrounding soft tissues 
(Hadjiargyrou et al, 1998). In addition, in areas such as the bone-muscle and 
bone-callus interfaces, much of the incident radiation energy is reflected, creating 
acoustic pressure variations throughout the tissue. Acoustic pressure may result in 
fluid flow through the extracellular matrix (Baker et al, 2001) and impart shear 
stresses and strains to osteoblasts. Osteoblasts are known to respond to applied shear 
forces from fluid flow and substrate strain similarly to the way in which they respond 
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to LIPUS (Tang et al, 2006，Mikuni-Takagaki, 1999)，which suggests that shear 
forces and LIPUS may share common mechanisms to influence cellular behavior. 
Therefore, the cells themselves may sense these mechanical stimuli in their 
environment and must then translate this change into a molecular response, thus 
modulating cell functions (Hadjiargyrou et al, 1998). Evidence of this molecular 
response is that a number of genes are expressed in response to LIPUS in various cell 
types (Table 1.1) and these gene products seem to play a key role in angiogenesis, 
chondrogenesis, endochondral ossification and osteogensis. 
6.2. Limitations and Further Studies 
The MTT assay is a standard colorimetric assay for measuring the activity of 
mitochondrial dehydrogenases that reduce MTT to formazan which in turn giving a 
purple color. It is suitable to determine cytotoxicity of potential medicinal agents and 
other toxic materials, since those agents would result in cell toxicity and therefore 
metabolic dysfunction and decreased performance in the assay. These reductions take 
place only when reductase enzymes are active, and therefore conversion is often used 
as a measure of viable (living) cells. Proliferation of MSCs was determined through 
MTT assay in this study. But the exact cell proliferation may be different from the 
MTT result as it cannot measure cells undergoing cell divisions. It is better to use 
other proliferation assays like thymidine incorporation assay. As the cell grows and 
divides, it progresses through stages in the cell cycle. DNA replication occurs during 
the S phase (Synthesis phase). Thymidine is used to synchronize the cells in S phase. 
The thymidine is incorporated into dividing cells and the level of this incorporation, 
measured using a liquid scintillation counter, is proportional to the amount of cell 
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proliferation. 
In order to increase the purity of the MSCs, other isolation methods such as 
using density-gradient centrifugation, fibroblastoid adherent cells sorting, specific 
cell surface antibody, and selective adhesion to laminin-coated plate could be applied 
to isolate higher purity of MSCs from bone marrow. Moreover, the phenotypic 
characterization of MSCs should be verified in the culture by analyzing surface 
antigens expression of MSCs (e.g. CD 105, CD73 and CD90) through flow 
cytometry. 
The optimum conditions of LIPUS observed in MSCs in the current findings 
(Chapter 3) also need to be taken in the light of limitations. Compared with the in 
vivo situation, the medium in well plate which cells are grown allows bubbles 
formation, expansion and contraction. This potential for cavitation and associated 
microstreaming may amplify the response of MSCs when exposed to LIPUS in vitro 
(1998). Additionally, as we used exposure that is clinically used, the level of 
exposure experienced by cells in vitro may not be same as in vivo. 
MSCs were aspirated in adolescent rabbit (13 week old). Therefore the 
effectiveness of LIPUS in osteogenesis, fusion rate might not reflect the exactly the 
same in older rabbit (adult age). Number, differentiation potential and maximal life 
span decline with age (Nishida et al., 1999, Stenderup et al., 2003). In human, it was 
not a linear age-related in MSCs over the entire age range of 14-66 years，but rather 
a sharp drop after the rapid juvenile bone growth period to a lower rate in mature 
adults. It was a logarithmic relation (Gan et al., 2008). Although bone marrow is the 
origin of MSCs, other sources like adipose tissue (AT), umbilical cord blood (UCB) 
also contain MSCs. Collecting MSCs from other sources can be an alternative to 
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solve the age-associated problem in bone marrow MSCs. Collection of MSCs from 
AT and UCB is relatively painless, simple, less invasive and easy than that from bone 
marrow (Rubinstein, 1993, Zuk et al.，2002). Moreover, higher proliferation capacity, 
longer culture period without changing in morphology and higher osteogenic 
differentiation were found in MSCs isolated from UCB and AT than those from BM 
(Kern et al., 2006). 
HR-pQCT can only detect mineralized tissue. Therefore, the changes of 
vascularization and endochondral ossification by LIPUS remain unknown in this 
case. As studies reported LIPUS enhanced angiogenic (Leung et al, 2004a, Lu et al., 
2008) and chondrogenic activities (Parvizi et al., 1999, Lu et al., 2008, Yang et al, 
1996). So histology is still necessary for further study to observe the LIPUS effect on 
changes in chondrocytes and blood vessel which may be possible for the enhanced 
bone formation in the LIPUS treatment group. 
6.3. Conclusions 
Low intensity pulsed ultrasound enhanced bone regeneration and fusion rate in 
posterior spinal fusion implanted with tissue engineered stem cells-calcium 
phosphate ceramics. 
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6.4. Summary Flowchart of the whole thesis 
Background 
今 Spinal deformities affect a large population with different ages. Adolescent 
idiopathic scoliosis is common form of spinal deformity. 
今 For severe spinal deformities, poster spinal fusion (PSF) coupling with 
instrumentation and correction of the deformity is one of the most common 
procedure performed. 
今 In PSF, decortication of the posterior elements of the spine with autograft 
implantation is the "gold standard" of the surgical procedures. 
今 However, with 5-35% non-union rate, the donor site complication, and limited 
autograft supply, there are continuous ongoing efforts to find better and 
effective bone substitutes to enhance the bony fusion critically important for 
successful long term stabilization of the spinal deformity. 
" ^少 
Previous studies showed: 
今 Mesenchymal stem cells (MSCs) are able to differentiate into osteogenic cells 
今 Osteoconductive biomaterial is a good candidate for bone extensor. 
今 Biophysical stimulation such as low-intensity pulsed ultrasound can enhance 
bone formation. 
Clear evidences of the effectiveness of tissue engineered MSCs 
cells-bioceramics in bone formation. 
今 Low intensity pulsed ultrasound improves fracture healing, delayed 
non-union and non-union clinically. 
Hypothesis: 
今 LIPUS may enhance osteogenic differentiation of MSCs and bone 
regeneration and improve fusion in posterior spinal fusion implanted with 
tissue engineered stem cells-calcium phosphate ceramics composite. 
Continue on next page 
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Objectives 
今 To study the optimum condition of LIPUS on osteogenic differentiation of 
MSCs; 
今 To determine the effect of LIPUS on bone formation in a standardized rabbit 
posterolateral spinal fusion model with calcium phosphate ceramic scaffold 
impregnated with mesenchymal stem cells; 
今 To develop a new method to monitor continuously the spinal fusion in vivo for 
better understanding the biology of spinal fusion using HR-pQCT. 
^^^^^ 
Question 1: 
令 What is the effect of LIPUS on proliferation and osteogenic 
differentiation on MSCs? 
Methods: 
今 Isolated MSCs from bone marrow of rabbits 
今 Tested the effect of LIPUS on proliferation of MSCs by MTT viability assay. 




今 Similar cell number in basal medium with or without LIPUS. 
今 Similar cell number in osteogenic medium with or without LIPUS. 
On osteogenic differentiation: 
今 Similar ALP activity in basal medium groups with or without LIPUS. 
今 The optimum osteogenic condition of bone marrow derived MSC was at 
Day? after daily 10 min LIPUS in osteogenic medium. 
Continue on next page 
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Summary： 
今 In vitro LIPUS could not enhance MSCs proliferation. 
今 In vitro LIPUS enhanced osteogenesis of MSCs. 
今 Is there any effect of LIPUS on bone formation in in vivo 
assessment? 
Question 2: 
今 What is the effect of LIPUS on bone formation and fusion rate of decorticated 




今 Rabbit bone marrow MSCs were isolated and proliferated in vitro. 
今 Cells were then loaded on TCP ceramic. 
今 TCP without cell (Group A), TCP with MSCs (Group B) and TCP with 
bFGF/OS treated MSCs (Group C) were implanted into L5 and L6 
intertransverse processes of the same rabbit. 
今 In vivo LIPUS treatment in TCP with bFGF/OS treated MSCs (Group D) started 
on day3 after the PSF surgery. 
今 Samples were harvested after 7 weeks and underwent pQCT and histology 
analysis. 
Findings: 
今 Manual palpation: Higher fusion rate in Group D 
今 pQCT: Higher BMC and BV of transverse processes in Group D 
� Histology: Longer transverse processes length, shorter gap distance 
between transverse process, higher relative integrated length in interface 
between transverse processes and TCP implant, larger mineralized tissue 
in TCP implant and larger cartilaginous tissue in intertransverse process 
region in Group D 
Continue on next page 
— 
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Summary: 
� In vivo LIPUS was effective in enhancing the fusion rate and bone regeneration in 
decorticated PSF implanted with tissue engineered osteogenic cell-calcium 
phosphate ceramic composite 
令 Apart from traditional pQCT and histology analysis, is there any new method to 
better understand the biology of spinal fusion? 
Question 3: 
今 What addition information on spinal fusion did high-resolution peripheral 
quantitative computed tomography provide? 
Methods: 
今 Pilot study 
今 Rabbits underwent decorticated PSF implanted with tissue engineered 
osteogenic cell-calcium phosphate ceramic composite with or without LIPUS 
treatment. 
今 Rabbits in both groups were scanned with HR-pQCT in week 1，4 and 10. 
今 3D images were reconstructed and fusion mass was evaluated. 
^ 
Finding: 
令 Clear 3D images of fusion site were reconstructed in posterior, anterior and 
sagittal view in week I, 4 and 10. 
今 High BMC in proximal and distal part of TCP in LIPUS treatment group. 
Summary: 
今 HR-pQCT can be a new in vivo monitoring approach for studying the biology of 
spinal fusion 
Continue on next page 
— 
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Conclusions: 
今 LIPUS enhanced in vitro osteogenesis on MSCs. 
今 The optimum osteogenic condition for LIPUS on MSCs was 10 min for 7 days 
in osteogenic medium. 
今 LIPUS promoted the bone formation and fusion rate in spinal fusion with tissue 
engineered osteogenic cell-calcium phosphate ceramic composite 
今 HR-pQCT can be a new in vivo monitoring approach for both qualitative and 
quantitative analysis of the fusion mass during PSF for better understanding the 
biology of spina丨 fusion. 
Further Studies 
今 Analysis on the histology changes of fusion mass correlated to the 
HR-pQCT data. 
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